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Abstract
Integrins are an important class of transmembrane receptors that relay signals
bidirectionally across the plasma membrane, regulating several cell functions and
playing a key role in diverse pathological processes. Specifically, integrin subtype
αIIbβ3 is involved in thrombosis and stroke, while subtypes αvβ3 and α5β1 play
an important role in angiogenesis and tumor progression. They therefore emerged
as attractive pharmacological targets. In the past decades several peptides and
peptidomimetics targeting these proteins and based on the integrin recognition motif
RGD (Arg-Gly-Asp) have been developed, whereby their affinity and selectivity for
a specific integrin subtype have been fine-tuned by modulation of RGD flanking
residues, by cyclization or by introduction of chemical modifications. Thus far, the
design and development of RGD-based cyclopeptides have been mainly based on
empirical approaches, requiring expensive and time-consuming synthesis campaigns.
In this field, the employment of computational tools, in the design and drug
optimization process, has been limited by the inherent difficulties to predict in
silico the three-dimensional structure and the inhibitory activity of cyclopeptides.
However, recent improvements in both computational resources and in docking and
modeling techniques are expected to open new perspectives in the development of
cyclopeptides as modulators of protein-protein interactions and, particularly, as
integrin inhibitors.
Within the PhD project described in this thesis, I have investigated the applicability
of computational techniques in predicting and rationalizing how the environment
of the recognition-motif in cyclopeptides (i.e. flanking residues and introduction of
chemical modification) could influence their integrin affinity and selectivity. These
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features can regulate integrin affinity both by favoring direct interactions with the
receptor and/or by modulating the three-dimensional conformation properties of
the recognition motif. To take into account both these aspects, I have proposed and
optimized a multi stage computational protocol in which exhaustive conformational
sampling, docking calculations and re-scoring techniques are combined. Specifically:
i) the exhaustive sampling could be achieved by using the enhanced sampling
technique Metadynamics in its Bias Exchange variant (BE-META), which represents
a valuable methodology for the acceleration of rare events, allowing to cross the
high free energy barriers characteristic of cyclopeptides and providing reliable
estimations of the populations of the accessible conformers. ii) The docking
calculations, complemented with the re-scoring technique MM-GB/SA (Molecular
Mechanics Generalized Born Surface Area) and the cluster analysis of the decoy
poses, allow to evaluate the ability of each peptide to engage interactions with the
receptors and to rank the docking poses according to their binding ability; iii) a
joint analysis of the previous outcomes results in a reliable ranking of cyclopeptides
based on their binding affinity and in the rationalization of their structure-activity
relationship. This computational protocol has been exploited in two different
applications, illustrated within the thesis.
In the following is presented a brief description of the thesis outline.
In Chapter 1 I have introduced the investigated biological system, integrins, pro-
viding information on their structures and their mechanism of action, meanwhile
evidencing why they are interesting therapeutic targets. Additionally, I have pro-
vided some background concerning the role of cyclopeptides as therapeutics, briefly
reviewing their application as integrin inhibitors.
In Chapter 2 I have presented the computational techniques employed during my
PhD work: Molecular Dynamics methods, especially focusing on the enhanced
sampling technique Metadynamics in its Bias Exchange variant, and docking tech-
niques, with a focus on the utilized docking software Glide and HADDOCK.
In Chapter 3 the first application of the computational protocol has been illus-
trated. Herein I have rationalized how the introduction of chemical modifications,
specifically backbone N-methylation, impacts on the equilibrium conformation and
consequently on the integrin affinity of five RGD containing cyclic hexapeptides,
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which were previously generated by the group of professor Kessler to modulate
their selectivity for αIIbβ3 integrin.
In Chapter 4 I have focused my attention on cyclopeptides harboring a recently
discovered integrin recognition motif: isoDGR (isoAsp-Gly-Arg). Firstly, I have
systematically tested the accuracy of eight Molecular Dynamic force fields in repro-
ducing the equilibrium properties of isoDGR-based cyclopeptides. Then, I applied
the computational protocol to rationalize the diverse selectivity and affinity profiles
for two cancer-related integrins, αvβ3 and α5β1, displayed by three isoDGR-based
cyclic hexapeptides. They differ in the residues flanking the isoDGR motif and show
appealing tumor-homing properties. Herein, I have also proposed a model explain-
ing why the conjugation of one cyclopeptide with a sulfo-SMCC-derived chemical
linker results in an improved affinity and selectivity for αvβ3 integrin.
Overall, in this PhD work I have shown that the combination of different compu-
tational techniques, BE-META, docking and MM-GB/SA re-scoring, could be a
reliable approach to perform structure-activity relationship studies in cyclopeptides.
Specifically, the proposed protocol is able to predict the influence of the recognition
motif environment (i.e. chemical modification and flanking residues) on integrin
affinities. These two features regulate integrin affinity differently: the first one
by conformational modulation of the recognition motif, the second by engaging
direct interactions with the receptor. Of note, the approach can deal with both
these mechanisms of affinity modulation. We expect that the protocol herein
described could be used in future to screen novel peptides library or to complement
biochemical experiments during the drug optimization stages, assisting organic
chemists in the design of more effective integrin-targeting peptides.
3

Chapter 1
Introduction: the biological
context
In the following I am going to provide a background about the system investigated in
this thesis: integrins. I will focus on their structure, their mechanism of action and
signaling, and I will explain why they are important therapeutic targets. Since the
aim of this project is to study the interaction of these receptors with cyclopeptides,
I will also briefly review the growing role of peptides as therapeutic and diagnostic
agents, focusing on two classes of integrin-targeting cyclopeptides based on the
Arginine-Glycine-Aspartate (RGD) and isoAspartate-Glycine-Arginine (isoDGR)
sequence.
1.1 Integrins
Integrins are large, heterodimeric, transmembrane proteins that are expressed
on the cell surface of multicellular animals. They are essential mediators of cell-
extracellular matrix (ECM) interactions and cell-cell interactions, regulating diverse
biological processes as cell attachment, proliferation, migration and differentiation. [1]
The name “integrin” was introduced for the first time in 1986 by Tamkun et al., [2]
to denote the role of these proteins as an integral membrane complex that linked
5
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Figure 1.1: Representation of the 24 heterodimers belonging to the integrin family. Figure
is reprinted from reference [6].
the extracellular matrix and the cytoskeleton. Since that first characterization, the
integrin family has been widely studied and its role in different pathologies, such as
thrombosis, cardiovascular disorders, inflammation, tumor invasion and metastasis,
is now well established. Based on both their easy accessibility as cell surface
receptors interacting with extracellular ligands and their involvement in several
diseases, integrins are currently considered important therapeutic and diagnostic
targets. [3–5]
All integrins are composed of two non-covalently bound domains; in vertebrates 24
heterodimers consisting of 18 α and 8 β subunits have been identified. A common
feature of these receptors is their ability to bind a wide variety of ECM ligands
with diverse binding affinities. [6] This characteristic, and their different tissue
distribution, makes them able to exert and regulate diverse biological functions.
Specifically, these 24 heterodimers can be classified, based on the nature of their
molecular interactions, in four subgroups: Collagen-, Laminin-, Leukocyte-specific-
6
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and RGD-receptors (see Figure 1.1). The group of RGD-receptors, that includes
all the αv integrins, as well as αIIbβ3, α5β1 and α8β1, share the ability to bind
ECM ligands at the α-β subunit interface through the recognition of the three
amino acids sequence RGD (Arginine-Glycine-Aspartate). The integrins of this
group are among the most promiscuous in the family, since the RGD sequence
is present in several ECM proteins such as Fibronectin, Vitronectin, Fibrinogen,
Laminin, Osteopontin, etc. Despite this wide variety of common ligands, the rank
of their affinity varies, presumably depending on how properly the RGD-ligand
conformation fits inside the specific integrin binding pocket. [7]
In the following the attention will be focused on this group of RGD-recognizing
integrin, and specifically on integrins αIIbβ3, αvβ3 and α5β1.
1.1.1 Integrins structures
From a structural point of view each integrin subunit is composed by a large extra-
cellular domain (700-1100 residues), a single transmembrane region (>20 residues)
and a short cytoplasmic tail (13-70 residues). [5] The domains that comprise the
extracellular region adopt a shape that resembles a large head on two legs, with the
head containing the site that is responsible for the extracellular ligand recognition.
The cytoplasmatic tail is fundamental for the interactions with intracellular signal-
ing molecules and for the formation of focal adhesion. The two subunits α and β of
these heterodimers do not show homology to each other, although the different α
domains present similarities among themselves and also in the β domains conserved
regions are found. [6]
The publication of the crystal structure of integrin αvβ3 extracellular segment in its
free state [8] and, the year later, in its bound state to the artificial ligand Cilengitide,
c(RGDf(NMe)V), [9] gave precious information about both the structure of the
ectodomain and the positioning of the RGD motif at the α-β subunits interface.
Later, the appearance of crystal structures of integrin αIIbβ3 in complex with
its antagonist Eptifibatide, [10] reveal an identical atomic basis for ligand-integrin
interaction.
In Figure 1.2 a schematic representation of all the subunits composing integrin
7
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Figure 1.2: Schematic representation of the subunits arrangement in αI-containing
integrins. Figure is adapted from reference [6].
domains is shown. The ectodomain of the α chain consists of a seven-bladed
β-propeller, which is linked to a thigh and two calf domains, together forming
the leg supporting integrin head. [11] In a subset of integrins, not including the
ones belonging to the group of RGD-receptors, the α chain contains also a fifth
extracellular domain called αI domain, which is found between blades 2 and 3
of the β-propeller. [12] In these αI-containing integrins, αI domain is the primary
ligand binding region.
The β chain contains a βI domain, inserted in a hybrid domain, which in turn is
found in a plexin-semaphorin-integrin (PSI) region; these domains are followed by
four cysteine-rich epidermal growth factor (EGF) repeats and a β-tail domain. In
the case of αI-lacking integrins (that include all the members of the RGD-receptors
group), the site of ligand binding is found at the interface between the β-propeller
of the α chain and the βI-domain of the β subunit. This βI-domain, which is
homologous of the αI-domain, adopts a Rossmann-fold characterized by the pres-
ence of up to seven β-sheets surrounded by α-helices, and presents three binding
sites for divalent cations (Ca2+, Mg2+ or Mn2+). It is known that the binding of
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divalent cations to the integrin head can determine the integrin activation state.
In particular it seems that Mn2+ and Mg2+ stimulate ligand binding, while Ca2+
is typically inhibitory. Out of the three sites, the metal-ion-dependent adhesion
site (MIDAS) is fundamental for ligand binding, it is located at the top of the
central β-strand and it is generally occupied by Mg2+ (or Mn2+) in ligand bound
integrins. The second binding site, called ligand-associated metal-ion binding site
(LIMBS), stabilizes the metal ion at MIDAS and consequently acts as a positive
regulator of ligand binding to integrins. Finally, the third site adjacent to MIDAS
(ADMIDAS) can be occupied by Ca2+ or Mn2+ metal ions both in the bound and
in the unbound state. [13]
As already outlined, crystal structures of different integrins ectodomain (as αvβ3,
αIIbβ3 and α5β1) in complex with RGD-based peptides or peptidomimetics, [9,14–16]
revealed similarity in the positioning of the RGD motif at the interface between
the α and β subunits. In particular, two fundamental anchor-points in the bind-
ing pocket can be individuated: i. the Arginine sidechain of the RGD sequence
engages electrostatic interactions with acidic residues belonging to the β-propeller
of the α chain; ii. the RGD-Aspartate carboxylate directly coordinates the MI-
DAS of the β subunit and can also interact or form hydrogen bonds with other
residues of this region. This canonical binding pose is often associated to an
"electrostatic clamp". Figure 1.3 shows the binding poses, based on crystallographic
data, of the following integrin RGD-peptide complexes: αvβ3 in complex with
Cilengitide (c(RGDf(NMe)V), Protein Data Bank code: 1l5g), αIIbβ3 with Eptifi-
batide (MpaHarGDWPC-NH2, PDB: 2vdn), α5β1 with a disulfide cycled peptide
(ACRGDGWCG, PDB: 4wk4). It is recognized that the residues flanking the
RGD sequence can play a role in fine-tuning the affinity and selectivity of these
peptides. This result is achieved both by engaging direct contacts in the integrin
binding pocket and by regulating the conformation adopted by the RGD sequence
(specifically, a distance between the Cβ atoms of Arg and Asp of approximately 9
Å is known to be suitable for the formation of the electrostatic clamp). [17]
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(a) αIIbβ3 with Eptifibatide. PDB: 2vdn (b) αvβ3 with Cilengitide. PDB: 1l5g
(c) α5β1 with ACRGDGWCG. PDB: 4wk4
Figure 1.3: In the picture are represented the ligand-integrin binding sites of αIIbβ3,
αvβ3, and α5β1, in complex with cyclic peptides. The integrin is represented in surface,
with the α chain in blue and the β chain in green; the residues important for the
interactions with the RGD-based cyclopeptides are highlighted in licorice. The ions
in MIDAS, ADMIDAS and LIMBS position are represented with white spheres, water
molecules are red small spheres, while ligands are in orange licorice. Hydrogen bonds are
shown in yellow.
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1.1.2 Integrin activation and signal transduction
It is well established that integrins can exist in multiple activation states, which
are linked to the ligand binding stability. These different activations states, which
correspond to global rearrangements of integrin tertiary structures, have been
observed by electron microscopy, exposure of activation epitopes (LIMBS, ligand-
induced binding sites) and have been confirmed by solution X-ray scattering. [10]
Mainly three different activation and conformational states can be identified (Figure
1.4): a bent inactive state, associated with low affinity for both ECM ligands and
intracellular activators, and characterized by the α and β transmembrane domains in
close proximity; an extended-primed state, associated with higher affinity for ECM
ligands; and a fully-activated state, in which integrin is coupled to both intracellular
and ECM ligands. [18,19] The mechanistic models describing this large conformational
rearrangement from the inactive to the active state are still controversial. Currently
two models of integrin activation, based on NMR and crystal structures, are widely
Figure 1.4: Schematic representation of the conformations adopted by integrins upon
outside-in and inside-out activation. Three main conformations can be observed: inactive
bent, extended-primed and fully-activated state. Figure is reprinted from reference [19].
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cited: the switchblade model, in which activation results in a stretched integrin
conformation and a loss of the dimer contacts in the transmembrane region, and the
deadbolt model, in which smaller changes are proposed, where the activation state
retains the bent conformation, with a movement in the transmembrane domain
and a subsequent opening of the ligand binding site. [20–22] However, according to
both the models, the proposed conformational changes lead to active structures
with heightened receptor avidity.
The bidirectional nature of integrin signaling allows the activation to be regulated by
both intra- and extracellular factors (referred as inside-out and outside-in signaling
events).
Inside-out signaling is triggered by changes in the cytoskeleton environment that
allows binding of intracellular activators to the cytoplasmatic integrin tails (Figure
1.5a). These changes in the intracellular environment are, on their side, caused by
external stimuli, such as integrin-collagen binding, P-selectin ligation or G-protein
coupled receptor activation by cytokines. The generated signaling cascades induce
changes in integrin tail conformations that facilitate the docking of intracellular
activators and the subsequent conformational rearrangements of the receptor
extracellular domain. This promotes the activation of integrin and increases its
binding affinity for ECM ligands. [20]
Integrin activation can be regulated also upon extracellular stimulation. The
main factors are the concentration of divalent cations, ligation and mechanical
stress. The binding of ECM ligand to integrin induces conformational changes
that allow the recruitment of intracellular proteins, including activators, various
kinases and related adaptor proteins (Figure 1.5b). The consequence is an outside-
in signaling cascade that governs diverse cellular processes including survival,
proliferation, differentiation, migration and adhesion. Inside-out and outside-in
signaling events are not independent and can occur simultaneously, reinforcing each
other. Importantly ligand binding promotes integrin clustering and formation of
focal adhesion. This happens thanks to the formation of large protein complexes
and the organization of the cytoskeleton: talin, which is bound to the activated
integrin β-tail, engages crosslinks firstly with actin, to initiate focal adhesion growth,
and then with both actin and vinculin, to provide stable adhesion. [20,23] It is known
12
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(a) Integrin inside-out signaling
(b) Integrin outside-in signaling
Figure 1.5: Representation of the "inside-out" and "outside-in" signaling cascade. Figure
is reprinted from reference [20].
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that inhibition of integrin focal adhesion has disruptive effects on cell adhesion,
motility and migration, finally inducing apoptotic cell death. [3]
It must be noted that, even if generally the bound-inactive state of integrin is
considered its default state, passively adopted by the receptor, several evidences
suggest that both active and inactive state can be actively regulated. Indeed
several molecules are now established as negative regulators of integrin activity. An
appropriate integrin function should be then the consequences of a proper balancing
between activators and inactivators. [19]
1.1.3 Integrins αIIbβ3, αvβ3 and α5β1 and their role as
therapeutic targets
According to the possible combinations of the α and β chains, 24 integrin families
exist in humans, all playing diverse biological functions and being involved in
different pathological processes (Table 1.1). Among these 24 integrin subtypes, 8
belong to the group of RGD receptors, which share the ability to recognize their
ECM ligands through the three-amino acids RGD motif; this thesis will focus on
integrins αIIbβ3, αvβ3 and α5β1, all belonging to this subgroup. In the following
I am going to describe their properties and their role as therapeutic targets.
αIIbβ3
Integrin αIIbβ3 is highly expressed on the platelets surface, at levels of approxi-
mately 50000-100000 receptors per platelet, being involved in blood coagulation
events. It recognizes two different consensus motifs: the canonical RGD sequence,
found in Fibrinogen, Fibronectin and Von Willebrand Factor; and the QAGDV
sequence, which is present in the C-terminus of the γ subunit of Fibrinogen. Several
evidences suggest that, although RGD-based peptides can compete with Fibrinogen
in the binding of αIIbβ3, the biologically important site for αIIbβ3 recognition
within Fibrinogen resides in its γ subunit. [14,24]Integrin αIIbβ3 is activated by
inside-out signaling, caused by the binding of soluble factors in the blood (e.g.
thrombin) to their respective platelet receptors. Activation of αIIbβ3 increases
14
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Table 1.1: Therapeutic indications for all the integrins subfamilies. [6,47,48] This Table has
been adapted from reference [46].
Integrins Main Ligands Potential Implications
RGD-receptors
αIIbβ3 Fbg, vWf Thrombosis, stroke, myocardial ischemia
α5β1 FN Cancer, age-related macular degeneration
α8β1 Npn, FN, VN None
αvβ1 VN, FN Cancer
αvβ3 VN, Opn, vWf, FN, Fbg Cancer, osteoporosis
αvβ5 VN Cancer
αvβ6 FN, TGF-β1,-3 Fibrosis, transplant rejection, cancer
αvβ8 FN, TGF-β1,-3 Cancer
Collagen-receptors
α1β1 Col Fibrosis, cancer
α2β1 Col Fibrosis, cancer
α10β1 Col None
α11β1 Col None
Leukocyte-specific-receptors
α4β1 VCAM-1, FN Multiple sclerosis, autoimmune, Crohn’s dis-
ease, inflammatory bowel disease
α4β7 MAd-CAM-1 Multiple sclerosis, autoimmune, arthritis
α9β1 VCAM-1, Opn, VEGF-C,-D Cancer
αLβ2 ICAM-1,-2,-3 Inflammation, psoriasis, stroke, ischemia,
fibrosis
αMβ2 iC3b, Fbg Inflammation, autoimmune
αXβ2 iC3b, Fbg Inflammation
αDβ2 ICAM-3, VCAM-1 Inflammation
αEβ7 E-cadherin Inflammation
Laminin-receptors
α3β1 LN-5 None
α6β1 LN-1,-2 None
α7β1 LN-1,-2 None
α3β1 LN-2,-4,-5 None
1Abbreviations: Col, collagens; Fbg, fibrinogen; FN, Fibronectin; LN, laminin; Npn, nephronectin;
Opn, osteopontin; VN, vitronectin; vWF, von Willebrand factor; ICAM, intercellular adhesion
molecule; VCAM, vascular cell adhesion molecule; MAd-CAM, mucosal vascular addressin cell
adhesion molecule; VEGF, vascular endothelial growth factor; TGF, transforming growth factor.
15
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receptor affinity and avidity to the ECM proteins (Fibrinogen, Fibronectin and
Von Willebrand Factor) and promotes platelets aggregation. Mis-regulated platelet
aggregation is related to the formation of thrombi and can be involved in several
pathologies as multiple Acute Coronary Syndromes, unstable angina, ischemic
stroke and sickle cell anemia. [20,25] Compounds targeting αIIbβ3 integrin can thus
act as anti-thrombotic agents. Currently, three FDA approved drugs targeting
αIIbβ3 are available: i. Abciximab, [26] a Fab fragment of monoclonal antibody,
which binds integrin in a site proximal to the RGD binding pocket, inhibiting
ligand binding and platelet aggregation via steric hindrance; ii. Eptifibatide, [27]
a synthetic cyclo-heptapeptide based on homoArgGD sequence and cycled with
a disulfide bridge; iii. Tirofiban, [28] a non-peptide small molecule RGD-mimetic.
Both Eptifibatide and Tirofiban compete with ECM proteins for the binding pocket
of αIIbβ3 integrin. Large and randomized clinical trails tested these antagonists,
showing their ability in preventing thrombosis and mortality. The major drawback
associated with the administration of these antagonists is the increasing risk of
bleeding events.
From a structural point of view, crystal structures with good resolution (2.9 Å) are
available for αIIbβ3 integrin, both in its free and bound state. [10,14] In this thesis
I will use as reference the crystallographic structure deposited in the PDB 2vdn,
where Eptifibatide has been co-crystallized with αIIbβ3 integrin. A representation
of the binding pose of this complex can be found in Figure 1.3.
αvβ3
Integrin αvβ3, as well as integrin αvβ5, are highly expressed on angiogenic en-
dothelial cells, osteoclasts and a variety of cancer cells, including glioma, melanoma,
breast, ovarian and pancreatic cancer. [29] The binding to ECM proteins (as Vit-
ronectin, Fibronectin and Fibrinogen) occurs through the canonical RGD motif
and promotes cell adhesion, migration and proliferation, thus favoring the forma-
tion of new vasculatures that feed the growing tumor. Additionally cell-platelet
interactions, mediated by both integrin αvβ3 and αIIbβ3, facilitate the capture
of circulating tumor cells from the blood, initiating the metastatic cascade. [20] It
has been shown that antagonism of αvβ3 is able to inhibit angiogenesis and tumor
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growth, [30] and that it can induce endothelial cell apoptosis. [31] For this reason sev-
eral αvβ3 antagonists are currently in clinical trials as antiangiogenic and antitumor
agents. Among these, it is worth mentioning the humanized monoclonal antibody
Vitaxin, [32] and the RGD-based cyclo-pentapeptide c(RGDf(NMe)V), known as
Cilengitide. [33] However, these antagonists did not appear to be as successful as
expected in clinical trials for cancer treatment. In particular c(RGDf(NMe)V),
despite the promising results observed both in preclinical studies and in phase 2
trials, failed in phase 3 trial for the treatment of patients with newly diagnosed
glioblastoma. [34] The reasons of this failure are still debated and will be addressed in
section 1.2.2. Nevertheless, Cilengitide still continues to be investigated in clinical
trials for the treatment of tumors other than glioblastoma. As well, antagonism
of integrin αvβ3 for the inhibition of angiogenesis and treatment of malignancies
remains an attractive therapeutic target.
Also for integrin αvβ3, crystallographic structures are available in both its free
and bound states. [8,9] The early publication of these crystallographic structures
could be among the reasons that made this integrin the most studied one in the
field of tumor targeting. In this thesis I will use as reference structure the PDB
1l5g, in which c(RGDf(NMe)V) was soaked in crystallized αvβ3. In Figure 1.3 the
intermolecular interactions characteristic of this complex are represented.
α5β1
In addition to αvβ3 and αvβ5, also integrin α5β1 is over-expressed on the endothe-
lium during tumor angiogenesis (with respect to quiescent endothelium) and is
upregulated in several cancer cells, playing a role in tumor migration and inva-
sion. [35] This integrin, in the ECM environment, primarily recognizes Fibronectin
through the canonical RGD sequence, and it is often referred to as the Fibronectin
receptor. It has been shown that antibody, peptide, and non-peptide antagonists of
this integrin are able to block angiogenesis, [36] thus α5β1 is currently targeted for
cancer therapy. Even if α5β1 has been far less studied with respect to αvβ3, and
despite the first appearance of its crystallographic structure is very recent, diverse
ligands targeting this integrin have been developed. These include antibodies,
RGD-like molecules and non-RGD-like peptides (the most famous one of this group
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is ATN-161, based on the amino acidic sequence PHSCN [37]). The potentiality of
these antagonists are explored either in preclinical studies, to clarify the integrin
pathological behavior, and in clinical studies as potential antiangiogenic agents. [38]
Among the interesting group of RGD-like small molecules we can cite SJ749, [39]
a spirocyclic isoxazolines antagonist of α5β1. The group of H. Kessler designed
compounds analogue of SJ749, in addition to new original compounds, in order to
find highly selective α5β1-targeting molecules. [40,41] Among these, one compound
(K34c) was shown to affect survival of glioma cells. [42] Also the pharmaceutical
groups Jerini AG and AstraZeneca developed RGD-like molecules showing selectiv-
ity for α5β1 compared to αvβ3. [43,44]
It is believed that the relatively recent elucidation of α5β1 ectodomain crystal
structure, [15,16] will strongly help the development of new potent and highly selec-
tive antagonists, increasing also the efforts in relative clinical studies. [38] In this
thesis I will use as reference structure for this integrin the one deposited in the
PDB 4wk4, which contains α5β1 in complex with a disulfide-linked cyclopeptide
ACRGDGWCG that was soaked inside the receptor (see Figure 1.3).
Integrins as therapeutic targets
In summary integrins are ideal pharmacological targets both for their accessibility,
being positioned on the surface of the cells, and for their role in several pathological
processes. For these reasons they have been for long time a main studied by
pharmaceutical industries as potential therapeutic targets.
Currently only 3 out of the 24 known human integrins, are targeted therapeutically
by antibodies or small molecules or peptides. [45] These 3 integrin subtypes are
all found on blood cells (leukocytes or platelets) and include integrin αIIbβ3,
belonging to the group of RGD-receptors, and the lymphocytes integrins α4β1 and
α4β7, which are involved in multiple sclerosis, ulcerative colitis and Crohn disease.
However, according to the list ClinicalTrials.gov, in 2015, in 80 clinical trials are
involved therapeutics, imaging agents or biomarkers targeting integrins. [45]
In this context, it is clear that there is a remarkable interest in the development
of novel integrin antagonists, which can be selective for one integrin or that can
target simultaneously different integrin subtypes (dual or multiple antagonists).
18
1.2. Peptides targeting integrins
The development of integrin ligands is also attractive for their utility as diagnostic
agents and for their ability to deliver chemotherapeutics, nanoparticles or other
therapeutic agents selectively to tumor. [20]
1.2 Peptides targeting integrins
Integrin functions depend on several factors, including ECM ligand binding, acti-
vation through conformational rearrangements, formation of focal adhesion and
interactions with proteins present in the cytoskeleton. In principle, all these events
could be inhibited in order to block integrin functionalities. This can be accom-
plished by targeting respectively: the ligand binding pocket, the site of allosteric
control or the intracellular integrin tails that are responsible of cytoplasmatic
interactions. All these strategies, even if with different extents, have been explored;
however, it is interesting to observe that all the integrin antagonists that are
currently on the market or in late-stage clinical trials, target the integrin binding
site of ECM ligands. On the contrary, all the allosteric inhibitors developed for
integrin resulted to be unsuccessful as therapeutics in clinical trials, suggesting
that something is still missing in order to have a comprehensive view of integrin
activation mechanisms. [45]
Among the therapeutics that target the integrin binding site, competing with
natural ligands, three main classes can be individuated: i. therapeutic antibodies,
which are currently the most abundant integrin targeting drugs; ii. small molecules
(synthetic compounds with low molecular weight); and iii. peptide based drugs.
In Table 1.2 the main advantages and drawbacks for each of these classes are
summarized. As this thesis will focus on integrin-targeting peptides in the following
I will briefly introduce the role of peptides in medicinal chemistry.
1.2.1 Peptides as therapeutics
The development of peptides as drugs has been under-exploited for a long time due
to their unfavorable pharmacokinetic properties, which include short circulation
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Table 1.2: Major advantages and drawbacks for the different classes of therapeutics. [20,49]
Therapeutic
Antibodies
Small Molecules Peptide-based drugs
Advantages
High specificity and
affinity
Low cost Good specificity and
affinity
Low toxicity Oral administration Low toxicity
Easy development Easy to synthesize Tolerability
Long lifetime Good stability Intermediate cost
Disadvantages High production cost Poor selectivity Short half-lifeHost immunogenicity Off-target side effect Not orally available
and infusion reactions Low stability
half-life in the body, low stability in physiological conditions, poor membrane
penetration and lack of oral bioavailability. [50] Additionally, among the criteria
of the famous ‘rule-of-five’, [51] proposed in 2000 by Lipinski and widely followed
in the process of drug development, it was stated that a molecule should have a
molecular weight lower than 500 Da to favor bioavailability. This rule is violated
by almost all the peptides with more than four amino acids, and this was a reason
for which peptides were not considered as good potential drugs for pharmaceutical
applications. [52]
However in recent years this trend has changed: small-molecules have clearly
showed their limitations and peptides are therefore attracting increasing interest
as plausible alternative. [53] Indeed it has been reported that the market of peptide
and protein-based drugs is growing faster than that of other pharmaceuticals,
and according to statistics the approval rate for peptides is twice that of small-
molecules. [52,54] According to data of 2015, more than 60 peptide drugs are currently
approved by US Food and Drug Administration, around 140 are in clinical trials
and more than 500 in preclinical development. [49] Figure 1.6 represents this trend,
showing the rising of peptide patent applications observed in the last years.
The reasons of this success for peptides are multiple. These include their high
affinity and specificity, as well as their safe mode of action; the development of
peptide rational design, which is able to improve the characteristic weaknesses of
this compounds; and the increasing challenges encountered in the development
of these small-molecules. [54] Peptides can combine the advantages of both small
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Figure 1.6: Trend in peptide patent applications from 1980 to 2012. Starting from 1996
the number of patent applications per year have always been over 10000. Figure is
reprinted from reference [54].
molecules, characterized by typical molecular weights of <500 Da, and antibodies,
which typically have molecular weights >5000 Da, filling the gap between these
entities. They are characterized by the high target affinity and specificity of
biologics, though preserving a small size; as consequence their production is cheaper
and more accessible, approaching the manufacturing cost of small molecules. [49,52]
An important role in this success was played by the rational design of peptide drugs,
which has focused on the development of techniques able to mitigate peptides major
drawbacks. A number of chemical modification strategies, that include cyclization,
substitution or N -methylation of specific amino acids, have been used to improve
their efficiency as therapeutics and to achieve oral bioavailability. [49,52] In particular
cyclic backbone contributes to protection against enzymatic cleavage and buries
the polar groups in the interior of the peptide; simultaneously, N -methylations
and formation of intra-molecular hydrogen bonds can reduce the number of solvent
exposed amide hydrogens, resulting in better oral bioavailability and enhanced
membrane permeability. [56,58] Other strategies exploit the binding of peptides to
the circulating protein albumin in order to increase their half-life in body. [49]
In this context, the seminal works of Kessler and coworkers gave advances in
our understanding of the role of these structural features (i.e. cyclization and
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N -methylation) on both pharmaceutical properties and biological activity. [57–59]
Since peptide activity is strictly related to its three-dimensional structure, it is
important to design chemical modifications that do not compromise the biologically
active conformation of the peptide. From a structural point of view, it has been
shown that cyclization can constrain peptides in specific stable active conformations,
yielding to higher affinity compounds with respect to their linear counterparts. [57]
Also N -methylation introduces significant changes in peptides structure, affecting
the conformation of both the modified amino acid and of the preceding residue. This
effect has a further long-range impact in the case of cyclopeptides and it is not easily
predictable since it depends also on the specific sequence and chirality. Considering
that these conformational changes can strongly influence the peptides biological
activity and selectivity, cyclization and N -methylation can be exploited to fine tune
their specificity towards particular targets and to improve their pharmacokinetic
properties. [60,61]
All these data, including the unique properties of peptides in terms of potency
and tolerability, together with the possibility to enhance their functionalities by
introducing chemical modifications, support the idea that peptides, and in particular
cyclopeptides, can represent a promising class of therapeutics to be used for the
target of protein-protein interactions. Moreover, the potentialities of peptides are
not limited to their role as drugs, and can be used for diagnostic and drug delivery
purposes taking advantage of their possible targeting activities. [53,55]
1.2.2 RGD-based cyclopeptides
The three amino acidic sequence RGD is currently the fundamental motif of the
majority of peptides targeting the integrins of the RGD-receptors subgroup. In
the last decades a plethora of RGD-based peptides has been developed. Until
2002, the drug design process relied on the hypothesized pharmacophoric regions,
derived only from the structures of known ligands. With the appearance of the
first integrin X-ray structure alone and in complex with an RGD-based ligand, [8,9]
structure-based rational design of selective inhibitors became possible. [62]
The developed peptides present different selectivity and affinity towards different
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Figure 1.7: Structure of c(RGDf(NMe)V), known as Cilengitide.
integrins. Since the RGD motif is conserved in all the ligands, it is clear that
integrin specificity is mainly dictated by the environment of the RGD sequence.
The amino acids flanking the RGD motif can regulate the affinity both by direct
interactions with integrin and by modulation of the conformational features of
the RGD motif. [63,64] Cyclization is often utilized to constrain peptides in specific
conformation: the conferred rigidity greatly improves selectivity towards specific
integrin subtypes, additionally cyclopeptides are more stable being less susceptible
to chemical degradation with respect to their linear counterparts. Furthermore
introduction of d-amino acids and of chemical modifications have fostered the
development of highly potent and selective RGD-cyclopeptides. [64,65]
Among these ligands the most famous one is c(RGDf(NMe)V), also known as
Cilengitide, a cyclic RGD-based pentapeptide developed by the group of Kessler in
the early 90s (structure in Figure 1.7). [66] This peptide displays a sub-nanomolar
affinity for αvβ3 integrin and has a 100-1000 fold increased activity over the
linear reference peptide. The characteristic features of this molecules include: the
cyclized conformation, the presence of a d-amino acid (d-Phenylalanine) and the
backbone N -methylation of the flanking residue Valine. c(RGDf(NMe)V) was
developed as antiangiogenic therapeutic by the pharmaceutical company Merck-
Serono (Germany). It obtained excellent results in preclinical and early-stage
clinical trials, showing safety profiles and no side effects in humans. It reached
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phase III of clinical development for the treatment of glioblastoma and phase II for
several other tumors. [67] However, in 2014, c(RGDf(NMe)V) failed in the treatment
of glioblastoma, it did not reach the goal of increased progression-free or overall
survival, and its further development as anticancer drug has been stopped. [34]
The reasons of this failure are still not fully understood. The main reason can be
ascribed to the complexity of c(RGDf(NMe)V) mechanism of action when targeting
αvβ3 integrin. Indeed dose-dependent opposing effects of c(RGDf(NMe)V) have
been observed: while at high doses it inhibits growth of blood vessels and tumor
angiogenesis, at low doses this process seems to be stimulated. [68] The doses
used in clinical trials might not be able to reflect the complexity of this effect.
Additionally, the short half-life (2-4 hours) of c(RGDf(NMe)V) in body could
have contributed to these negative results. [68] Finally, it must not be excluded
the possibility of paradoxical effects. Indeed, the inhibition of one integrin could
induce, via conformational changes, signaling in the intracellular environment; as
consequence the upregulation of other related receptors, which bind the same ligands,
could be promoted in order to maintain adhesion and signaling. [67,69] Overall, these
data suggest that the role of integrin ligand as agonists or antagonists must be
carefully considered.
1.2.3 isoDGR-based cyclopeptides
In 2006 biochemical studies showed that the NGR (Asparagine-Glycine-Arginine)
motif of the ECM protein Fibronectin can spontaneously transform into the isoDGR
(isoAspartate-Glycine-Arginine) sequence, resulting in a gain of function for the
protein and in the creation of a new adhesion binding site for integrins. [70] The
deamidation of Asparagine at the NGR site occurs via hydrolysis of the succinimide
intermediate, as represented in Figure 1.8; this leads to formation of DGR and
isoDGR in a 1:3 ratio.
Subsequent investigations demonstrated that isoDGR sequence can fit into the RGD-
binding pocket of αvβ3 integrin, recapitulating the canonical RGD/αvβ3 contacts
and establishing additional polar interactions. [71] This motif gained increasingly
attention from 2012, when it was shown that, at variance to c(RGDf(NMe)V),
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Figure 1.8: Representation of the NGR deamidation reaction, which leads to the formation
of DGR and isoDGR. Figure is reprinted from reference [70].
CisoDGRC, an isoDGR-based peptide cyclized through a disulfide bridge, behaves
as a pure integrin antagonist blocking αvβ3 conformational changes and allosteric
activation. [72] Since it cannot be excluded that the c(RGDf(NMe)V) failure in
clinical trials could be related to its agonist-like activity, and the subsequent
paradoxical effects, the intrinsic ability of the isoDGR motif to block receptor
allosteric activation holds promise for improved real integrin inhibitors.
It was suggested that peptides containing the isoDGR motif could be exploited
both as new integrin antagonists and as ligands for the targeted delivery of drugs
or imaging. [73] Similarly to the case of RGD motif, structure-activity studies
revealed that cyclization of isoDGR-based peptides improves ligand affinity for
integrin; additionally, introduction of chemical modification (e.g. acetylation) and
modification of the flanking residues are strategies that can be exploited to fine-tune
affinity and selectivity towards specific integrin subtypes. [74,75]
In recent years the isoDGR-motif has been used to develop cyclopeptides and
peptidomimetics. The group of Corti, which mainly contributed to the discovery
the isoDGR motif as integrin binding sequence, designed a set of head-to-tail
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isoDGR hexapeptides to be coupled with human serum albumin and nanoparticles
via a free thiol group. Notably they found a peptide that, after conjugation with
albumin, showed high affinity and selectivity for αvβ3, and was able to inhibit
tumor growth. All these characteristics can be favorably exploited for the delivery
of nanomedicines to tumor neovasculature. [76] Kessler and coworkers investigated
the role of flanking residues in cyclic pentapeptides based on the isoDGR motif,
studying their affinity and selectivity for several integrins, including αvβ3, αvβ5,
αvβ6 and α5β1. [77,78] Finally, cyclic isoDGR peptidomimetics containing a bi-
functional diketopiperazine scaffolds have been developed and studied by the
group of Gennari, leading to the individuation of two ligands characterized by low
nanomolar activity for αvβ3 receptor. [79]
26
Chapter 2
Methods
Computer simulations and modeling of molecular systems are widely used techniques
to study the basic mechanisms of biological processes, including the motion and the
assembly of proteins and molecules. The present chapter, divided in three sections,
deals with the computational methods used in this thesis. In the first two sections
the basic concepts of Molecular Dynamics (MD) simulations are presented, with a
special focus on the problem of simulating rare events and on the use of enhanced
sampling techniques to study equilibrium properties of systems involving complex
free energy landscapes. The last section is dedicated to molecular docking, cluster
analysis methodologies and MM-GB/SA (Molecular Mechanics-Generalized Born
Surface Area) methods. All these techniques are useful to predict the binding mode
and the affinity of biomolecular assemblies.
2.1 Molecular Dynamics
Molecular Dynamics (MD) simulations are currently very popular and routinely
applied in the field of biochemistry to investigate the basis of protein structure,
dynamic and function. Their first applications date back to 1950s and early 1960s,
with pioneering works on the dynamics of liquids, but only in 1977 the first MD
simulation of a biologically relevant macromolecule has been published by the
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group of Martin Karplus. [80,81] While these earliest MD simulations were performed
considering isolated proteins in vacuum, nowadays macromolecules can be simulated
in a more realistic environment, consisting in a solvation box filled with water
molecules and, optionally, ions. Simulations performed in these conditions, known
as explicit solvent model, are currently the most utilized in studies on conformation
and dynamics of biomolecules. In these decades the role of MD is growing faster
and faster, thanks both to the increasing power of computational resources and the
continuing advances in methodologies, making it possible to study bigger systems,
longer time scales and larger conformational rearrangements. [82,83] An important
acknowledgment to this field has been given with the 2013 Nobel Prize in Chemistry,
which was awarded jointly to Martin Karplus, Michael Levitt and Arieh Warshel
for the development of multiscale models for complex chemical systems. All these
reasons are contributing in the emerging of MD as a fundamental complement of
experiments in several contexts: the major applications of MD in biology include the
study of conformational and allosteric changes in macromolecules, the description
of protein folding, the prediction of binding free-energy and the investigation of
mechanisms regulating molecular recognition.
MD simulations are based on the integration of Newton equations of motion and
allow to follow the particles’ position as a function of time, being able to provide
information on the thermodynamic and kinetic properties of the investigated system.
The link between microscopic data (i.e. distribution and motion of atoms) and
macroscopic observables (e.g. pressure, heat capacity and free energies) is provided
by statistical mechanics. [84] In this framework a physical quantity can be computed
from MD by averaging over the microscopic states (configurations sampled in the
trajectory) of the system, which are distributed according to a certain statistical
ensemble. Assuming that the ergodic hypothesis holds, in the limit of infinite
simulation time, the MD trajectory is able to explore all the accessible states: in this
case time averages equals ensemble averages, therefore allowing the determination
of thermodynamic properties. [80,85] This condition, that requires an exhaustive
sampling of the accessible configuration space, is often prohibitive in the case
of big systems, when dealing with complicated free-energy landscapes, or when
studying biological processes that take place on long time scales. To alleviate
28
2.1. Molecular Dynamics
this problem, which is a major issue in MD, several methodologies capable to
accelerate rare events, generally known as “enhanced sampling techniques”, have
been developed.
In the following I am providing more detailed information on the equation of motion
used in MD and on the potential energy function that describes the inter- and
intra-molecular interactions, also known as force-field. Afterward I will discuss the
limitations of MD, specifically focusing on the problem of sampling rare events and
presenting some methods developed to overcome this issue.
2.1.1 Equation of motion
In principle the motion of a molecular system is accurately described by the laws of
quantum mechanics. However calculating the evolution of a system based on these
laws requires a high computational cost, setting strong limitations to the size of
the molecules and to the time-lengths that can be simulated. Hence classical MD,
based on the numeric integration of the Newtonian equation of motion, is needed
to overcome these drawbacks. This reduction implies mainly two approximations:
i. the motion of electrons and nuclei can be treated separately due to their
considerably different weight (as stated by the Born-Oppenheimer approximation);
ii. the heavy nuclei can be approximated as classical point particles moving in a
potential energy surface generated by the electron clouds (which indeed equilibrate
quickly for each instantaneous configuration of the nuclei). [80] These assumptions
allow to represent a molecule in terms of atoms, whose centers are represented by
the nuclei, interacting through a potential energy that takes into account the effect
of the electrons. In this framework, classical equation of motion can be used to
follow the evolution of each atom.
Indicating the position vector of atom i at time t with ri(t), its mass with mi and
the force acting on it with Fi(t), the Newton equation of motion can be written
as:
Fi(t) = mi
d2ri(t)
dt2
. (2.1)
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Hence, the time-evolution of the system can be provided integrating equation 2.1
once it is given: i) the initial structure of the system (i.e. the set of coordinates for
each of the N atoms at a reference time t0), ii) a set of initial velocities consistent
with the simulated temperature and iii) a potential energy function Etot, for which
Fi = −∇riEtot(r1, . . . , rN). Because of the complexity of biological systems, which
generally consist of a huge number of atoms, finding an analytical solution for this
equation is not possible. For this reason, numerical integrators which approximate
the Taylor expansion at different orders, are used to propagate positions and
velocities with a finite time step ∆t. Several different integrators are available and
are implemented in dedicated MD software packages (e.g. GROMACS, AMBER,
NAMD and CHARMM). [86–89] The simplest integrator is the Euler one, which
consists in a first-order approximation of the Taylor expansion of positions and
velocities. Second-order algorithms include Verlet, velocity-Verlet and leap-frog
integrators. [90–92] In Verlet, atomic position and acceleration at time t, as well
as positions from the prior step t −∆t, are used to determine new positions at
t+ ∆t. Differently, velocity-Verlet and leap-frog algorithms include explicitly the
velocities vi(t) = dr(t)/dt in the calculations. Another family of algorithms, known
as predictor-corrector methods, is available and allows to correct integration to
a selected error order at the cost of extra computations and storage. [93] Within
this thesis I will use the highly popular and versatile GROMACS package, which
makes use of the leap-frog algorithm by default. In leap-frog integrator positions
are updated at every time step ∆t, while velocities are computed at intermediate
times (this specificity is at the origin of the algorithm’s name) according to the
equations:
ri(t+ ∆t) = ri(t) + vi(t+ ∆t/2) ∆t, (2.2a)
vi(t+ ∆t/2) = vi(t−∆t/2) + Fi(t)
mi
∆t. (2.2b)
The iteration of this procedure allows to follow the evolution of the system in time.
From equations 2.2 it is clear the importance of choosing an appropriate value
for the time step ∆t. On one side it should be small enough to avoid significant
deviation from the exact analytical trajectory, which corresponds to the limit of an
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infinitesimally small time step, thus guaranteeing numerical stability and accuracy
in conserving energy. On the other side it should be as big as possible in order
to save computational time, allowing to sample longer trajectories and thus to
simulate more relevant biological processes. Typically the time step ∆t should be
at least an order of magnitude smaller than the fastest time scale in the system
(i.e. the oscillations of bonds involving light atoms as hydrogen). Since these
bonds vibrations are generally of poor interest in the study of biomolecular system,
it is possible to fix their lengths using constraining algorithms (as SHAKE or
LINCS) [94,95] thus allowing to increase the time step up to a factor of four without
affecting significantly the quality of the trajectory. In this condition, appropriate
values for ∆t in atomistic simulations are usually around 2 femtoseconds. It is worth
noting that all the frequently employed integrators are time reversible, meaning
that the direction of the simulation in time is arbitrary.
2.1.2 Thermodynamic ensembles
An aspect that must be considered is that Newtonian dynamics implies the conserva-
tion of energy. As consequence a dynamic which is based on the simple integration
of the Newton equation would provide a set of configurations distributed according
to the microcanonical ensemble NV E (corresponding to the conditions of constant
number of particles N , volume V and energy E). This ensemble is generally not
representative of common experimental or physiological conditions. More realistic
situations can be simulated using the canonical ensemble (NV T , characterized by
constant number of particles, volume and temperature) or the isothermal-isobaric
ensemble (NPT , with constant number of particles, pressure and temperature).
Thus, in order to mimic experimental or physiological conditions in MD, the use of
a thermostat and/or a barostat along the simulation is needed.
It is worth noting that the goal of a thermostat is not to maintain constant temper-
ature fixing the kinetic energy, but it is to keep the average simulation temperature
close to the desired one. A common strategy to this aim consists in modifying or
rescaling properly the atomic velocities of all the particles. Indeed the instantaneous
temperature T (t), which can vary due to the interconversion between kinetic and
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potential terms of the total energy, is related to the kinetic energy via particles
velocities as follows:
1
2 Nf kb T (t) =
1
2
∑
i
mi v
2
i (t) (2.3)
where Nf is the number of degrees of freedom, kb is the Boltzmann’s constant, mi
and vi are the mass and velocity of atom i. Analogously, in order to maintain
constant pressure, the volume of the box containing the molecule can be adjusted
during the simulations, rescaling the atomic positions accordingly. Among the most
famous algorithms used to control temperature there are Berendsen, Nosè-Hoover,
velocity-rescaling and Langevin thermostats. [96–99]Popular barostats instead include
Berendsen and Rahman-Parrinello barostat. [96,100]
2.1.3 Force field
As stated in section 2.1.1, in order to numerically solve the Newton equation of
motion for a system of N atoms, it is necessary to know the potential energy
Etot(r1, . . . , rN ), which is function of the 3N atomic positions and that determines
the forces Fi = −∇riEtot(r1, . . . , rN) acting on each atom i at different time steps.
Since this potential energy function must be evaluated several times during the
simulation, it is advisable to maintain its form as simple as possible; for this
reason anharmonic and cross-terms are often neglected and it is usually based
on sets of empirical parameters. These parameters are derived and optimized
by fitting to high-level Quantum Mechanics (QM) calculations and experiments
(X-ray, electron diffraction, NMR spectroscopy or infrared spectroscopy), using as
test-cases small molecules or fragments. The main assumption here is that these
parameters are transferable and that they can be used to study larger and more
complicated biomolecules of interest. The combination of the functional forms
and of the associated set of parameters is called force-field. Despite their classic
nature, force-fields performances are extremely good, being able to approach the
high accuracy of QM calculations in a fraction of time. Several force-fields exist,
differing both for the form of the energy potential and for the approaches adopted
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to derive the parameters. Among these, the most popular and computationally
efficient ones are additive and assign to each atom a fixed partial charge, which is
not influenced by its electrostatic environment. In these force-fields the potential
energy equation has the following form:
Etot = Ebonds + Eangles + Edihedrals + Evdw + Ecoulomb, (2.4)
resulting from the summation of bonded interactions, namely the first three addends,
and non-bonded interactions, i.e. the last two addends. Each term of 2.4 is
calculated as:
Ebonds(rij) =
1
2 k
r
ij (rij − r0ij)2, (2.5a)
Eangles(θijk) =
1
2 k
θ
ijk (θijk − θ0ijk)2, (2.5b)
Edihedrals(φijkl) =
1
2 k
n
φ (1 + cos(nφijkl − γn)), (2.5c)
Evdw(rij) =
Aij
r12ij
− Bij
r6ij
, (2.5d)
Ecoulomb(rij) =
qi qj
4pi0rij
. (2.5e)
The terms Ebonds and Eangles, representing the bond stretching (2-body interaction)
and the angle bending (3-body interaction), have the form of harmonic potentials,
which maintain bonds and angles close to their equilibrium values, r0ij and θ0ijk
respectively. While r0ij and θ0ijk values are derived from structural database, the
force constants krij and kθijk generally result from fitting to experimental data.
The dihedral energy term Edihedrals approximates a Fourier series with a small
number of terms; in this equation knφ is the dihedral force constant, n is the
dihedral periodicity and γn is a phase of the dihedral angle φ. This term is also
used to enforce planarity of certain groups (e.g. aromatic rings) and to maintain
proper chirality. Concerning the non-bonded interactions, the van der Waals (Evdw)
potential takes into account both the short range repulsion term and the attractive
long-range term. The coefficients Aij and Bij depend on pairs of atom type; the
distance between atoms i and j is indicated with rij . Finally, the Coulomb potential
describes the electrostatic interactions involving two atoms i and j, characterized
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by partial charges qi and qj , where 0 rij is a distance-dependent dielectric function.
In the case of simulations incorporating explicit solvent representations the value
0 is usually set to unity.
The role of force-field in MD is of outstanding importance. Choosing an appropriate
energy function with adequate parameters is indeed critical to have a reliable
simulation. Several force-fields, sharing analogous mathematical forms but differing
in the optimization of the parameters, have been developed and are routinely used
in MD. Among the most popular force-field families it is worth to cite AMBER, [101]
OPLS-AA, [102] CHARMM [103] and GROMOS, [104] for which several variants are
available. All these force-fields use an all-atoms representation, with the exception
of GROMOS that adopts an united-atom treatment, in which the parameters
for non-polar hydrogens are not provided. Due to the importance of this issue,
continuously updated and optimized force-field versions are published. In the
last year OPLS-AA and AMBER have made available novel optimized force-field
variants; [105,106] additionally new residue-specific force-fields are being developed
and tested. [107,108] Even if numerous studies have been conducted to evaluate their
reliability, [109–112] it is not possible to say which of these force-field variants is the
best one. Indeed their performance strongly depends on the system investigated
and on the information that one wants to retrieve from the simulation. In any
case the guidelines originating from these studies can be helpful in the choice of a
proper force-field variant.
Since most of the MD simulations are currently conducted in explicit solvent
conditions, diverse models for parametrization of water molecules are also available.
These include TIP3P, TIP4P, TIP5P and SPC. [113–115] The main difference among
these models, which all make use of a rigid geometry, consists in the number
of interaction points used to represent the water molecules. While TIP3P and
SPC use three interaction points (representing the three atoms of the molecule),
TIP4P and TIP5P use four and five interaction points respectively, by adding one
or two dummy atoms with negative charge. The increasing of interaction sites
generally improves the electrostatic distribution around the molecule, however it
also increases the computational cost. As consequence three-site models, thanks to
their high computational efficiency, constitute the most widely used models. To
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save computational time it is also possible to use the implicit solvation model, in
which the average action of water molecules is represented by a potential. This
model is particularly efficient when dealing with huge systems but it can not be
considered as accurate as the explicit solvent one.
Most of the force-fields herein cited have been primarily developed and optimized to
deal with protein and nucleic acid systems, having only limited sets of parameters
for organic molecules. However, in the field of drug discovery, where the study of
protein-ligand and nucleic acid-ligand complex is fundamental, force-fields working
for both biological and organic molecules are highly desirable. Several general force-
fields have been developed to describe organic molecules: these include MMFF,
Tripos, the CHARMM General Force Field (CGenFF) and the General AMBER
Force Field (GAFF). [116–119] Specifically, the widely adopted general force-field
GAFF, which has been developed in 2004 along with Antechamber, [120] a tool that
allows the assignment of parameters to an arbitrary molecule in automatic fashion,
has the advantage to be consistent both in form and parametrization with the
traditional AMBER force-fields developed for proteins and nucleic acids. GAFF can
be thus considered an extension of AMBER force field to be used for a wide range
of organic molecules. This feature makes it suitable for the study of protein-ligand
complexes. In any case one must consider that the accuracy of this kind of generic
force-field is lower with respect to the standard ones due to the use of very general
parameters.
2.1.4 Computing the interactions
It is worth noting that the computation of non-bonded interactions is the most
demanding portion of an MD simulation. Indeed these terms must be calculated
for each pair of atoms (separated by at least three covalent bonds): thus in a
system of N atoms the number of non-bonded interactions to evaluate grows as N2,
often resulting in prohibitive calculations. To alleviate this problem, earlier MD
simulations applied a cutoff truncation, where interactions beyond a chosen cutoff
distance were ignored or smoothly switched to zero. While this technique introduces
only small errors in the evaluation of van der Waals interactions, the electrostatic
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Figure 2.1: Schematic representation of periodic boundary conditions in two dimensions.
If a particle moves out the simulation box an image particle comes to replace it. Figure
is reprinted from reference [123].
potential is considerably affected, since it decays less rapidly with the distance. [84,121]
Inclusion of longer range electrostatic interactions by simply increasing the cutoff
distance is unfeasible, since the computational cost is dramatically increased.
Currently, the most commonly used technique to compute electrostatic long-range
interactions in MD is the Particle-Mesh Ewald method, an improvement of the
traditional Ewald summation in which the long-range contribution is calculated as a
Fourier transform. [122] This method allows to obtain good accuracy and reasonably
fast computational time.
Particle-Mesh Ewald method is applicable in the case of infinite periodic systems
and thus it is generally used in combination with the periodic boundary conditions
(PBC) method, a technique able to minimize the boundary effects which inevitably
affect a finite system. PBC technique consists in duplicating the box containing the
system periodically in all directions. Practically only one box is simulated, while
all the image particles move conjointly with the original ones (see Figure 2.1). In
this framework a particle i in the box is able to interact not only with particle j in
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the same box, but also with their images, virtually eliminating surface effects. The
minimum image criterion, which states that among all the images of the particle j
only the closer to i should be considered, guarantees that duplicate interactions
are not included. In such a way the simulated system mimics the behavior of a
macroscopic system, characterized by a huge number of particles (of the order of
1023) and which is negligibly affected by interactions with boundaries.
2.1.5 Limitations of MD
Being aware of MD limitations is important to use simulations properly.
A first obvious limitation is related to the classical nature of the Newton equation of
motion, which is the basis of MD time evolution. For this reason, all the processes
involving quantum effects, as enzymatic or chemical reaction mechanisms, can not be
studied by means of classical MD. To this aim hybrid quantum mechanical/molecular
mechanical methods can be used, in which a restricted number of interesting
coordinates is treated with QM while the residual coordinates are analyzed with
MD.
A second limitation concerns the reliability of the force-fields. As already outlined,
a simple mathematical form to describe the interatomic potential is advisable to
save computational time; however this simplification requires the definition of a set
of empirical parameters, which are critical for the fitting of the energy function
to the potential acting on real atoms. The optimization of these parameters is
carried out by fitting simulations’ outcomes with both experimental data and QM
calculations, using as data sets small molecules or fragments that are then used as
building blocks. Additional refinement is usually performed comparing simulations
with experimental results for well-characterized systems. Despite all the efforts
dedicated to this aim and the huge improvements obtained, it is clear that having
transferable empirical parameters, applicable on different systems under diverse
conditions, is not an easy task. This challenge is becoming even more complicated:
indeed, with the increasing power of computational resources, longer simulation
times are becoming accessible, thus force-fields with improved stability and accuracy
are required.
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Figure 2.2: Typical time scales involved in protein dynamics. While the bonds vibrations,
which set limits to the time step ∆t, occur in a range of few femtoseconds, the most relevant
biological processes are characterized by a time constant ranging from nanoseconds to
hours. Figure is adapted from reference [124].
The most severe limitation in MD is probably related to the time-scales. As
illustrated in Figure 2.2 the timescales linked to the most relevant biological
processes are quite big with respect to the proper values for the time step ∆t
to be used in the integration of the Newton equation (usually these values are
around 2 femtoseconds as explained in section 2.1.1). It follows that to simulate
an event occurring on the scale of seconds, a number of time steps (and thus of
integration of equation of motion and evaluation of the potential energy function)
of 1015 is needed. Despite the enormous improvement in computational power
observed in last years, this kind of simulation are commonly not affordable. In the
following section I will discuss this problem, presenting few approaches, alternative
to brute-force MD, that have been developed to overcome it. Specifically, I will
focus on a method (Metadynamics in its Bias-Exchange variant), belonging to the
group of the enhanced sampling techniques, which is widely adopted to accelerate
rare events and to reconstruct the free energy of the system.
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2.2 Enhancing the sampling with Bias-Exchange
Metadynamics
Processes taking place on very long time scales are generally associated to com-
plicated and rude free-energy landscapes, characterized by the presence of several
local minima, in which the system remains trapped and that can be separated
by high energy barriers (see Figure 2.3). In a finite MD simulation at standard
ambient temperature the probability of overcoming these energy barriers can be
negligible, even in several hundreds of nanoseconds. Consequently, simulating pro-
cesses associated to major conformational changes or protein folding, or generally
events characterized by complex free-energy landscapes, requires a huge amount of
MD steps and computational time. [126] Several strategies have been explored to
overcome this obstacle.
To this aim, two main classes of methodological approaches can be identified: coarse-
grained methodologies and enhanced sampling techniques. [127] Coarse-grained meth-
ods rely on a simplification of the investigated system (obtained reducing a group
Figure 2.3: Representation of a typical rude free energy landscape characterized by the
presence of several local minima. Figure is reprinted from reference [125].
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of atoms to a single particle which is supposed to represent their properties) to
speed up the calculation. Even if these approaches have been widely and success-
fully applied, [128] they lack atomic details and therefore are not suitable for the
investigation of several phenomena. On the contrary enhanced sampling techniques
maintain the atomic description of the system trying to enhance the sampling by ac-
celerating the dynamic of the system. The most famous and applied methodologies
include simulated annealing, [129] replica-exchange molecular-dynamics, [130] umbrella
sampling [131] and Metadynamics (MetaD). [132,133] While the first two approaches
are based on the idea of raising simulation temperature to overcome easier the
free-energy barriers, the last two methods involve the addition of a potential bias
to improve the sampling. In the following I will briefly review MetaD technique,
and specifically its variant Bias-Exchange Metadynamics (BE-META), [134] which
has the advantage to directly provide a good estimate of the free energy of the
system as a function of few relevant degree of freedom, named Collective Variables
(CVs). [85]
2.2.1 Metadynamics
MetaD is a well recognized method to accelerate rare events, which has proven its
effectiveness in structural biology context. This technique allows to: i. overcome
high free-energy barriers escaping the local minima, ii. reconstruct the free energy
landscape of the investigated system as a function of few CVs, which should describe
all the slow events relevant to the process under investigation. [132,133] MetaD is
based on a history-dependent potential, defined in equation 2.6, that is added to
the traditional force field potential forcing the system to visit unexplored regions.
The history-dependent potential biases the dynamic of the system in a reduced
dimensionality space, defined by a set of few CVs S(x), which must be selected
before starting the simulations. At fixed time intervals τG a Gaussian centered
along the trajectory of the CVs is added according to:
VG(S(x), t) = w
∑
t′=τG, 2τG... t′<t
e−
(S(x)−s(t′))2
2 δ2 , (2.6)
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Figure 2.4: Illustration of the MetaD procedure, adapted from reference [135]. Dots
represent structures, while yellow lines are representative of the biasing potential.
where s(t) = S(x(t)) is the value of the CV at the time t, w and δ are the height
and the width of the Gaussians, respectively. The accumulation of these Gaussians
along the simulation leads to the flooding of the free-energy minima, as illustrated in
Figure 2.4. In such a way the system is encouraged to escape the local minima and
to visit unexplored region in a reasonable simulation time. The main assumption
of MetaD is that the sum of the Gaussians provides the opposite profile of the free
energy, F (s), once the convergence has been reached and after an initial transient
time, which is necessary to fill the free energy minima:
lim
t→+∞VG(s, t) ∼ −F (s). (2.7)
Of note, the estimation of the free energy does not converge to a definite value,
but fluctuates around the correct result with a mean error being proportional to
the square root of w/τG. [136,137] Interestingly several variants of MetaD have been
developed in the last decade, among which it is worth to cite the widely adopted
Well-Tempered Metadynamics (WT-MetaD) and Bias-Exchange Metadynamics
(BE-META). In the first variant, WT-MetaD, the height of the Gaussians w
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decreases with time according to the equation w = w0 τG e−V (s,t)/∆T , where w0
is the initial bias deposition rate, τG is the time interval at which Gaussians are
deposited and ∆T is a temperature. [136] Of note, this adaptive bias allows a smooth
convergence to limt→+∞ VG(s, t) = − ∆T∆T+T F (s), enabling a rigorous estimation
of convergence and errors. In this framework, where the limiting cases ∆T = 0
and ∆T → ∞ correspond to canonical sampling and MetaD, respectively, the
parameter ∆T can be fine-tuned to increase the free-energy barriers crossing,
meanwhile restricting the exploration of the CV space to physically interesting
regions. The BE-META variant, instead, is a technique suitable to compensate the
problems related to the proper choice of CVs. [134] It is indeed well known that the
reconstruction of the free energy in MetaD is accurate only when: i. all the relevant
variables, related to the slow events, are included, ii. only a limited number of CVs
is used (usually not more than three since, for uncorrelated variables, the time
needed to rebuild the free energy surface scales exponentially with the number of
CVs). [137] This fact constitutes a major limitation when more CVs are required
or when it is difficult to select a priori a limited number of variables describing
the process: by combining replica exchange methods and MetaD, BE-META aims
to overcome this issue. Since this technique has been widely adopted within the
thesis, a more detailed description is following.
2.2.2 Bias-Exchange Metadynamics
BE-META is a combination of replica exchange techniques [130] and MetaD, whereby
multiple MetaD simulations (N) are performed at the same temperature T . Each
replica of the system is biased with a monodimensional potential acting on a single
CV Sk, with k = 1, ..., N (actually it is possible to bias more than one CV in each
replica, but this option is not considered in this thesis). Exchange between pairs of
replica are attempted at fixed time intervals. Considering two replica described
by coordinates xi and xj, with bias potentials VG(Sa(xi), t) and VG(Sb(xj), t), an
exchange is accepted with a probability Pab according to:
Pab = min(1, e
VG(Sa(xi),t)+VG(Sb(xj),t)−VG(Sa(xj),t)−VG(Sb(xi),t)
kb T ) (2.8)
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where kb is the Boltzmann constant and T the simulation temperature. These
exchanges enhance the ability of the system to efficiently explore a complex multi-
dimensional free energy landscape, aiding the system to cross the barriers which
are orthogonal to the reaction coordinates.
2.2.3 Free-energy reconstruction from BE-META trajecto-
ries
The output of the simulation consists in several mono-dimensional projections
of the free energy surface along each CV. To assess the convergence, it must be
verified that the bias potential grows parallel to itself: in this condition the force
from the bias cancels out the average natural force (free-energy gradient) on the
collective variable and the bias potential VG(S(x), t) of each replica is stable, being
an unbiased estimator of the free-energy. Hence, analysis of BE-META trajectories
allows to reconstruct the multidimensional free energy landscape of the system in
a reduced CVs space (a subset of all the initial CVs can be used to this aim). This
can provide information about its equilibrium properties.
To allow the free-energy reconstruction, the reduced CVs space is arbitrarily divided
in hypercubes, called microstates. Each structure sampled during the simulation
is assigned to a given microstate according to its CVs values, whereby the free
energy of each microstate is estimated exploiting the mono-dimensional free energy
profiles obtained from each replica by a weighted histogram analysis (WHAM)
approach. [131,138] The reliability of free energy estimation strongly depends on
microstate assignment, which should satisfy the following requirements: a) to
densely cover the configuration space explored during the simulation, including also
the barrier region; b) to be sufficiently populated to guarantee a good statistic; c)
the structures belonging to the same microstate should satisfy a similarity criterion
to allow for consistency. [139] To satisfy all these criteria care must be taken in
the choice of the reconstructed CVs space dimensionality and of the size of the
microstate.
Additionally, it is possible to cluster microstates into different metastable states,
in order to individuate the most significant local free energy minima. To this aim
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an approximate rate matrix among microstates is constructed and its spectrum is
analyzed as described in references [140,141]. The inverse of the obtained eigenvalues
provides the relaxation times (τ) of the system, which are related to the transition
time between different metastable states. The number of relaxation times determines
the number of metastable states composing the microstates space. In order to
consider only the relevant relaxation processes of the system, it is possible to choose
an appropriate number (i) of relaxation times, when a gap between τi and τi+1 is
present. [140] Finally, performing a commitor analysis, each microstate is assigned
to a metastable state, which corresponds to one of the main minima of the system.
All these analysis can be performed with the help of the Metagui tool. [141]
2.3 Docking techniques
Most of the processes occurring in the cells involve the interaction between two
or more biological systems. The molecular characterization of these recognition
processes, as well as the ability to predict possible interactions among molecules,
are crucial elements for a deep comprehension of biological mechanisms, for diseases
research and for the development of drugs. [142,143] These non-trivial tasks can be
achieved computationally by means of molecular docking techniques, a powerful
methodology able to predict the three-dimensional structure and the binding
affinity of a molecular complex starting from the knowledge of the coordinates of
the unbound components (which can be proteins, nucleic acids, peptides or small
molecules). The initial unbound structures may come from crystallographic and
NMR experiments, as well as from homology models; in the case of small-molecules
or ligand, the input conformation can be also created de novo. [144]
During the docking procedure several possible complex models, which are commonly
known as decoy poses or binding modes, are generated. Since the molecular
recognition process can be associated to a free-energy landscape, all these poses
represent different local minima: the aim of docking is to individuate the global free-
energy minimum corresponding to the native binding mode. This procedure involves
two basic steps: sampling and scoring. The sampling step consists in a search
algorithm that allows the exploration and generation of several possible binding
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modes, varying the conformation and the orientation of the ligand in the binding
site of the receptor. The scoring procedure involves the use of some quantitative
method (referred to as scoring function) to rank the generated decoy poses and to
distinguish native-like poses from non-native ones. These two highly interrelated
tasks, which are generally iterated until convergence to a solution of minimum
energy, can be treated at different levels of accuracy in diverse docking algorithms.
Since they are the basis of docking procedures a more detailed presentation will
follow in this chapter.
It is worth noting that the goals of molecular docking can go beyond the prediction
of a reliable binding pose and of the associated chemical intermolecular interactions.
Several algorithms indeed aim also to individuate active molecules from large
compounds libraries, to rank ligands in a database and to give an estimation of
binding affinities towards a specific target. [145] Thanks to all these features, the
docking programs have gained increasingly importance and are currently used for a
wide range of applications. In the field of computer-aided drug design & development
docking software are exploited both in virtual screening campaigns, to individuate
novel molecules targeting proteins of therapeutic interest or nucleic acids, as well
as in the phase of lead compounds optimization. [146] The description of molecular
interactions underlying protein-protein or protein-ligand binding is also useful in
the context of protein engineering, to identify hot residues which could be mutated
to favor or discourage binding. [147,148] Additionally, in silico analysis of protein
mutations and of their influence on ligand binding is helpful to provide the basis
for the development of drug-resistant ligands. [144] Another possible applications
of docking techniques consists in the elucidation of the molecular mechanisms of
selectivity, which can be achieved by docking the same molecule into different
receptor targets. [149]
This wide variety of needs is reflected by a great number of software packages
devoted to perform molecular docking, which can differ for several factors including
scoring function, exhaustiveness of the sampling and speed.
In the following, after an introduction about the main challenges in the docking
field, which include the sampling and scoring problems, I will present two popular
docking software exploited in this thesis: Glide, [150–152] a program distributed by
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the Schrödinger company (Schrödinger, LLC, New York), which offers diverse
ligand docking options ranging from virtual screening to more accurate protocol;
and HADDOCK, [153] an information-driven docking software, developed and freely
distributed by the Bonvin group, that was initially designed for the prediction of
protein-protein interactions but that has been recently adapted to handle also the
docking of ligands and peptides. [154,155] Finally, I will introduce how cluster analysis
methods can be used to better analyze and interpret the decoy poses.
2.3.1 Sampling and Scoring
As already outlined, docking is based on two main stages: a sampling procedure,
which generates a wide variety of possible binding modes, and a scoring step that
aims at individuating native or near-native poses. Even if it is helpful to make a
clear distinction between searching and scoring methodologies, the two tasks are
strongly interrelated. Docking programs indeed make use of them iteratively and
often a scoring-function is used to guide the generation of the poses. [146,156] Usually
rough scoring-functions, which give priority to speed with respect to accuracy,
are used to guide the search algorithms, when a huge number of poses must be
considered; more accurate scoring-functions are instead applied for the ranking
of the final poses. The accuracy of the docking depends on both these stages,
specifically on the exhaustiveness of the sampling, which ideally should be able to
generate the native binding mode, and on the reliability of the scoring-function,
which should be able to rank as first the correct binding mode. Obviously, higher
accuracy implies higher computational costs and thus a lower number of compounds
that can be analyzed in the same time. Depending on the needs different search
algorithms and scoring-functions can be used: in the following I will present a brief
description of the most used ones.
Sampling
The binding process involves changes in the respective position and orientation
of the binders, but also entails conformational rearrangements that can occur
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in both the receptor and the ligand. Computing exhaustively all the possible
binding modes, considering also molecular flexibility, is extremely expensive from a
computational point of view. To handle this issue docking algorithms can adopt
mainly three strategies with different degrees of exhaustiveness: i) rigid docking, in
which both the receptor and the ligand are treated as rigid bodies and only the
six rotational and translational degrees of freedom are explored; ii) rigid receptor
and flexible ligand, in which also the conformational degrees of freedom of the
ligand are sampled; iii) fully or partially flexible protein with flexible ligand, where
all the degrees of freedom of the ligand are considered and few or all the relevant
conformational degrees of freedom of the protein are also investigated. [145] Currently,
to have good efficiency, balancing speed and accuracy, the most popular docking
method treats the ligand as flexible and the receptor as a rigid-body. [157]
The sampling is performed by applying incremental modifications in the structural
parameters of the ligand, which include the translational, rotational and conforma-
tional (e.g. torsional angles) degrees of freedom. Mainly two methodologies can be
adopted to perform the sampling: systematic and stochastic. In the first case, by
performing gradual variations in each structural parameters, the algorithm explores
the free-energy landscape associated to the conformational space until convergence
to a solution of minimum energy. [158] Even if this method is effective in finding
free-energy minima, it is clear that its computational cost increases when handling
highly flexible ligands: in this situation indeed the number of combinations of
structural parameters would enormously increase, leading to a phenomenon known
as combinatorial explosion. Conversely, in stochastic methodologies the structural
parameters of the ligand are randomly changed at each step, allowing for the
generation of a wide variety of possible solutions. Stochastic algorithms, including
Monte Carlo, Genetic Algorithms, Tabu Search and Swarm Optimization, can be
employed to accept or reject the proposed solutions according to a probabilistic
criterion, in order to limit the computational cost of the procedure. The main
drawback of this methodology is that there is no guarantee of convergence to the
global minimum, thus multiple independent runs should be performed to increase
the probability of reaching the optimal solution. [145]
While ligand flexibility is often included in algorithms by sampling its possible
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conformations on the fly, receptor flexibility still constitutes one of the major chal-
lenges in the docking field. This aspect, despite being often overlooked, plays an
essential role in the process of molecular recognition: indeed the receptor commonly
experiences structural rearrangements upon ligand binding due to the induced fit
effect. These changes can range from small variations, limited to the region of
binding site, to more significant conformational rearrangements, involving elements
of secondary and tertiary structure. [158] Additionally, it should be considered that
the free receptor could exist in multiple conformational states rather than as a
unique native state. [159] Even if an exhaustive treatment of this aspect is often out
of the reach, diverse methods can be adopted to deal with this issue. These can be
divided in five classes, which differ in the degree of exhaustiveness and accuracy,
according to the classification of references [145,160]:
i) soft-docking, where the repulsive contribution of the van der Waals potential is
softened to permit small atoms overlaps, allowing the ligand to accommodate more
easily in the binding pocket. This method is fast but it is adequate only when
small local receptor motions occur.
ii) Side-chain flexibility, where diverse side-chain conformations are sampled while
backbone is kept fixed. Also this approach can be employed only for local motions
of the receptor.
iii) Molecular relaxation, usually performed in post-processing steps using Monte
Carlo or MD minimization. It is useful to optimize the complex structure and to
evaluate its stability.
iv) Ensemble docking, in which the ligand is docked in multiple receptor confor-
mations generated before the run. These putative structures can come both from
NMR and crystallographic experiments or from computational models (e.g. MD
and molecular modeling). Even if this method seems to be quite promising, a major
drawback is constituted by the lack of protocols that help in a priori selection
of an optimal subset of protein structures. [161] Additionally also this method fails
when large receptor structural rearrangements occur.
v) Collective degrees of freedom approaches, that aim at considering the full flexi-
bility of the receptor by reducing its high-dimensional conformational landscape
in a representation that captures only the dominant motion modes. These results
can be achieved by using techniques such as normal mode analysis or principal
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component analysis. Its use is limited in several applications because of the high
computational cost required.
Scoring
The main goal of a scoring-function is to individuate native or near-native poses
among the huge amount of binding modes that are generated during the sampling
step. Additionally, they aim at discriminating active from inactive ligands and
at estimating the binding energies of diverse compounds, possibly ranking them
according to their affinity. [145] The form of a scoring-function is a mathematical
equation that takes into account the physical properties of the two interacting
molecules. To be able to treat several compounds in a reasonable computational
time, diverse assumptions and simplification are usually adopted. Some scoring-
functions merely consider the properties of the non-covalent ligand receptor interface
(e.g. salt bridges, hydrogen bonds, hydrophobic contacts). [146] Conversely, more
complicated and time-consuming functions take into account also desolvation
contributions and entropic effects. [158,162]
In this context, diverse scoring-functions, offering different accuracy vs speed
balances, have been developed. Mainly three classes can be individuated: force-
field-based, empirical, and statistical scoring-functions. [163]
Force-field-based approaches rely on a molecular mechanic formalism, where the
estimation of the binding energy is computed as the sum of bonded (bond stretching,
angle bending and torsional energy) and non-bonded terms (electrostatic and van
der Waals interactions). This kind of functions can be extended by introduction
of terms accounting for desolvation and entropic energies. [157] A major limitation
of these methods is the high computational cost required, due to the relatively
complicated functional form. Additionally, it has been observed that these scoring-
functions often overestimate interactions between charged atoms. [145]
A second class of scoring-functions is represented by the empirical methods, which
are based on the concept that it is possible to relate the binding free energy
with a weighted sum of unrelated variables. [145] As in the case of force-field-based
approaches, the scoring-function is a sum of terms describing the general features
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of the complex (e.g. hydrogen-bonds, hydrophilic and hydrophobic interactions,
desolvation and entropic effects). However these terms have a simplified functional
form and are weighted with proper coefficients, which have been optimized to
reproduce known binding affinity data of experimentally determined complexes.
The parametrization of these coefficients is usually conducted with regression or
machine learning approaches. [144] While these functions allow a faster scoring than
the force-field-based ones, their accuracy is strictly related to the quality of the
training set and it is limited by the over-simplification of some physical interactions.
Finally, there are statistical (also called knowledge-based) potentials, which rely on
a statistical analysis of experimentally determined receptor-ligand structures. The
main assumption here is that frequent contacts, appearing in several complexes,
correspond to favorable interactions. [157] These frequency distributions are thus used
to construct an interaction potential that is function of the distance between atom-
types. The relationship that links the frequency of a contact and the associated
energy term is provided by the inverse-Boltzmann equation. These scoring-functions
are fast and have the advantage that, in their interaction potential, are included
also those features that can not be easily modeled explicitly. [146] However, the
accuracy of this method strongly depends on the number and diversity of the
training set used to create the potential.
To improve the performance of these scoring-functions, which are all affected
by some limitations, it is possible to use a consensus scoring approach. In this
strategy diverse docking software and functions are used and the scores obtained
are combined through a consensus scheme. It has been shown that this approach
provides notable improvement in terms of accuracy. [164]
Currently, most scoring-functions show good performance in the identification of
native or near-native binding modes, however it is still challenging to achieve a
reliable estimation of the free energy of binding, as well as a proper ranking of
different compounds toward a target receptor. Indeed in the scoring functions
developed to date, it has been observed a weak correlation with experimental
binding affinities and a diversity in the performance depending on the target. [161]
These difficulties in reproducing experimental data can be ascribed to several
reasons, which include a poor quality of the input structures, a rough treatment of
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long-range interactions and receptor flexibility and particularly an inappropriate
handling of solvent and entropic effects. [147,165]
Even if it is recognized that conformational entropy plays a relevant role in the
determination of binding free energy, its contribution is still neglected or oversim-
plified in most of the docking software. This is due to the enormous computational
cost required to its rigorous quantification, which is not practicable especially
for big systems as protein-ligand complexes. [145] Conversely, some methodologies
have been developed to deal with solvent effects. In this context, a special atten-
tion is given to structural waters, which are present in approximately 65% of the
crystallographic complexes mediating receptor-ligand recognition. [144] It has been
shown that the inclusion of structural waters in docking calculations allows the
formation of hydrogen-bonds networks between the ligand and the binding pocket,
leading to a significant improvement in accuracy. [144,158] In addition, some methods
that explicitly account for water molecules during the docking process have been
proposed, [166–169] but they are computational expensive due to the large number of
degrees of freedom associated to solvent molecules. To save computational time it
is possible to treat water molecules implicitly, representing them as a continuum
dielectric medium. The most widespread approaches based on this strategy are
the Molecular Mechanics Poisson-Boltzmann surface area (MM-PB/SA) and the
Molecular Mechanics generalized-Born/surface area (MM-GB/SA) models. [170–172]
According to these techniques the solvation contribution can be computed con-
sidering separately the polar and non-polar terms. The first term, which refers
to the energy needed to transfer the solute from a continuum medium with a
low dielectric constant ( = 1) to a medium with the dielectric constant of water
( = 80), is computed by solving either the Poisson-Boltzmann equation or by using
the simplified Generalized Born model. Specifically, in this last model the solute is
represented as a set of spheres characterized by a different dielectric constant with
respect to the external solvent. The non-polar contribution instead, which aims to
include an approximation of hydrophobic-hydrophobic interactions, is considered
proportional to the solvent accessible surface area (SASA). These approaches are
usually employed in a post-processing phase to rescore the previously generated
docking poses, with the aim to improve the accuracy of ranking and binding en-
ergy predictions. Of note, MM-PB/SA and MM-GB/SA have been successfully
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employed to estimate the free energy of binding in diverse protein–ligand interac-
tions. [173,174] They usually show good correlations with experimental data, being a
good compromise between efficiency and efficacy.
2.3.2 Glide software
Glide (Grid-based Ligand Docking with Energetics) software is a docking program
distributed commercially by the Schrödinger company. It makes use of a systematic
conformational search and of a scoring-function that relies on the combination of
empirical and force-field-based terms. Specifically different protocols, with different
accuracies, can be used in this framework: i) Standard-Precision Glide (SP), which
uses a soft scoring function with the aim of identifying a wide pool of possible binders
minimizing false negatives and ii) Extra-Precision Glide (XP), characterized by a
harder scoring-function, which attempts at minimizing false positives by inclusion
of severe penalties. [150–152] This last approach is more demanding than the SP mode
but it is useful during leads optimization or when few compounds to be synthesized
must be individuated.
During the sampling step, hierarchical filters are used to approach an exhaustive
systematic search of the conformation, position and orientation of the ligand within
the receptor binding pocket. At a first stage, several ligand conformations are
generated by exploring its torsional angle space and the ones with lower torsional
energy are selected. Secondly, all the possible positions and orientations of these
conformers on the active site of the receptor are screened. To allow a fast evaluation
of all these placements, the energetic-like properties of the protein are represented
on a grid, assigning precomputed scores (derived from a discretized version of the
empirical ChemScore function [175]) to boxes of 1Å3 dimensions. This kind of score
penalizes steric clashes and is able to recognize favorable hydrophobic interactions,
hydrogen-bonds and metal-ligation interactions. Afterwards, starting from the best
poses (typically few hundreds) herein individuated, the ligand is minimized in the
field of the receptor, using a molecular mechanics scoring function (OPLS-AA)
and a multi-grid strategy: in order to guarantee more accuracy the side-dimension
of the boxes, which store the Coulomb/van der Waals fields of the receptor, are
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gradually decreased in the area where the two molecules are in contact. Finally, the
best three to six lowest-energy decoys are minimized with a Monte Carlo approach:
this last phase is critical to have accurate docking poses.
In the case of Glide XP mode, the sampling method is more extensive and it is
based on an anchor and refined growth strategy. The set of poses derived from the
SP procedure are exploited to identify ligand anchor fragments, which are then
used to reconstruct the whole molecule by growing one side-chain at time. Several
cycles of minimization and XP scoring are run to guide the growing, in order to
reduce the scoring penalties and to refine the best poses. As a result, this algorithm
is able to locate an increased number of penalty-free poses.
Both in SP and XP modes the flexibility of the receptor is not considered, however
scaled van der Waals radii of selected atoms can be used to allow an easier
accommodation of the ligand in the binding pocket.
The Glide scoring function (GScore), which is an extension of the empirical Chem-
Score function, can be described as follows: [150]
GScore = Clipo−lipo
∑
f(rlr) + Chbond−nn
∑
g(∆r)h(∆α)+
+ Chbond−nc
∑
g(∆r)h(∆α) + Chbond−cc
∑
g(∆r)h(∆α) + Cmetal−ion
∑
f(rlm)+
+ CrotbHrotb + Cpolar−phobVpolar−phob + CcoulEcoul + CvdwEvdw + solvation terms.
(2.9)
In this equation the summations are extended over all the ligand-receptor (lr) atoms
pairs that are defined as lipophilic (first term), which are involved in hydrogen-bonds
(second to forth terms) or that forms ligand-metal (lm) interactions (fifth term).
The f , g and h functions give a full score (1.00) to distances ∆r or angles ∆α that
adopt values within defined cut-offs; conversely, they assign scores between 1.00 and
0.00 when ∆r or ∆α have values outside these limits but within a larger threshold.
As an example in hydrogen-bonds, a full score is assigned for hydrogen-acceptor
distances in the range 1.85± 0.25Å, while the score is linearly decreased to 0.00 for
distances between 2.10Å and 2.50Å. The coefficients CX have been optimized using
a simulated-annealing algorithm testing training sets of 1000 drug-like molecules
towards sixteen receptor sites.
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The first term in 2.9 rewards favorable lipophilic interactions and is derived by the
hydrophobic grid potential. The hydrogen-bonds terms (second to forth) reward the
formation of hydrogen-bonds, weighting their contributions differently depending
on whether the donor and acceptor are both neutral (nn), one is charged and the
other neutral (nc) or both are charged (cc). The fifth term concerns metal-ligand
interactions involving anionic receptor atoms; the sixth term assigns a penalty for
freezing rotatable bonds, while the seventh term rewards polar but non-hydrogen-
bonding atoms in a hydrophobic region. A major contribution to the GScore
is given by the ligand-receptor Coulomb and van der Waals interaction energies
(eighth and ninth terms). Herein the reduction of net ionic charges for formally
charged groups (e.g. guanidiniums and carboxylates) is employed to have a better
overall prediction of the interaction energy. Finally, a contribution is given by the
incorporation of solvent effects: Glide explicitly dock water molecules in the binding
pocket of the best-scored poses to check and evaluate with empirical scoring terms
the exposure of various groups to water. Particular attention is given to exposure
to solvent of charged groups, additionally situations as water molecules trapped in
hydrophobic pockets are penalized.
In Glide XP-mode this scoring-function has been further extended. Specifically the
following features have been included: i) hydrophobic enclosure contribution, which
accounts for groups of lipophilic ligand atoms that are surrounded on two opposite
sides by lipophilic protein atoms; ii) improvements in the scoring of hydrogen
bonds, by considering special neutral-neutral hydrogen bonds in hydrophobic
environment and by using five different categories of charged-charged hydrogen
bonds; iii) detection of pi-cation and pi-pi stacking interactions. Additionally, due
to the improved sampling, higher penalties can be assigned to violations concerning
solvation effects.
Overall it has been shown that Glide performs well both in pose and binding affinity
predictions. It has been reported that it outperforms other docking programs, such
as GOLD, FlexX, HYDE and AutoDock Vina; [176,177] however, similarly to the other
software, its efficacy is lower when dealing with highly flexible ligands. [161] Moreover
it has been demonstrated that the quality of the outcomes strongly depends on input
structures preparation, thus it is worth, prior to performing docking, to correct
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protonation and tautomeric states, missing ligand atoms, protein side chains,
hydrogen atom positions, and side-chain conformational errors in crystallographic
structures. The Schrödinger company offers some programs to handle this issue,
specifically these are the Protein Preparation Wizard, for the optimization of the
receptor structure, and LigPrep, for ligand preparation.
As already outlined binding-energy predictions can be further improved by using
MM-GB/SA or MM-PB/SA methods, which can give estimation of desolvation
energy by employing implicit solvent model. To this aim the Schrödinger suite of
programs Prime [178,179] can be exploited. Prime MM-GB/SA takes as input the
single minimized receptor-ligand poses obtained from the docking screening to
refine and rescore them. For the refinement the Prime local optimization feature is
utilized, while for the binding-energy prediction it is employed a combination of the
OPLS-2005 molecular mechanics force-field and of the Generalized-Born/Surface
Area continuum solvent model. With Prime MM-GB/SA it is also possible to
partially account for receptor flexibility defining a protein region within a certain
distance from the ligand, which is relaxed during the process. Different options are
available for the minimization: it is possible to minimize only polar hydrogens, only
side-chains or both side-chains and backbone. Obviously, the computational cost
required is higher when more accurate options are selected and when a larger protein
region is defined. Another possibility consists in constraining the movements of
the flexible residues by applying an harmonic potential, to avoid high deviation
from the receptor initial structure. Several papers have shown that binding energy
predictions are substantially improved by using Prime MM-GB/SA method, leading
to good correlations with experimentally determined affinities. [180,181]
2.3.3 HADDOCK
HADDOCK (High Ambiguity Driven biomolecular DOCKing) is a docking program,
originally developed by the Bonvin group in 2004 to predict protein-protein binding
modes by exploiting data from NMR (Nuclear Magnetic Resonance) titration or
mutagenesis experiments. [153,182–184] Unlike Glide, the main goal of HADDOCK is
to provide reliable binding modes for unknown complexes rather than screening
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large number of compounds. The characteristic feature of HADDOCK is that,
differently with respect to traditional docking protocols, for which only the initial
coordinates of the unbound components are considered, it makes use of experimental
or predicted information during the docking process. These data are not merely
used as filters in the post-processing steps, but they are employed directly to drive
the calculations, reducing the search in a fractions of the whole available interaction
space (see Figure 2.5).
From 2004 HADDOCK has been extended and currently it can deal with molecules
of different nature, such as proteins, peptides, small molecules, nucleic acids and
oligosaccharides. Additionally, several sources of experimental information can
now be used besides the mutagenesis data and the NMR-derived parameters (e.g.
chemical shift perturbations, nuclear Overhauser effect distances and residual dipo-
lar couplings). These sources include chemical cross-linking, small angle X-ray
scattering (SAXS), cryo-electron microscopy (cryo-EM), collision cross section
(CCS) data, as well as interface predictions obtained with bioinformatics methods.
The derived information can be either translated in structural restraints or in addi-
tional scoring terms. Usually low resolution data, e.g. those derived from SAXS,
cryo-EM or CCS experiments, are only considered in the scoring, by computing
Figure 2.5: Representation of how information-driven search methods can reduce the
sampling in a section of the conformational space explored by global search methods. The
set of solutions generated by information-driven search are more homogeneous. Figure is
reprinted from reference [185].
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Figure 2.6: Representation of how AIRs are generated. Any atom of the active residue i
of protein A is forced to interact with the atoms of all the active and passive residues (x,
y and z) of protein B. Analogous restraints are applied on the other active residues k
and z, but not on the passive residues j, x and y. Figure is reprinted from reference [186].
differences between the experimental values and the back-calculated ones. Con-
versely, information such as chemical shift perturbations, alanine-scan mutagenesis
and cross-linking, are translated into distance restraints between residues. Since
the exploited experimental techniques are usually able to highlight the residues
engaged in interactions but are not able to specify which are the pairs of interacting
residues, different levels of ambiguity (one-to-one or one-to-many) can be assigned
to these distance restraints. To deal with ambiguous interaction restrains (AIRs)
HADDOCK classifies residues as active or passive: the first ones are forced to
interact at the interface with passive or active residues of the other molecule,
otherwise penalties are applied; the second ones instead can or can not interact
(see Figure 2.6). A network of AIRs is then generated, by defining an effective
distance (deffiAB) between each active residue i of protein A and all the active and
passive residues of protein B, according to this formula: [182]
deffiAB = (
Natoms∑
miA=1
NresB∑
k=1
Natoms∑
nkB=1
1
d6miAnkB
)− 16 (2.10)
where Natoms are all the atoms of a given residue and NresB indicates all the
active and passive residues for protein B. The d−6 summation is used to mimic
the attractive contribution of the Lennard-Jones potential; additionally it allows
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to have short effective distances (and thus to satisfy AIRs) when any two atoms
of the proteins to be docked are in close proximity. These effective distances are
restrained by applying a flat-bottom potential, which behaves harmonically up
to violations of 2Å from the target value (usually set to 2Å, that corresponds to
real distances between 3 and 5Å) and that is smoothly linearized after the upper
bound to avoid large forces. The criteria to define active and passive residues
are not universal and depend on the experimental data available and on their
interpretation. Generally, active residues are the ones that are experimentally
identified as interacting residues at the interface, while passive residues are defined
as the neighbors of active residues with high (>40%) solvent-accessibility.
The docking procedure of HADDOCK is constituted by three steps:
• it0, a first docking stage by rigid-body energy minimization. The two
molecules are first separated and randomly rotated around their center of
mass; then their relative orientation is optimized and they are subjected to
rotational and translational energy minimization. To explore as much as
possible the interaction space, it is advisable to generate a large number of
models (∼ 1000) and to select a fraction of them (∼ 200) for the subsequent
refinement. The selection is performed by scoring the models as described in
the following.
• it1, a semi-flexible refinement step in torsion angle space. Each model from
it0 is optimized applying a three-stage simulated-annealing protocol followed
by a short energy minimization to relax the poses. During this procedure the
flexibility of side-chain and backbone atoms belonging to interface residues,
i.e. all residues within 5Å from the partner protein, is gradually allowed. A
further selection of the models to be refined in the following stage, based on
the HADDOCK score, can be performed.
• water, a final refinement step in a layer of explicit water. During this stage
few changes in the binding modes are expected, however it should improve
the reliability of the simulations and the scoring of the poses by optimizing
the hydrogen-bond networks and the electrostatic interactions at the interface.
All the refined docking poses are scored and saved as output.
58
2.3. Docking techniques
In each of this stage and for each model, an HADDOCK score (HS) is computed.
The form of this score is a sum of weighted energy-like terms according to the
following equation:
HS = wvdw Evdw +welecEelec +wdesolv Edesolv −wBSABSA+wairEair; (2.11)
where Evdw and Eelec are the van der Waals and electrostatic energy terms, Edesolv
is an empirical desolvation contribution, [187] BSA is the buried surface-area and
Eair is the ambiguous interaction restraint energy. The weights wx vary at each
of the three stages of the docking protocols, guaranteeing an adequate scoring-
function for the goals of each step. In order to identify the best poses, expected to
be the native-like ones, a cluster analysis is usually performed on all the models
produced in the water stage: this is done following a structural similarity criterion
as described in section 2.3.4. After this procedure an energetic value is assigned
to each cluster, which is obtained by averaging the scores of the single binding
modes (or of the N best binding modes) belonging to it. The best scored cluster
is expected to be a reliable representation of the native, or near-native, complex
structure.
Several variants and options to improve the efficacy of this program are available. To
consider molecules flexibility, besides the flexible-refinement stage, it is possible to
use ensembles of ligand and receptor structures as input. Additionally, HADDOCK
is able to model multimeric molecular assemblies, handling up to six different
molecules. [183] A novel methodology, called Flexible Multi-domain Docking, has
been proposed to deal with significant conformational changes upon binding: in
this approach the flexible molecule is represented as a collection of sub-domains
connected by restrains; these separated domains are then docked to their partner
simultaneously using the multi-body docking option. [185,188] Moreover, updated
protocols to model protein-ligand and protein-peptide interactions have been
recently published. [154,155] Finally, different clustering algorithms and methods to
estimate binding affinities have been proposed. [189–191]
Of particular interest is the possibility to use a solvated docking protocol in which wa-
ters are explicitly modeled since the first stage of the docking procedure. [166,192] This
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protocol includes modifications mainly in the it0 stage. According to this method-
ology the two proteins are initially solvated in explicit shell of water molecules,
then a rigid-body minimization is performed to form a complex, treating each
protein and its associated hydration layer as one rigid-body. After full removal
of non-interfacial waters, a biased Monte Carlo approach is iteratively adopted
to remove water molecules at the interface until only 25% of them remains. The
Monte Carlo procedure is driven by the propensity to find water-bridged amino
acid-amino acid contacts at the interface, as derived from the analysis of several
protein-protein crystal structures. Afterward, a further rigid-body energy mini-
mization is performed on the docked molecules and the remaining water. From
this point on, the canonical HADDOCK procedure is employed on the resulting
models, which include the remaining water molecules. It has been shown that
despite docking results do not always improve by using this protocol, the scoring is
improved and the water molecules at the interface are correctly positioned.
Currently HADDOCK is one of the most used and cited docking programs for the
prediction of unknown protein-protein interactions. [193] It is periodically tested in
both CASP (Critical Assessment of Techniques for Protein Structure Prediction)
and CAPRI (Critical Assessment of PRedicted Interaction) evaluation and it has
always achieved successful results. [194,195] However, HADDOCK remains mainly
effective for the prediction of binding-modes and is not designed to be used in the
screening and ranking of several compounds.
2.3.4 Cluster analysis
Cluster analysis is a post-processing methodology designed to gather objects sharing
common features into groups (clusters). This approach is widely adopted in diverse
applications, including statistical data analysis, data mining and bioinformatics. In
the field of computational biology this technique is mainly applied to analyze the
huge amount of data deriving from molecular dynamics simulations or to organize
the several poses produced in docking calculations. It has been reported that the
use of clustering algorithms generally leads to improved results both in protein
structure prediction and in protein-protein docking. [190,196,197] Indeed this kind
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of statistical analysis helps in identifying near-native structures better than the
scoring-function alone, which is generally affected by high inaccuracies due to the
simplified physics it is based on. [190]
A key point when performing cluster analysis consists in defining a similarity
function that measures the distance between each pair of elements, giving rise to
a distances matrix. The most commonly used distance is the root mean square
deviation (RMSD) computed on the atomic coordinates of the molecules. Generally
in the post-processing phase of docking calculations, the poses are aligned on the
backbone atoms of the receptor and the RMSD matrix is computed on a subset of
the atomic coordinates of the ligand (this kind of measurement is often referred to
as ligand interface RMSD).
After this preliminary step, a wide variety of algorithms is available to group
together the different poses. Within this thesis I will make use of the clustering
algorithms proposed by Daura et al. in 1999, [198] which is implemented both in
HADDOCK and in GROMACS. According to this algorithm the procedure to
define clusters is the following: i) compute the RMSD matrix; ii) given an RMSD
cutoff, compute the number of neighbors (i.e. objects with a distance lower than
the cutoff) for each element; iii) define a cluster identifying the element with the
highest number of neighbors and all its neighbors; iv) repeat steps ii and iii on the
elements that have not yet been clustered until no more clusters, with a number
of elements above a threshold, can be generated. The parameters that must be
provided by the user, and which must be optimized according to the investigated
system, are the RMSD cutoff and the minimum number of elements that are
necessary to define a cluster. It is worth noting that this algorithm belong to the
group of hard clustering approaches, in which one element can be assigned only to
one group.
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Chapter 3
Predicting the effect of
cyclopeptide N -methylation on
integrin affinity
Cyclopeptides are a promising class of compounds that can be used as therapeutics
for the modulation of protein-protein interactions. Their favorable pharmacokinetic
properties, as well as their target selectivity, can be further improved by the
introduction of chemical modifications, such as N -methylation or acetylation.
These widely adopted approaches have found successful applications in the context
of integrin inhibition.
Despite all these advantages, the use of cyclopeptides has been limited due to the
inherent difficulties to predict in silico their three-dimensional structure and their
inhibitory activity. Because of these challenges, their development and optimization
have been mainly based on empirical approaches, requiring expensive and time-
consuming synthesis campaigns. In this context the employment of computational
tools could be useful in accelerating the drug design process.
In the following chapter I am going to describe a multi-stage computational protocol
that has been optimized during my thesis work to achieve reliable prediction
concerning cyclopeptides conformations and their interplay with receptor affinity.
This approach is based on an exhaustive conformational search of the ligands,
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performed by means of an enhanced sampling technique (i.e. Bias-Exchange
Metadynamics), followed by docking calculations and re-scoring via MM-GB/SA.
The reliability of this strategy was tested investigating the impact of single and
multiple N -methylations on the equilibrium conformation of five RGD (Arg-Gly-
Asp) containing cyclic hexapeptides, which were previously generated by the group
of professor Kessler to increase their selectivity for αIIbβ3 integrin. The method
proposed proved its efficacy: the conformational sampling was in good agreement
with available NMR data and it was possible to discriminate between integrin
binders and non-binders. Additionally, I offered a structural rationale for how
N -methylation modulates peptide affinities for αIIbβ3 integrin.
The approach herein described can represent a promising in silico screening strategy,
that can be exploited to predict the effect of chemical modifications in cyclopeptides
conformations before entering expensive synthesis and binding experiments.
3.1 Introduction
In recent years there has been a growing interest in the study and development of
cyclic peptides, which represent a promising class of compounds for the inhibition
of protein-protein interactions and other challenging therapeutic targets. [56,199]
Cyclopeptides present several favorable pharmacokinetic properties, showing en-
hanced stability and better bioavailability with respect to their linear counterparts
and being safer and more target-specific than small molecules. In particular, they
provide unique opportunities to achieve enhanced binding affinity by increasing the
molecular size and the contact area, meanwhile decreasing the conformational free-
dom of the ligand and reducing possible entropic penalties. [200] These approaches
resulted to be particularly efficient in the context of integrin inhibition, where
several cyclopeptides reached advanced stage in the drug development pipeline.
Herein cyclization helped in constraining peptides, already in the unbound state,
in specific pre-organized conformations, which could be suitable for the binding to
a specific receptor. [79,201–203]
In this context, introduction of chemical modification is a frequently used strategy
to modulate the conformational properties of synthetic cyclic peptides and to
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influence their lipophylicity, proteolytic stability, and bioavailability. [61,204] Specifi-
cally, it has been shown that backbone N -methylation, commonly occurring also
in natural peptides, can be used to modulate the cyclopeptides target specificity,
their binding affinity and the related biological down-stream signaling. [61,205] These
effects are generally ascribed to the ability of N -methylation in constraining the
peptide backbone conformation. [206]
Despite this interest, the difficulties in predicting de novo the conformations
adopted by cyclopeptides and consequently their binding affinity are limiting their
development as drugs. In this context, the optimization of cyclopeptides remains
mainly based on empirical approaches, demanding brute force synthesis of different
compound’s variants in order to individuate the ones with appropriate target-
binding properties. Recently, improvements are being observed in computational
techniques able to deal with the modeling and docking of cyclopeptides. [207,208]
The main challenges to be faced by computational methods rely in the constrained
geometry of macrocycles, which can populate several conformations separated by
high free-energy barriers. Additionally, the introduction of chemical modifications,
which can strongly affect the equilibrium between conformers, further entangles
the correct prediction of their preferred conformations and, consequently, of their
binding affinity. [199,202]
In this scenario, the original “lock-and-key” binding concept, in which a frozen
ligand accommodates into a static receptor, had to be revisited in favor of more
dynamic models of molecular recognition able to account for the conformational
preferences of the ligand. [181,209,210] However, due to the constrained nature of
cyclic peptides, the algorithms implemented in the common docking software are
generally not suitable to this aim. Herein, the poor conformational sampling of the
cyclopeptides and/or the inclusion of unrealistic high-energy ligand structures as
input strongly affect the performance of molecular docking, compromising accuracy
in the scoring of the decoy poses. [211] It has been suggested that an exhaustive
and reliable study of cyclopeptides conformations prior to docking calculations is
strongly advisable to get better computational efficiency and predictability. [207]
Nevertheless, exhaustive conformational sampling of cyclopeptides is not trivial: in
these molecules the transition from one conformation to another requires a concerted
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motion of several dihedral angles, [207,212] complicating the investigation of their
equilibrium conformation with common simulation techniques. In this framework,
Metadynamics (MetaD) represents a valuable enhanced sampling methodology for
the acceleration of rare events, able to provide reliable estimations of the populations
of the accessible conformers, as well as relative heights of free-energy barriers
(see Section 2.2). [127,132,133] The applicability of MetaD in analyzing cyclopeptides
conformations had been previously tested in our laboratory, showing that it could
be helpful in discriminating αvβ3 integrin binders from non binders. [75] Additionally,
similar approaches have been also recently adopted by other groups, confirming
the reliability of this methodology. [199,208] In the work described in this chapter I
have further explored the possibilities and the applicability range of this enhanced
sampling technique, adopting the Bias Exchange variant of MetaD (BE-META), [134]
and extending the protocol by introduction of docking calculations and rescoring
via MM-GB/SA methods. The employment of BE-META in place of plain MetaD
allowed to increase the number of biased collective variables, enabling a systematic
bias of all the backbone dihedral angles of the investigated cyclopeptides, ultimately
resulting in improved sampling and convergence. This technique also allows to easily
reconstruct multidimensional free-energy landscapes of the studied system. [141]
As already outlined, cyclization is a widely used strategies in the field of integrin
inhibition, to constrain peptides in specific conformations with ideal features for the
binding target (i.e. proper orientation and distance of the pharmacophores). These
peptides are usually based on the RGD (Arg-Gly-Asp) integrin recognition motif
and their affinity and selectivity for different integrin subtypes is controlled by
the RGD motif’s environment, including the type and stereo-chemistry of flanking
residues, the number of amino acids in the cycle and the presence of chemical
modifications. All these features concur to regulate cyclopeptide affinity towards
a specific integrin both by means of direct interaction with the receptor and/or
by modulation of the RGD sequence conformation. [201] Thus, integrin inhibitors
represent an ideal field to test the applicability of the proposed computational
protocol.
Specifically, I decided to focus my attention on how cyclopeptides integrin affinity
is regulated by the introduction of chemical modifications. This represents an ideal
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Figure 3.1: 2D-structure representation of the investigated cyclic hexapeptides.
For each molecule its IC50 value for integrin αIIbβ3 is reported. [205] N -methylated amino
acids are shown in bold.
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Figure 3.2: Workflow. The multistage approach relies on a combination of: BE-META
conformational search, docking calculations, MM-GB/SA rescoring and cluster analysis.
Boxes in dark gray show the filters used after each stage. Boxes in light gray report
the number of structures (and how they are subdivided within the BE-META minima)
satisfying the filters conditions. [213]
test-case for the proposed approach that strongly relies on a conformational search:
indeed the introduction of these features is more likely to influence affinity through
conformational modulation than through direct interaction with the receptor.
To this aim, I reasoned to exploit a small library of head-to-tail cyclic RGD
hexapeptides, previously generated by Kessler and coworkers to improve their
selectivity towards αIIbβ3 integrin. [205] The five cyclopeptides of the library share
the same sequence of six amino acids and differ only in position and number of
backbone N -methylations. Despite these small variations, the affinities displayed
by the five cyclopeptides for αIIbβ3 integrin are largely different (see Figure 3.1)
ranging from 12 to 2000 nanomolar in terms of IC50 values. Applying the multi-stage
computational protocol based on the combination of BE-META conformational
sampling, docking calculations and MM-GB/SA rescoring (Figure 3.2), it has been
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possible to rationalize the conformational effects of N -methylation on the free
peptides and to highlight its interplay with receptor affinity. [213]
3.2 Results and Discussion
3.2.1 Preliminary BE-META calculations
It is known that backbone N -methylation can decrease the height of energy barrier
between the cis and trans amide bond isomers. [214] To investigate the impact of
N -methylation on cis-trans isomerization in the five studied cyclopeptides, I ran a
preliminary 400 ns ten-replicas BE-META simulation on each molecule, for a total
of 2 µs, using the settings described in Section 3.4. Each replica was biased on one
of the following ten CVs: the six Ω dihedral angles, which describe the planarity
of the peptide bond, and the φ dihedral angles of Arginine (R2), Aspartate (D4),
D-phenylalanine (f5) and Leucine (L6). The φ dihedral angles of Glycines were not
biased since these residues are considered the most flexible ones, as they lack the
side-chain. After convergence check, the free energy surfaces were reconstructed
and analyzed in a reduced six-dimensional space, defined by the Ω dihedral angles.
Consistently with observations previously reported, [58] the calculations revealed
that no significant isomer interconversion is present. Specifically, I found that
minima containing isomers characterized by cis peptide bond conformations were
always populated less than 10%. Accordingly, the subsequent investigation was
restricted to the trans-isomers conformational space, excluding the Ω dihedral
angles from the CVs.
3.2.2 Conformational analysis
Subsequent BE-META calculations were carried out biasing the φ and ψ dihedral
angles of all the non-Glycine amino acids (i.e. R2, D4, f5 and L6), running for each
of the five molecules an eight-replicas simulation of 320 ns, for a total length of
1.6 µs. The convergence was carefully checked monitoring the mono-dimensional
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Table 3.1: BE-META conformational analysis. [213] For each molecule, the popula-
tion of the minima (when populated more than 10%) and the experimental IC50 values
for integrin αIIbβ3 are reported.
Peptides1 N -methylated Minima population [%] IC50 [nM]2
residues A B C D
c(GRGDfL) - 96 - - - 195
c(GRGDfL) R 26 73 - - 12
c(GRGDfL) f 49 - 46 - 2000
c(GRGDfL) R,f 32 37 13 18 165
c(GRGDfL) R,f,L 18 82 - - 30
1 N -methylated residues are highlighted in bold.
2 See reference [205].
bias potential of each replica. Specifically I compared the bias potential profiles
obtained by averaging on the two halves of the simulations after an equilibration
time of 1 ns. In all the cases the energy-difference between the two halves was lower
than 2kbT , demonstrating that the potential was stable and that the simulation
reached convergence (Figure A.1).
The analysis and the reconstruction of the free-energy landscape have been per-
formed in a reduced space determined by the φ and ψ dihedral angles of R2,
f5 and L6: these are the amino acids alternately N -methylated in the different
cyclopeptides. These variables, which are a subset of the biased CVs, have been
selected after several tests and they were shown a posteriori to accurately describe
the free energy of the systems highlighting the differences between them.
In this six-dimensional space the main free-energy minima are identified and their
population is evaluated as described in Section 3.4 (Table 3.1). Each minimum
populated more than 10%, was identified according to the values adopted by its φ
and ψ dihedral angles (see Table A.1 and Figure A.2 in Appendix A). Analysis of
the conformers’ positions in the six-dimensional dihedral space allowed to identify
a subspace of minimal dimensions in which each minimum can be uniquely charac-
terized. Therefore a FES projection on this bi-dimensional subspace, defined by
the φ dihedral angles of R2 and f5, is reported in Figure 3.3 for each cyclopeptide.
It can be observed that, while the unmethylated reference molecule c(GRGDfL) sig-
nificantly populates only minimum A (96%), the other cyclopeptides can adopt also
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c(GRGDfL)c(GRGDfL)
c(GRGDfL)c(GRGDfL)
c(GRGDfL)
Figure 3.3: 2D-energy surfaces. FES projections in the space defined by the φ dihedral
angles of R2 and f5.
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Figure 3.4: N -methylation effects. Representation of the effects triggered by N -
methylation on the φ and θ (HN/CN-N-Cα-Hα) dihedral angles of the corresponding
residue. Methylation of one amino acid induces the corresponding θ dihedral angle to
adopt a syn-periplanar conformation.
different conformations. Specifically, the single N -methylation of R2 (c(GRGDfL))
and of f5 (c(GRGDfL)) favors the accessibility of the additional minima B (73%)
and C (46%), respectively. Notably, the characteristic features that make these
minima different from A are the φ dihedral angles of R2 (in the case of minimum
B) and of f5 (for C), evidencing how the N -methylation of one residue can induce a
flip in its φ dihedral angle (Figure 3.4). Following the same principle, simultaneous
methylation of R2 and f5 (c(GRGDfL)) induces the formation of the above men-
tioned minima B (37%) and C (13%), and of a fourth conformational minimum D
(18%), which displays different φ dihedral angles of both R2 and f5 with respect
to A. Lastly, the triple N -methylated peptide c(GRGDfL) shows a FES similar
to the one of the molecule with single methylation on R2, resulting only in the
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Figure 3.5: Similarity matrix. Matrix representing the Root Mean Square Deviation
between all the conformers extracted from BE-META. [213] RMSD is calculated on the
backbone, Cβ and O atoms.
formation of the additional minimum B (82%). This unconventional behavior can
be explained observing that multiple methylations on two adjacent amino acids
could create a steric hindrance effect, blocking the modified residues in the original
conformation and eliminating the expected methylation-induced conformational
changes.
I next investigated the conformations of all the cyclopeptides pooling together
the structures extracted from the BE-META minima (A-D). It was found that
the single minima were structurally very similar among the different molecules,
as highlighted by the root mean square deviation (RMSD) matrix in Figure 3.5.
Structures within the same minimum displayed an average RMSD, computed on
the backbone, Cβ and O atoms, lower than 0.6 Å.
Next, the conformers within each minimum have been characterized, focusing
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Table 3.2: Structural features of the BE-META conformers. [213] The minima
have been characterized according to: the syn or anti periplanar conformation of dihedral
angle θ, the presence of backbone hydrogen bonds and the average distance between the
Cβ atoms of R2 and D4.
Minimum θ [°] H-bonds1 d(CβR2,CβD4) [Å]
R2 D4 f5 L6
A anti anti anti anti HNG1 −OD4 7.8 ± 0.5
B syn anti anti anti - 8.6 ± 0.6
C anti anti syn anti HNG1 −OD4 7.2 ± 0.4
D syn anti syn anti HNG1 −OD4 5.9 ± 0.4
OG1 −HND4
1 Hydrogen bonds were individuated with the VMD [215] Hbonds plugin. A donor-acceptor
distance of 3.5 Å and an angle cutoff of 35° have been considered. Only hydrogen bonds
present in at least 50% of the structures are reported.
on: i. the conformations (syn or anti-periplanar) adopted by the dihedral angle
θi of amino acid i (excluding Glycine), defined by the atoms HN/CN-N-Cα-Hα
(see Figure 3.4); ii. the presence of intra-molecular backbone hydrogen bonds,
if observed in at least 50% of the structures; iii. the distance between the Cβ
atoms of R2 and D4 (d(CβR2,CβD4)), which is strongly related to the positioning
of RGD-cyclopeptides pharmacophores, namely the charged groups of Arginine
and Aspartate (Table 3.2). [14]
Concerning the θ dihedral angles, in minimum A all the residues adopt an anti-
periplanar conformation, while in structures of minima B and C a syn-periplanar
conformation can be observed for residues R2 and f5, respectively; finally, in
conformers belonging to minimum D, both these amino acids, R2 and f5, adopt
a syn-periplanar geometry. Overall these data suggest that N -methylation of
a residue favors the accessibility to conformers, which otherwise would not be
significantly populated, characterized by the θ dihedral angle of the corresponding
residue in syn-periplanar conformation, i.e. with the methyl CN atom and the Hα
atom pointing in the same direction (Figure 3.4).
These different geometries of the backbone dihedral angles induce a different pattern
of intramolecular hydrogen bonds. On one hand, structures belonging to minima A,
C and D present one or two hydrogen bonds between residues G1 and D4, showing
a relatively short distance d(CβR2,CβD4) (lower than 8 Å). Conversely, the absence
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A B C D
7.8 ± 0.5
8.6 ± 0.6
7.2 ± 0.4
5.9 ± 0.4
Figure 3.6: Representative conformers. Structures from BE-META minima are
shown in sticks, with carbon, nitrogen, oxygen and hydrogen atoms colored in marine
blue, blue, red and white, respectively. Hydrogen bonds and the distance d(CβR2,CβD4)
(for which the average is reported) are indicated with orange and black dashed lines.
of backbone hydrogen bonds in minimum B, allows more extended conformations,
characterized by a distance d(CβR2,CβD4) that is approximately 9 Å (see Table 3.2
and Figure 3.6).
Taken together, these data suggest that the introduction of backbone N -methylation
in cyclopeptides modulates their structural preferences, enlarging their accessible
conformational space and favoring a twist by about 180° of the peptide bond plane
preceding the methylated residue (syn-periplanar geometry). This rearrangement
displays relevant consequence in the case of R2 N -methylation: herein the induced
θ syn-periplanar geometry prevents the formation of an intramolecular backbone hy-
drogen bond, favoring an extended conformation that satisfies the pharmacophoric
requirements for the accommodation of the RGD motif in the integrin αIIbβ3
binding pocket. [14]
3.2.3 Experimental validation of the conformational sam-
pling
To validate the hypothesis that backbone residue N -methylation affects the syn-anti
conformational equilibrium of the corresponding θ dihedral angle, I quantitatively
compared the experimental 3JHN,Hα scalar couplings, available only for c(GRGDfL)
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Table 3.3: Experimental validation of BE-META conformational sampling.
The comparison between the experimental values of 3JHN,Hα scalar couplings and the
back-calculated ones is shown. For N -methylated residues the inter-residue distances
dCN,Hα, derived from the ROESY spectra, and the back-calculated distances from BE-
META minima are reported. Additionally, the corresponding θCN,N,Cα,Hα conformation
is indicated. The estimated errors for scalar couplings and distances are 0.91 Hz and 0.3
Å, respectively.
c(GRGDfL) c(GRGDfL)
Residue 3JHN,Hα [Hz] dCN,Hα [Å] θ1 3JHN,Hα [Hz] dCN,Hα [Å] θ1
Exp2 Comp Exp2 Comp Exp2 Comp Exp2 Comp
G1 4.4 4.5 - - - 3.8 5.1 - - -
R2 - - 2.1 2.7 syn - - 1.9 2.6 syn
G3 6.0 5.8 - - - 5.9 5.8 - - -
D4 8.0 8.1 - - - 9.7 7.1 - - -
f5 7.0 8.9 - - - - - 2.9 3.4 anti
L6 8.0 7.4 - - - - - 2.9 3.4 anti
1 the conformation adopted by the θ dihedral angle in structures extracted from BE-META
minimum populated more than 70% is reported.
2 see reference [205].
and c(GRGDfL), [205] with the back calculated ones (Table 3.3). The 3JHN,Hα were
computed as described in Section 3.4.3. The agreement between experimental and
simulated data was quantified according to the following equation: [216]
χ2(3Jexp,3 Jcomp) = N−1
N∑
i=1
(3Jcomp,i −3 Jexp,i)2
σ2
(3.1)
where σ = 0.91 Hz is the estimated systematic error and N = 8 is the number
of J-couplings considered. The value obtained for χ2(3Jexp,3 Jcomp) was of 1.8,
indicating a satisfactory agreement. [217]
For N -methylated amino acids a direct comparison with the 3JHN,Hα scalar couplings
is not possible. Therefore, in these cases I calculated the average intra-residue
distances dCN,Hα. The residues displaying θ syn-periplanar geometry are expected to
be characterized by short dCN,Hα, indeed in this situation the atoms CN and Hα point
in the same direction; conversely, anti-conformations are expected to display longer
distances. The averages have been calculated using all the structures extracted from
BE-META minima and weighted with their population (Section 3.4.3). A qualitative
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comparison of these data with the ones obtained from the ROESY spectrum [205]
was performed. In agreement with experimental data, those residues which often
adopt the syn-periplanar conformation of the θ dihedral angle, show shorter dCN,Hα
distances than the ones that mainly adopt anti conformation (Table 3.3).
Overall, this comparison supports the finding that N -methylation of a residue
induces its θ dihedral angle to adopt a syn-periplanar conformation.
3.2.4 Docking calculations
As second stage of the protocol, I investigated by means of docking calculations
the relationship linking cyclopeptides’ conformation and their binding affinity for
αIIbβ3 integrin. To this aim I exploited the software Glide of the Schrödinger suite
in its Extra Precision variant. [152] As input for the docking procedure I used the
bundles of structures extracted from all the BE-META minima populated more
than 10%, for a total of 1480 structures. Since an exhaustive conformational sam-
pling had already been performed on this structure I did not apply any optimization
or refinement strategy on the ligand. The structure of the protein was instead
retrieved from the PDB 2vdn [14] (crystallographic integrin αIIbβ3 in complex with
Eptifibatide) and optimized as described in Section 3.4. No constraints were applied
during the docking procedure. The grid, necessary to drive the docking of the
peptides towards the binding pocket, was defined using as reference Eptifibatide,
which was subsequently removed (details are in Section 3.4).
The decoy poses obtained were scored according to the Extra-Precision Glide Score
(GS) and only the ones satisfying the filter GS < (GSbest + 5 kcalmol
−1) were
retained for the subsequent rescoring. It is worth noting that approximately the
60% of the structures belonging to minima A and B passed this first filter, while
structures belonging to minima C and D were less prone to obtain a satisfactory
GS: indeed, only 23% and 13% of the structures of minima C and D, respectively,
were accepted (see Figure 3.2).
The remaining 727 decoy poses were then rescored using the MM-GB/SA (Molecu-
lar Mechanics-Generalized Born Surface Area) protocol implemented in the Prime
software (Schrödinger company). [178] MM-GB/SA strategy indeed represents a valu-
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able technique to estimate binding free-energy, [218] being a fair compromise between
empirical methods and computationally intensive approaches. Even if this method
generally is not able to reproduce the absolute binding free-energy values (due to
the several approximations employed, including the lack of treatment of the entropy
contribution), it often exhibits a good relative correlation with experiments. [218]
Additionally, it has been demonstrated in several cases that the post-processing of
poses with this implicit solvent technique greatly improves the prediction accuracy
as compared to default Glide Extra Precision docking. [219] Accordingly, in this work,
a clear improvement in the ranking of the docking poses when using MM-GB/SA
with respect to the Extra Precision Glide Score was observed: while MM-GB/SA
assigns low energy values to poses able to summarize canonical interactions and high
energy values to the non-native poses, the Glide Score is not able to discriminate
good poses from bad ones (Table A.2 in Appendix A).
Since it is known that clustering of decoy poses helps in improving structure and
binding affinity prediction, I clustered the 727 decoy poses according to geometric
criteria and I assigned an average MM-GB/SA score to each cluster. Specifically,
all the poses were aligned on the receptor residues within the binding pocket and
the RMSD was computed on all the backbone atoms and on the side-chain atoms of
R2, G3, D4 and f5; clusters were identified using an RMSD threshold of 2.5 Å (see
Section 3.4 for details). Herein thirteen clusters containing at least ten decoy poses
have been identified. In Figure 3.7, the average MM-GB/SA score as a function
of the RMSD, calculated with respect to the lowest energy structure of the best
cluster (in term of MM-GB/SA score), is represented. Nicely, a funnel-like shape
can be observed in this Figure, with the average MM-GB/SA score getting worser
for clusters having a higher RMSD.
Details regarding the average MM-GB/SA score per cluster and the different ener-
getic contributions, including the polar (obtained as the sum of the Coulomb and
the Generalized Born electrostatic solvation energies) and non-polar (accounting
for both van der Waals and lipophilic energies) terms, are reported in Table 3.4.
The fact that the polar energetic contributions are positive could be disorienting,
specially considering the importance of the electrostatic clamp in the integrin
binding. In this situation it is worth to observe that, in all the clusters of poses,
the Coulomb contribution is favorable (see Table A.3) but it is counterbalanced by
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Figure 3.7: MM-GB/SA vs RMSD. In Figure is reported the average MM-GB/SA
score energy value assigned to each cluster as a function of the cluster RMSD. The RMSD
is calculated with respect to the lowest energy structure of the best cluster (in term
of MM-GB/SA score). [213] Bars indicate energy and RMSD fluctuations within each
cluster. The horizontal red bar represents the threshold of the filter 〈MM-GB/SA〉 <
(〈MM-GB/SA〉best cluster + 20 kcalmol−1).
the Generalized Born solvation energy, resulting in an overall positive polar term.
Nevertheless it is easy to observe that the sum of these two contributions remains
fundamental to discriminate among poses, being the best clusters characterized by
a notably lower polar penalty. Lastly, it must be underlined that these kinds of
calculations are reliable in estimating the variation in binding free energy but they
are generally not accurate in reproducing the absolute binding free energy values.
An analysis of the six best-scored clusters, i.e. the ones satisfying the filter
〈MM-GB/SA〉 < (〈MM-GB/SA〉best cluster + 20 kcalmol−1), revealed that in these
poses the cyclopeptide always adopts minima A or B conformations (Figure 3.8).
Conversely, minima C and D resulted to be unproductive, not being able to generate
decoy poses with an acceptable MM-GB/SA score.
Of note, by visual inspection of the decoy poses belonging to these six clusters,
I observed that the cyclopeptides were able to stably recapitulate the character-
istic electrostatic clamp, necessary for the binding, bridging the two domains of
integrin αIIbβ3 and being able to coordinate the MIDAS metal ion through the
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Table 3.4: Energetic contributions per cluster. The average MM-GB/SA values
and individual contributions are reported for each cluster. The Polar term is computed as
sum of Coulomb and Generalized Born electrostatic solvation energy; the Non-Polar term
is the sum of van der Waals and lipophilic energy, while Additional contributions include
covalent binding, hydrogen-bonding, pi-pi packing energy and self-contact correction.
Cluster Energetic Contributions [kcal mol−1]
〈MM-GB/SA〉 〈Polar〉 〈Non Polar〉 〈Additional〉
1 -68.3 ± 6.1 15.8 ± 3.3 -88.9 ± 5.9 4.7 ± 2.2
2 -57.7 ± 6.5 12.5 ± 4.1 -73.7 ± 5.7 3.5 ± 2.9
3 -56.3 ± 9.5 12.7 ± 5.7 -73.6 ± 6.3 4.6 ± 5.7
4 -56.2 ± 7.0 15.2 ± 4.4 -77.7 ± 6.7 6.3 ± 5.1
5 -53.4 ± 8.4 16.5 ± 3.9 -73.7 ± 6.3 3.8 ± 4.5
6 -49.9 ± 10.7 18.6 ± 6.0 -75.7 ± 6.1 7.2 ± 5.2
7 -46.9 ± 8.6 34.8 ± 6.5 -92.0 ± 6.7 10.2 ± 6.9
8 -43.2 ± 10.1 29.0 ± 8.8 -79.9 ± 5.1 7.7 ± 3.8
9 -43.1 ± 9.2 25.6 ± 6.6 -74.3 ± 7.6 5.6 ± 5.5
10 -40.8 ± 7.5 31.9 ± 5.7 -77.5 ± 7.1 4.8 ± 4.0
11 -36.0 ± 7.7 32.1 ± 5.9 -72.3 ± 4.6 4.2 ± 3.4
12 -34.8 ± 6.1 28.2 ± 4.4 -68.3 ± 5.6 5.2 ± 4.3
13 -28.2 ± 5.1 39.6 ± 6.1 -71.7 ± 6.0 3.9 ± 4.0
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Figure 3.8: Peptides conformation in decoy clusters. Cyclopeptides conformational
distribution, according to BE-META minima, in the six lowest energy clusters. [213]
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D4 carboxylic group (Figure 3.9). Accordingly, these clusters are all characterized
by a significantly lower polar contribution with respect to the others (Table 3.4).
However, only in four of the six clusters the canonical interactions were perfectly
summarized, with the guanidinium group of R2 engaging a salt bridge with the
carboxylic group of αIIb:Asp224 and an hydrogen bond with the carbonyl of
αIIb:Phe160. In the other two cases different residues of the αIIb subunit were
engaged in polar interactions. Herein it is worth to observe that in the presented
binding modes the MIDAS is coordinated in a bidentate manner, while it would
be expected a monodentate coordination: this discrepancy could be ascribed to
defects in Glide XP scoring function, specially arising in situations where a metal
ion is involved in ligand binding.
Focusing on the best cluster in terms of MM-GB/SA score, further observations
can be done. First of all its score is significantly better with respect to the others;
herein the main contribution that differentiates it from the other clusters with
acceptable (i.e. satisfying the filter) MM-GB/SA score is the non-polar term
(Table 3.4). Accordingly, the decoy poses of this best cluster, besides recapitulat-
ing the canonical electrostatic clamp, establish additional stabilizing hydrophobic
interactions. Specifically, L6 engages hydrophobic interactions with αIIb:Val156
and αIIb:Phe160, G3 interacts with β3:Ala218 and, finally, f5 contributes with
β3:Tyr122 and β3:Tyr166 to create an aromatic cage around β3:Arg214 (see Ta-
ble 3.5 and Figure 3.9). Secondly, in all the decoy poses of the best cluster, the
cyclopeptide adopts minimum B conformation. Of note, all the molecules populat-
ing this minimum (i.e. c(GRGDfL), c(GRGDfL) and c(GRGDfL)) were able to
generate decoy poses belonging to this cluster.
Overall these data suggest that: i. minimum B conformations, which are generated
as consequence of R2 N -methylation, possess the ideal structural features to bind
αIIbβ3 integrin: herein the appropriate orientation and distance between the
pharmacophoric groups guarantee to summarize the canonical electrostatic clamp
and to stabilize additional hydrophobic interactions; ii. minimum A conformations
allow to recapitulate the canonical interaction but not to engage additional contacts;
iii. minima C and D conformations do not satisfy the structural requirements to fit
in the αIIbβ3 binding pocket.
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Cluster 2Cluster 1
Cluster 4Cluster 3
Cluster 5 Cluster 6
αIIb β3
MIDAS
Tyr122
Ser123
Arg214
Tyr166
Ala218
Val156
Phe160
Asp224
αIIb β3
Asp232
Tyr190
MIDAS
Tyr122
Ser123
Arg214
Ala218
Phe160
αIIb β3
MIDAS
Tyr122
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Asp232
Tyr190
Lys125
αIIb β3
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αIIb β3
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Asp224
αIIb β3
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Asp224
Figure 3.9: Representative decoy poses of the six best clusters. [213] Integrin
αIIbβ3 is represented as a surface with the αIIb and β3 chains in light-blue and pale
green, respectively; receptor amino acids engaging direct interactions with the ligands
are shown in stick and labeled with the three-letter code. The metal binding sites,
corresponding to MIDAS (Mg2+), ADMIDAS (Ca2+) and LIMBS (Ca2+) cations, are
represented as yellow spheres and the peptides are shown in marine blue sticks. Molecular
graphics were produced with Pymol. [220]
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Table 3.5: Receptor-peptide interactions. Summary of the stable interactions en-
gaged by peptides of the best cluster with integrin αIIbβ3. Stable interactions include
intermolecular distances shorter than 3 Å, occurring in more than 70% of the decoy
poses. Cyclopeptide and receptor residues are labeled with one-letter and three-letter
code, respectively.
Stable interactions
Cyclopeptide residues αIIbβ3 residues
HXR21 OαIIb:Phe160
OXαIIb:Phe1602
HαG3 Hββ3:Ala218
OXD42 Mg2+
HNβ3:Ser123
Phf53 HXβ3:Arg2141
Hδ/HβL6 HγαIIb:Val156
PhαIIb:Phe1603
1 HX denotes guanidinium protons.
2 OX denotes carboxylate oxygens.
3 Ph denotes phenyl group.
Based on these remarks and on the population distribution of the five cyclopeptides,
it is possible to rationalize the interplay between conformational effects induced
by N -methylation and peptides binding affinity for αIIbβ3. In accordance with
the experimental IC50 values, cyclopeptides c(GRGDfL) and c(GRGDfL) are
predicted to have the best affinity for αIIbβ3: indeed they are pre-organized,
already in the free state, in the bioactive conformer B, which is populated more
than 70%. In these two peptides minimum B is highly populated because only the
effect of R2 methylation is appreciable; in fact the calculations revealed that the
multiple methylation of the two adjacent residues f5 and L6 in c(GRGDfL) does
not induce any conformational rearrangement. Conversely, c(GRGDfL), which
equally populates several conformers including both the bioactive minimum B as
well as the unproductive minima C and D, must pay an entropic penalty to bind
the receptor, which then reflects into a lower binding strength (i.e. higher IC50
value, 165 nanomolar). An affinity of the same order of magnitude is displayed
also by the unmethylated molecule c(GRGDfL), which only populates minimum A.
Herein, the inability to adopt the ideal features characterizing minimum B results
in a lower affinity with respect to the molecules that are pre-organized in this
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conformation. Finally, cyclopeptide c(GRGDfL), in which unproductive minimum
C conformations are favored, is characterized by the lowest affinity for the receptor,
again obtaining a good correspondence with the available IC50 values.
3.3 Conclusion
Cyclopeptides, and especially their chemically modified variants, are emerging as
promising therapeutics for the target of protein-protein interactions because of their
several favorable properties, in terms of pharmacokinetic, bioavailability, metabolic
stability and target specificity. Despite all these advantages their application and
development as drugs is hindered by the difficulties to predict in silico their three-
dimensional structure and their binding strength. Currently, empirical approaches
are the most employed ones for the identification, optimization and development of
cyclopeptides as potential therapeutics.
In this chapter I have shown how the combination of different computational
techniques, namely BE-META, docking calculations and MM-GB/SA rescoring,
could be exploited to rationalize and predict the effect of chemical modifications,
and specifically backbone N -methylation, on receptor affinity for a small set of
cyclopeptides. In particular, I have analyzed five cyclopeptides, sharing the same
sequence of six amino acids and differing for the position of a single or multiple N -
methylation, which displayed highly different affinities for αIIbβ3 integrin, ranging
from 12 to 2000 nanomolar in terms of IC50 values. These divergences in binding
strength are expected to be caused by a modulation of the cyclopeptides’ preferred
conformations rather than by a direct interaction of the modified atoms with the
receptor. Herein it has been confirmed that pre-organization of cyclopeptides in
solution strongly affects their binding strength to the receptor, demonstrating that
the knowledge of the conformations preferentially adopted by the free cyclopeptide,
as well as an estimation of their relative equilibrium, is fundamental to provide
reliable affinity predictions. In particular it has been shown that: i. BE-META is
an ideal tool to individuate the main conformers and assess their population; ii.
docking calculations, complemented by MM-GB/SA rescoring and cluster analysis,
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allow to classify the conformers according to their binding ability; iii. a joint
analysis of the previous outcomes results in a reliable ranking of cyclopeptides
based on their binding affinity and in the rationalization of their structure-activity
relationship.
From a structural point of view, I observed that introduction of N -methylation in
the investigated RGD-based cyclopeptides, does not induce a significant cis-trans
interconversion, neither constrains the molecules in a previously existing backbone
conformation, as expected. Conversely, I found that N -methylation regulates the
structural preferences of cyclopeptides favoring additional conformations, charac-
terized by a syn-periplanar geometry of the θ dihedral angle, corresponding to a
180° twist of the peptide bond plane preceding the methylated residue. In this
class of cyclic hexapeptides, this effect was found to be particularly significant
in the case of R2 N -methylation: indeed the induced rearrangement in this site
results in the adoption of the bioactive conformation B, allowing a proper relative
positioning of the pharmacophoric groups for the binding to αIIbβ3 integrin. The
ranking of cyclopeptides according to their αIIbβ3 binding affinity, derived by the
combination of conformational sampling and docking calculations, is in excellent
agreement with the experimental IC50 values, supporting these findings.
It is expected that the computational protocol herein described could be extended
and used for other applications in the future. It could be applied to investigate the
impact of backbone N -methylation and other chemical modifications on diverse
set of cyclopeptides, as well as to study the effects of residues’ chemistry and
stereo-chemistry on cyclopeptides structure and activity. Conceivably, the synergy
between BE-META, which guarantees an exhaustive conformational sampling of
the cyclopeptides, and docking, which allows the identification of unproductive
poses, will allow for a successful application of this protocol, also to screen novel
peptides library and before entering expensive synthesis campaign and binding
assays.
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3.4 Methods
3.4.1 Simulation set up
All the MD simulations have been performed using the Gromacs-4.5.3 software [87]
and the Plumed 1 plugin. [221] The TIP3P [113] model was employed to simulate
water molecules while the OPLS-AA force field [222] was used for cyclopeptides. This
force field has been chosen among the available ones since it had been previously
employed in our laboratory for the simulation of cyclic peptides [75] and since it
allows a coherent treatment of the system in both the MD sampling and the
subsequent docking and rescoring analysis (Prime MM-GB/SA is indeed based
on this same force field). The parametrization of the N -methylated residues was
derived from the OPLS-AA parameters for N -methylacetamide, postulating charges
and dihedral angles coherence as done in [75]. Each cyclopeptide has been solvated
in a cubic box containing 4105 water molecules, with dimension of (5 nm)3. After
an initial energy minimization, a 1 ns equilibration was performed in the NPT
ensemble using the md integrator and a time step of 1 fs. The pressure was set
to the value of 1 atm using the Berendsen barostat with a relaxation time of
1 ps, while the temperature was maintained at 300 K by using the Berendsen
thermostat [96] with a coupling time constant of 100 fs (cyclopeptide and solvent
molecules were coupled to independent thermostats). During the equilibration the
LINCS algorithm was applied to constraint the bond lengths involving hydrogen
atoms. A cut-off of 0.9 nm was used to truncate both the van der Waals and
the electrostatic interactions. In the case of electrostatics, long range interactions
beyond the cut-off were treated with Particle-Mesh Ewald method (Fourier grid
spacing of 0.12 nm and interpolation order of 4). [122,223]
The BE-META simulations, in standard formalism, were performed in the NVT
ensemble, setting the temperature at 300 K by means of the v-rescale thermostat. [98]
During this production run the time step was set to 2 fs and all the bond lengths
have been constrained. Every 1 ps a Gaussian hill (height: 0.24 kcal mol−1, width:
0.2 rad) was added; exchanges between pairs of replica were attempted every 15 ps.
Preliminary BE-META simulations have been performed to investigate the impact
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of N -methylation on cis-trans peptide bond interconversion. During each of these
simulations 10 CVs have been biased, namely the six Ω (Cαi-1-Ci-1-Ni-Cαi) dihedral
angles and the four φ (Ci-1-Ni-Cαi-Ci) dihedral angles of the non-Glycine residues
(R2, D4, f5 and L6). For each peptide a total simulation time of 400 ns was carried
out. Since the calculations did not reveal any significant isomer interconversion,
the subsequent investigations were restricted to the trans-isomers conformational
space. Thus, I ran for each molecule an eight-replica BE-META simulation (320
ns, 40 ns per replica). In each replica one CV, among the eight φ and ψ dihedral
angles of R2, D4, f5 and L6, was biased.
3.4.2 Analysis of the BE-META simulations
The analysis and the reconstruction of the free energy landscape were performed,
using the Metagui tool, [141] in a six-dimensional subspace defined by φ and ψ (Ni-Cαi-
Ci-Ni+1) dihedral angles of R2, f5 and L6, where it was possible to identify the main
minima and to evaluate their population. The consistency of the reconstruction
was assessed by varying the employed grid space (specifically, grid spaces ranging
between 20° and 30° were all able to lead to consistent results). In order to consider
only the relevant conformations of the system, during the analysis devoted to the
identification of metastable states by clustering of BE-META microstates, I choose
a number i of relaxation times, when a gap between τi and τi+1 was present (see
section 2.2.3).
The population of each minimum (X) was estimated according to:
popX =
∑
µ∈min(X) e
−Fµ
kb T∑N
i=1
∑
µ∈min(i) e
−Fµ
kb T
100% (3.2)
where kb is the Boltzmann constant, T is the temperature, N is the total number
of minima, µ indicates a generic microstate, min(i) is the ensemble of all the
microstates belonging to minimum i and Fµ represents the free energy difference
associated to the microstate µ and the microstate with the lowest free energy. Only
minima populated more than 10% have been considered for further analysis and
docking calculations.
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3.4.3 Comparison with NMR data
The 3JHN,Hα were computed using the Karplus equation: [224]
3JHN,Hα(θ) = A cos2(θ) +B cos(θ) + C, (3.3)
where A = 5.4Hz, B = -1.3Hz, C = 2.2Hz, [225] θ = φ−60° in the case of L-amino
acids and θ = φ+60° in the case of D-amino acids. Average values for the φ dihedral
angles (〈φ〉) were obtained from the ensembles of structures extracted from the
BE-META main minima (minimum A and B). Then the weighted average for
3JHN,Hα was obtained as:
3JHN,Hα(θ) =
J(〈θ〉A) popA + J(〈θ〉B) popB
popA + popB
, (3.4)
where popA and popB are the populations of minima A and B, respectively; while
〈θ〉X is the average value for θ (computed as 〈φ〉 ± 60°) within minimum X.
Analogously the averages dCN,Hα distances have been calculated according to:
dCN,Hα =
〈dCN,Hα〉A popA + 〈dCN,Hα〉B popB
popA + popB
, (3.5)
where 〈dCN,Hα〉X is the average distance within minimum X.
3.4.4 Docking Calculations
The software Glide [152] of the Schrödinger suite (version 5.8) was employed to
perform docking runs. As input structures for the ligands I used the conformers
extracted from the BE-META minima populated more than 10% (for a total of 1480
conformers). Since these structures had already been subjected to an exhaustive
conformational search, no further energy minimization or sampling was performed.
The receptor input structure (PDB: 2vdn [14], crystallographic αIIbβ3 in complex
with Eptifibatide) have been prepared with the Protein Preparation Wizard tool of
the Maestro Package. [226] Herein I removed all the crystallographic waters, added
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missing hydrogens, optimized protonation and tautomeric states; lastly I ran a
restrained minimization, employing the OPLS-AA force field, [222] with an RMSD
tolerance on heavy atoms of 0.3Å to remove steric clashes and reorient side-chain
hydroxyl groups. The grid center was determined by using as reference ligand
Eptifibatide, which afterwards was removed. The default cubic grid dimensions
were adopted.
The decoy poses have been generated by using the Extra-Precision mode of Glide
with flexible ligand (that in the case of head-to-tail cyclopeptide means flexible
side-chain) and without applying any constraints. For each input structure only
the best decoy pose was printed. After docking calculations the poses were ranked
according to their Extra-Precision Glide Score (GS). A first filter was then applied
(GS < (GSbest+5 kcalmol
−1)) and only poses satisfying this condition were retained
for MM-GB/SA rescoring and further analysis.
3.4.5 MM-GB/SA and cluster analysis
All the selected poses have been refined and rescored using the Prime MM-GB/SA
tool of the Schrödinger suite. For the refinement the local optimization feature was
utilized, [178] while for the rescoring it was employed a combination of the OPLS/AA
molecular mechanics force-field and of the GB/SA continuum solvent model. [227]
During this procedure the backbone and the Cβ atoms of the ligand were kept
fixed, while the other atoms were considered flexible. Concerning the receptor, all
the residues within a 5 Å cutoff from the ligand were treated as flexible.
A cluster analysis was subsequently performed using the cluster_struc program
provided with HADDOCK. [153,198] The poses were aligned on the receptor residues
within the binding pocket (i.e. residues within 10 Å from the ligand) and the RMSD
was computed on all the backbone atoms and on the side-chain atoms of R2, G3,
D4 and f5. For the clustering an RMSD cutoff of 2.5 Å was employed and clusters
containing less than 10 poses were excluded. For each of the obtained clusters, an
average MM-GB/SA value was assigned, by averaging the scores of all the members.
An average RMSD was also computed, using as reference the lowest energy structure
of the best cluster (in term of MM-GB/SA score). Finally a second filter was applied
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(〈MM-GB/SA〉 < (〈MM-GB/SA〉best cluster + 20 kcalmol−1)), in order to identify
the most reliable clusters of poses. These poses have been subjected to visual
inspection, investigation of energetic contributions and analysis of intermolecular
stable interactions (i.e. distances shorter than 3 Å, occurring in more than 70% of
the decoy poses).
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Integrins belonging to the class of the RGD (Arg-Gly-Asp) recognizing receptors
constitute an ideal pharmacological target because of their role in several pathologi-
cal processes, including thrombosis, stroke (αIIbβ3), angiogenesis and cancer (αvβ3,
α5β1, αvβ6, αvβ8). [46] These integrins share the ability to bind extracellular matrix
proteins through the three amino acidic sequence RGD, therefore several peptides
and peptidomimetics mimicking this recognition motif have been developed and
studied in the last decades as integrin inhibitors. [63,64]
In 2006, biochemical studies showed that the NGR (Asn-Gly-Arg) motif of the ex-
tracellular matrix protein fibronectin can spontaneously transform into the isoDGR
(isoAsp-Gly-Arg) sequence, resulting in a gain of function for the protein and in the
generation of a new adhesion binding site for integrins. [70] Studies on CisoDGRC,
a disulphide-bond cyclic peptide mimicking the isoDGR sequence in fibronectin,
demonstrated that CisoDGRC can fit into the RGD-binding pocket of αvβ3 integrin,
recapitulating the canonical electrostatic clamp. [71] The same cyclopeptide was
also able to inhibit endothelial cell adhesion, proliferation, and tumor growth. [70]
Subsequent investigations showed also that, at variance to Cilengitide, CisoD-
GRC behaves as pure integrin antagonist blocking αvβ3 conformational changes
and allosteric activation. [72] In recent years some isoDGR-based head-to-tail cy-
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clopeptides have been developed and synthesized: for the most interesting ones
structure-activity relationship studies have been conducted in order to rationalize
their affinity and selectivity profiles and their ability to work as drugs-carriers has
also been explored. [76–79]
Considering that this is a relatively recent research field, and since none of the
developed peptides displays an affinity for αvβ3 integrin comparable to the one
of Cilengitide, new efforts are needed to explore the potential of isoDGR-based
cyclic peptides as antiangiogenic therapeutics, drug carriers or agents for diagnostic
imaging. In this context, the design and development of novel isoDGR-based
integrin therapeutics could benefit from a systematic computational screening of
the impact of the chemistry/stereo-chemistry of isoDGR flanking residues on ligands
conformation and consequently on their integrin binding affinity. To this aim I
propose to use the computational protocol previously presented in Chapter 3, relying
on the combination of BE-META, docking and rescoring techniques. Nevertheless,
two major issues could compromise this project: i. the force fields implemented
in MD software could be not appropriate for the in silico structure determination
of highly constrained cyclic peptides containing non-standard amino acids as
isoAspartate; [228] ii. docking software could not properly evaluate differences in
binding affinities upon modification of the stereo-chemistry and/or type of residues
flanking the recognition motif.
These two aspects have been thoroughly investigated within this thesis. Specifically,
in the next Section I have systematically tested the ability of eight different force
field variants to reproduce NMR-derived experimental data for 5 isoDGR-based
cyclic peptides. Herein I have shown that only two out of eight investigated
force fields allowed to accurately reproduce the equilibrium properties of isoDGR-
containing molecules, suggesting that transferability of parameters is a not-trivial
issue. Afterwards, in Section 4.2 I have faced the problem of binding affinity
predictability via docking calculation techniques. Specifically, I investigated the
rationale for the affinity/selectivity profiles displayed by three cyclic head-to-tail
isoDGR hexapeptides, differing for the type of residues flanking the isoDGR motif.
Herein I have shown that the combination of Glide docking and MM-GB/SA
rescoring allows to discriminate integrin binders (inhibition constants in the order
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of tens of nanomolar) from weak binders (inhibition constants in the order of
hundreds of nanomolar).
Overall, the positive results obtained holds promise for the future applications of
the proposed computational protocol, which could be employed in the screening of
the effects of isoDGR flanking residues on cyclopeptide conformation and integrin
affinity.
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4.1 Are current MD force fields reliable for the
study of isoDGR-cyclopeptides?
4.1.1 Introduction: the force field problem
In the previous Chapters I have evidenced the increasing importance of cyclic
peptides in the modulation of protein-protein interactions and specifically in the
targeting of integrins. [53] Their constrained cyclic geometry supplies several advan-
tages: firstly, they are characterized by improved stability and bioavailability with
respect to their linear counterpart, moreover they avoid the possible side effects
of small molecules. Importantly, cyclization allows the peptides to adopt, already
in the unbound state, specific bioactive conformations, suitable for the selective
binding to the receptor. [201]
In this context, the knowledge of the conformations preferentially adopted by
cyclic peptides in their free state can help in the prediction of their binding prop-
erties. [207] Computational tools could be extremely useful to this aim. We have
previously shown that enhanced sampling techniques, such as Metadynamics in its
Bias Exchange variant, [134] provide a perfect framework to exhaustively sample the
conformations of cyclopeptides, guaranteeing a full coverage of the relevant confor-
mational space. [75,213] Nevertheless, the reliability of the sampling strongly depends
also on the accuracy of the molecular force field employed in the MD simulation.
This aspect is particularly relevant in the case of cyclic peptides, and it is even more
remarkable in simulations requiring non standard amino acids. [199,228,229]
Molecular force fields are energy functions that determine the potential energy neces-
sary to numerically solve the Newton equation of motion during the MD simulation
(as described in Section 2.1.3). They consist in the sum of several energetic terms,
which account for both bonded (i.e. bond stretching, angle bending and torsion
potential) and non-bonded (i.e. Coulomb and van der Waals) interactions. Their
general form has been reported in equations 2.4 and 2.5, where their dependencies
upon several parameters is highlighted. These parameters are usually determined in
order to reproduce high level Quantum Mechanics calculations for small molecules,
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and are then optimized to fit experimental data (e.g. crystallography and NMR
spectroscopy). This set of parameters, along with the specific functional form of
the energetic function, determines the specificity of the force field.
The gain in computational power observed in the last decade, which allowed acces-
sibility to longer simulation times, has unveiled some weaknesses and limitations in
force fields accuracy. This fact has stimulated the development of new force field
variants, in which improved torsional potentials for both backbone and side-chain
atoms have been proposed. Additionally, an interest in testing force fields accuracy
in diverse situations raised, thus allowing a better comprehension of their limitations
sources. [109–112,230–232]
The problem of force field accuracy in the simulation of cyclic peptides is even
more prominent. Indeed molecular force fields are generally developed and tested
on protein systems or linear peptides, but they are not designed to reproduce
the equilibrium properties of constrained cyclic peptides. In this context, the
canonical dihedral angles distribution observed in a Ramachandran plot could
not be satisfied due to the constraints imposed by the cyclic geometry. Recently
this issue has gained some attention. [199,229] Specifically, the group of Wu [229] has
tested the ability of some popular force fields, including their recently developed
force fields RSFF1 and RSFF2 (Residue Specific Force Field 1 and 2), [107,108] in
reproducing the crystallographic structures of twenty 5-12 residues cyclopeptides.
The simulation of isoDGR-based cyclic peptides, where the conformation adopted by
isoAspartate has relevant consequence on their integrin binding ability, could be even
more challenging. Herein the presence of the non standard amino acid isoAspartate
could further affect the predictability and accuracy of the simulation. Indeed,
despite the high similarity shared by isoAspartate backbone and Asparagine side-
chain, it is not obvious that the parameters, and particularly the torsion potentials,
optimized for Asparagine side chain could be transferable to isoAspartate (see
Figure 4.1).
In order to evaluate the ability of MD simulations to reproduce the equilibrium prop-
erties of isoDGR-based cyclic peptides I have performed a systematic study testing
some popular force fields on 5 peptides, for which NMR experiments have been
acquired. The 5 investigated molecules include two pentapeptides cycled through a
95
Chapter 4. Structural characterization of isoDGR-based cyclopeptides
Figure 4.1: Asparagine and isoAspartate dipeptides. The high similarity shared by
isoAspartate backbone and Asparagine side-chain is shown in a 2D-representation. Specif-
ically the characteristic backbone dihedral angle of isoAspartate, and the corresponding
dihedral in Asparagine, are highlighted in yellow.
disulfide bond, namely CisoDGRC and its acetylated variant acCisoDGRC, [70,75]
and three head-to-tail cyclic hexapeptides, c(CGisoDGRG), c(GCisoDGRG) and
c(CphgisoDGRG) (see Figure 4.2). [76] Each of the 5 cyclopeptides was simulated
with 8 different force field variants in explicit water, for a total of 40 simulations.
To guarantee an exhaustive coverage of the conformational space Bias Exchange
Metadynamics was employed, for a total simulation time of 17 µs.
The selected force fields comprise the most recent variants among the major
families of force field (AMBER, OPLS, CHARMM and GROMOS), if implemented
in the Gromacs software. These include: AMBER ff99sb-ildn, [101,233] AMBER
ff99sb*-ildn, [216,234] AMBER ff14sb, [106] OPLS-AA/L, [102,222] CHARMM-27 [103,235]
and GROMOS-54a7. [236] Additionally, two variants of the AMBER ff99sb-ildn and
of the OPLS-AA/L force fields (denoted as ff99sb-ildn_ASN and OPLS-AA/L_ASN
respectively) were included: herein the torsional potentials specifically optimized
for Asparagine side-chain have been used in the parameterization of isoAspartate.
In particular, AMBER ff99sb-ildn force field is an improvement of the f99 force
field, developed in 1999 by the Kollman group. [237] Herein the energy functions
associated to both the backbone φ/ψ dihedral terms (sb correction [101]) and to the
side-chain χ dihedral angles of Isoleucine, Leucine, Aspartate and Asparagine (ildn
correction [233]) have been optimized to fit high level ab initio quantum mechanical
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Figure 4.2: 2D-representation of the five molecules used for the force field
evaluation. 2D-structures of the isoDGR-based cyclopeptides CisoDGRC, acCisoDGRC,
c(CGisoDGRG), c(GCisoDGRG) and c(CphgisoDGRG).
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calculations and NMR-derived experimental measurements. In the force field variant
denoted as ff99sb-ildn_ASN, the torsional parameters optimized for Asparagine
within the ildn correction are used for isoAspartate. The force field ff99sb*-ildn
differs with respect to ff99sb-ildn for simple backbone energy corrections, which
were introduced to obtain a correct balance of secondary structure propensities. [216]
The last force field considered for the AMBER family is the recently optimized
ff14sb: [106] herein, starting from the ff99 force field with the sb correction, QM-
based side-chain dihedral parameters and empirical adjustment to the backbone
torsional energies have been introduced. Within the OPLS family of force field I
have considered OPLS-AA/L: [222] it is an improvement of the original OPLS [102]
force field where quantum mechanical data are used for refitting of side-chain and
torsional parameters. Unfortunately, I have not been able to test the recently
optimized OPLS-AA/M force field, [105] since a version compatible with Gromacs is
currently not available. Concerning the CHARMM group I selected the CHARMM-
27 variant, in which the CMAP correction, a grid-based energy correction map for
backbone dihedral angles was introduced. [103,235] Finally, for the GROMOS family
of force fields, which are characterized by the use of an united-atom treatment, I
selected the relatively recent GROMOS-54a7, [236] where several aspects have been
improved with respect to the preceding versions, including the secondary structure
propensities, the N-H, C=O repulsion, the free energy of hydration of Na+ Cl− ions,
as well as new improper dihedral angles. The new interesting Residue Specific Force
Fields (RSFF1 and RSFF2) [107,108] have not been included in the evaluation since
they could be not appropriate to simulate molecules containing non traditional
amino acids.
The accuracy of each force field was evaluated by comparison with NMR data.
Indeed NMR, thanks to its intrinsic ability to quantify the dynamic of a system, is
an ideal technique to study flexible molecules and peptides, which can show a high
internal mobility populating several conformational minima. NMR-derived observ-
ables, including J scalar couplings, residual dipolar couplings, nuclear Overhauser
enhancement and chemical shifts, are averages of the values expected for each of the
multiple possible conformations, if these conformations are in fast exchange with
respect to the NMR time-scale. This condition is satisfied by cyclic peptides so that
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only averages can be measured. In this situation, the experimental values should
quantitatively correspond to the ensemble averages of the corresponding values
computed with simulations. This is true if the following assumptions are satisfied:
i. the sampling of configuration is exhaustive, ii. the relation used to compute the
observable from the 3d configuration is correct, iii. the empirical potential function
(or force field) that governs the statistical-mechanical distribution of configurations
used to obtain a proper Boltzmann-weighted ensemble is reliable. [238]
For all these reasons NMR-based data constitute a commonly used benchmark to
quantitatively assess the accuracy of force fields. [110,231,238] In this project I have
used chemical shifts and J scalar couplings data. The latter are particularly relevant
in the study of cyclic peptides since they are related to dihedral angles and bond
distances. The agreement between experimental and back-calculated data has been
quantify by means of a χ2 metrics. These comparisons suggest that, while most
of the investigated force fields can properly reproduce the equilibrium J couplings
of cyclic peptides, only two (i.e. ff99sb-ildn and ff99sb*-ildn) are able to recover
the NMR observables characteristic of isoAspartate with an accuracy close to the
systematic uncertainty. Overall these data demonstrate that the parameterization
of isoAspartate is not trivial and that care must be taken when introducing non
canonical amino acids in the simulation.
4.1.2 Results and Discussion
In order to evaluate the ability of MD simulations to reproduce the equilibrium
properties of isoDGR-based cyclic peptides I tested 8 force field variants on 5
peptides, for a total of 40 BE-META simulations. Each simulation has been
performed biasing all the dihedral angles related to the cycles of the five molecules,
with the exception of the Ω dihedral angles describing peptide bonds planarity,
running 30 or 40 ns per replica (see 4.1.4.2 for details). After an accurate check
of the convergence, the simulated structures have been clustered in microstates
in a space defined by a subset of the biased CVs (see section 4.1.4.3), and the
microstates free-energies have been estimated through a WHAM procedure. [138]
For each of the structures clustered in microstates, the Karplus equation has been
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used to back-calculate the J coupling constants, while the Sparta+ program [239]
was employed to estimate the chemical shifts. Then, the average equilibrium values
of these observables have been computed according to equation 4.1. [138]
In order to evaluate the ability of the selected force fields to reproduce experimental
quantities the χ2 metric reported in equation 4.2 was used. Herein, for each
force field, the collected experimental data, including both scalar couplings and
chemical shifts, are quantitatively compared with the ensemble average values of the
same observables retrieved from BE-META simulations. The deviations between
experimental and computed values are weighted with the uncertainty associated to
these observables. These errors are the ones arising from the parameterization of
either the Karplus equation or the Sparta+ chemical shift model (see Table 4.2
and 4.3).
4.1.2.1 Force field performances
Chemical Shifts
I firstly investigated the ability of the different force fields to reproduce chemical
shift values. To this aim a set of 38 chemical shifts was considered, involving the
C, Cα, Cβ, HN and Hα atoms of natural amino acid (see Section 4.1.4.1). As
shown in Figure 4.3, for all the force fields a similar deviation between predicted
and experimental chemical shifts was observed, with a χ2 ranging from 0.5 to 0.75.
Also the analysis of chemical shift predictions, subdivided per type (Figure B.1),
does not evidence significant differences between force fields.
The good agreement (χ2 always lower than 1) observed in all the cases is quite
surprising for mainly two reasons: i. different behaviors were expected depending
on the force field; ii. several limitations can affect the chemical shift prediction
performed with the software Sparta+. Indeed this tool is based on empirical
approaches and has been trained on proteins, limiting its applicability to small
peptides with cyclic topology and containing non standard residues (e.g. Phenyl-
glycine and isoAspartate). [240]
This unexpected result could be explained observing that the deviation between
the experimental chemical shifts and the corresponding random coil values (as
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Figure 4.3: Chemical shift χ2. For each force field, the ability to reproduce experimental
chemical shifts is quantified through the χ2 function.
provided by Sparta+) was negligible, indicating that the investigated peptides are
highly flexible. Since I believe that this kind of comparison for this specific system
is not significant to evaluate force field performance, the following of this chapter
will be focused on the analysis of J scalar couplings.
J scalar couplings
Since it has been reported that coupling constants calculations are sensitive to the
implementation of Karplus parameters, [106,230] I evaluated the agreement between
predicted and experimental 3JHN,Hα scalar couplings using two different sets of
Karplus parameters (ORIG [241] and DFT [242], see section 4.1.4.3). In Figure B.2
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in Appendix B the χ2 values, estimating the accordance between experimental
and computed 3JHN,Hα, obtained with these two different parameterization sets
are compared. Even if some differences can be observed, mainly for the force
fields displaying poor agreement with experiments (i.e. with high χ2 values), the
overall trend is maintained. These data suggest that this evaluation of force fields,
according to their ability to reproduce the equilibrium properties of the systems,
is robust with respect to variations of the Karplus parameters. In the following,
the results obtained with the ORIG set of parameters will be present. For sake
of completeness, the same data obtained using the DFT set, will be reported in
Appendix B. It is easy to see that both the sets lead to consistent conclusions.
To evaluate the agreement between experimental and calculated J scalar couplings I
analyzed separately 3JHN,Hα and 3J isoDHα,Hβ. The first of these observables can provide
general information about force field accuracy in simulating cyclic peptides, since
it is related to the φ dihedral angle common to all the amino acids. Conversely,
the latter observable is more focused on the appropriateness of isoAspartate pa-
rameterization: indeed 3J isoDHα,Hβ couplings are related to the characteristic dihedral
angle ξ (N-Cα-Cβ-C), which is present in isoAspartate backbone.
The χ2 values, estimating the ability of the different force fields to reproduce
3JHN,Hα, 3J isoDHα,Hβ and both these variables together, are reported in Figure 4.4.
Concerning the 3JHN,Hα scalar couplings (orange bars), the χ2 spans from a min-
imum value of 1.14, in the case of AMBER ff99sb-ildn_ASN force field, to a
maximum of 5.53, for the OPLS-AA/L force field. Herein, the AMBER force
field ff99sb-ildn, its two variants ff99sb-ildn_ASN and ff99sb*-ildn, as well as the
CHARMM-27 force field, perform exceptionally well, displaying a χ2 lower than 1.3.
Good results are also achieved by the recently optimized AMBER ff14sb (χ2=1.93),
while a slightly worse accordance with experiments is observed for GROMOS-54a7.
Finally, the OPLS-AA/L force field and its variants OPLS-AA/L_ASN show a
poor/moderate agreement with experiments. This is not surprising since it is well
recognized that a major weakness of OPLS-AA/L force field consists in its poor
ability to reproduce quantities relying on torsional energetics. [105] Additionally,
it must be considered that force fields have been optimized to reproduce protein
dynamics and could be not perfectly suited for the simulation of small constrained
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Figure 4.4: Comparison between experimental and computed J scalar cou-
plings. For each force field, the ability to reproduce experimental J scalar couplings is
quantified through the χ2 function. The χ2 values obtained, considering alternatively
3JHN,Hα, 3J isoDHα,Hβ , or both these variables together, is shown with orange, blue and gray
bars, respectively. In order to avoid flattening of the data a gap in the y axis has been
introduced.
cyclic peptides containing non standard residues.
A considerably worse general agreement is observed for 3J isoDHα,Hβ scalar couplings
(blue bars). Herein, only two force fields, the ff99sb-ildn and its variant ff99sb*-ildn,
obtained a satisfactory agreement with experiments (χ2=1.90 and 2.51, respectively).
All the other force fields revealed their inability to properly sample isoAspartate
conformations, displaying χ2 values bigger than 3, and in most of the cases bigger
than 6. These results suggest that the dynamic of isoAspartate backbone within
head-to-tail cyclic peptides can not be properly approximated by the one of As-
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paragine side-chain. Conceivably, the environment in which Asparagine parameters,
and particularly torsional angle energetics, have been optimized is too diverse
with respect to the context in which isoAspartate is found (at least when it is
included in cyclic peptides). This remark is corroborated by the fact that the
variant ff99sb-ildn_ASN, in which torsional potentials specifically optimized for
Asparagine have been used in isoAspartate parameterization, does not improve the
performance of ff99sb-ildn force field, but conversely worsens its agreement with
experimental 3J isoDHα,Hβ.
Of note, the performances of ff99sb-ildn and ff99sb*-ildn are similar in both the
comparisons with 3JHN,Hα and 3J isoDHα,Hβ scalar couplings. These two force fields
indeed merely differ for a simple backbone energy correction, [216] introduced to
achieve a better balance of proteins’ secondary structure propensities. Reasonably,
this modification is not relevant in the simulation of cyclic peptides. Additionally,
it must be observed that the residues optimized within the ildn correction (i.e.
Isoleucine, Leucine, Aspartate and Asparagine) are not present in the investigated
cyclopeptides. Therfore it is expected that, in this test, analogous performances
could be achieved using the force fields variants ff99sb and ff99sb*.
It is worth noting that 3JHN,Hα couplings are related to the dihedral angle H-
N-Cα-Hα, which is common to all the amino acids, including isoAspartate. I
thus investigated whether the inclusion of these isoAspartate-related observables
could affect the accuracy of force fields in reproducing 3JHN,Hα scalar couplings.
In Figure 4.5 for each force field the χ2 values, estimating agreement with the
experimental 3JHN,Hα couplings, computed including or excluding the coupling
constants associated to isoAspartic residue, are reported. Since no relevant differ-
ences between the two situations can be detected, it can be concluded that these
isoAspartate-related observables can be reproduced by force fields with an accuracy
comparable to the one of the other amino acids.
Overall the reported data suggest that all the AMBER force fields considered
(specially ff99sb-ildn and ff99sb*-ildn) and the CHARMM-27 force field are adequate
to reproduce with good accuracy cyclopeptides 3JHN,Hα scalar couplings. A worse
agreement with these observables was found for GROMOS-54a7 and for OPLS-
AA/L force field, which has confirmed its weakness in predicting equilibrium
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Figure 4.5: Influence of isoAspartate on 3JHN,Hα reproducibility. For each force
field, the ability to reproduce experimental 3JHN,Hα scalar couplings is quantified through
the χ2 function. The χ2 values, computed including or excluding the coupling constants
associated to isoAspartate H-N-Cα-Hα dihedral, are reported as orange and yellow bars,
respectively.
properties associated to torsional dihedral angles. Concerning the isoAspartate
parameterization, it can be observed that most of the force fields do not provide
an accurate description of its equilibrium conformations. Simulations of peptides
containing isoAspartate (or more generally β amino acids) could thus benefit by
an ab initio parameterization of these residues. Herein it has been shown that only
the AMBER force fields ff99sb-ildn and ff99sb*-ildn allow to obtain a satisfactory
reproducibility of 3J isoDHα,Hβ, providing a good framework for the simulation of isoDGR-
based peptides.
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4.1.2.2 Influence of isoAsp parameterization on force field performance
I finally investigated whether the parameterization of isoAspartate ξ (N-Cα-Cβ-C)
dihedral angle could affect the overall force field performance, influencing the
conformations, and thus the back-calculated scalar couplings, of the adjacent
atoms and residues. To this aim I focused the attention on two force fields:
AMBER ff99sb-ildn and OPLS-AA/L, for which alternative torsion potentials for
isoAspartate dihedral angles, based on the parameters optimized for Asparagine
side-chains, [222,233] have been considered (AMBER ff99sb-ildn_ASN and OPLS-
AA/L_ASN, respectively).
In Figure 4.6 the comparison between the 3JHN,Hα scalar couplings computed with
either ff99sb-ildn and OPLS-AA/L force field or with their ASN variants is reported.
The 3JHN,Hα scalar couplings predicted with the two AMBER ff99sb-ildn force field
variants are highly correlated (R2=0.94), suggesting that the different torsion poten-
tials employed for isoAspartate dihedral angles have only a local effect and do not
influence the conformation of the surrounding residues. Consistently, the χ2 values,
concerning 3JHN,Hα, displayed by these two force field variants are highly similar.
Conversely, quite different 3JHN,Hα coupling constants are predicted when using
diverse isoAspartate parameterization in OPLS-AA/L (R2=0.58). Conceivably, in
this framework, the conformations of residues and atoms adjacent to isoAspartate
are affected by the choice of the torsion potentials used to describe this amino acid.
To investigate which residues are mostly affected by the different OPLS parameter-
izations, I re-performed the same comparison excluding alternatively:i. the 3JHN,Hα
couplings of isoAspartate residue (Figure 4.7 B); ii. the 3JHN,Hα couplings of the
residue preceding isoAspartate (Figure 4.7 C); iii. the 3JHN,Hα couplings of the two
residues preceding isoAspartate (Figure 4.7 D); iv. the 3JHN,Hα couplings of the
residue following isoAspartate(Figure 4.7 E); v. the 3JHN,Hα couplings of the two
residues following isoAspartate (Figure 4.7 F). It can be observed that the exclusion
of the scalar couplings associated to isoAspartate and to its preceding residues
does not help in improving the correlation (Figure 4.7 B, C and D). Conversely,
the exclusion of the two residues following isoAspartate allowed to obtain a high
correlation between the 3JHN,Hα computed with the two OPLS-AA/L variants
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Figure 4.6: Correlation of 3JHN,Hα computed with different force field variants.
Panels show the correlation between 3JHN,Hα computed with (A) AMBER ff99sb-ildn
force field or its variant ff99sb-ildn_ASN; (B) OPLS-AA/L force field or its variant
OPLS-AA/L_ASN.
(R2=0.94, Figure 4.7 E and F). This suggests that in OPLS the torsion potentials
used for isoAspartate can strongly influence the conformations adopted by the
two residues following isoAspartate (i.e. the Glycine and Arginine of the integrin
recognition isoDGR motif). Overall, it seems that, while AMBER ff99sb-ildn force
field is robust with respect to variations of local parameters, the OPLS-AA/L force
field is more sensitive to these variations and needs a more careful analysis upon
introduction of non standard amino acids.
I finally investigated whether the poor performance of OPLS-AA/L force fields in
reproducing experimental 3JHN,Hα scalar couplings (χ2>3, Figure 4.4) could be due
to the influence of isoAspartate parameterization on the two following residues. We
thus excluded the 3JHN,Hα couplings of the one/two residues following isoAspartate
from the computations of χ2 (see Figure 4.8). Since no significant variations in the
overall χ2 are observed I conclude that the poor agreement with experimental data
is not dependent upon the presence of isoAspartate.
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Figure 4.7: Correlation of 3JHN,Hα computed with OPLS-AA/L and OPLS-
AA/L_ASN force field variants. Panels show the correlation between: (A) all
3JHN,Hα, (B) all 3JHN,Hα except isoAspartate, (C) all 3JHN,Hα except the residue preceding
isoAspartate, (D) all 3JHN,Hα except the two residues preceding isoAspartate, (E) all
3JHN,Hα except the residue following isoAspartate, (F) all 3JHN,Hα except the two residues
following isoAspartate, computed with OPLS-AA/L force field or its variant OPLS-
AA/L_ASN.
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Figure 4.8: Influence of isoAspartate parameterization in OPLS on the 3JHN,Hα
χ2. For OPLS-AA/L and OPLS-AA/L_ASN force fields, are reported the χ2 values,
estimating the ability to reproduce: all the experimental 3JHN,Hα scalar couplings (orange
bars), all the 3JHN,Hα couplings except the ones of the residue following isoAspartate
(3J#HN,Hα, yellow bars), all the 3JHN,Hα couplings except the ones of the two residues
following isoAspartate (3J##HN,Hα, brown bars).
4.1.3 Conclusion
The in silico determination of the three-dimensional conformation of cyclopeptides
is challenging for mainly two reasons: i. their constrained geometry results in
the presence of high free-energy barriers between local minima, entangling the
achievement of an exhaustive sampling; ii. the force fields implemented in MD
software could be not appropriate for the simulation of highly constrained cyclic
peptides. We and others have shown that the first issue can be solved by using
enhanced sampling MD techniques, such as Metadynamics. [75,199,213] The second
issue, which is particularly relevant in the case of isoDGR-based cyclopeptides
because of the presence of the non-standard amino acid isoAspartate, has been
faced in this Chapter. Here I have presented a systematic investigation, in which
the ability of eight popular force fields (AMBER ff99sb-ildn, AMBER ff99sb*-
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ildn, AMBER ff14sb, OPLS-AA/L, CHARMM-27, GROMOS-54a7 plus the two
variants ff99sb-ildn_ASN and OPLS-AA/L_ASN) to reproduce NMR-derived
observables for five isoDGR-containing cyclopeptides has been tested. I performed
40 simulations, for a total of 17 µs, using BE-META to guarantee the exhaustiveness
of the sampling. The accuracy of each force field has been quantified by means of
a χ2 metrics, where experimental J scalar couplings and chemical shifts have been
compared with the corresponding back-calculated observables.
The comparison between experimental and back-calculated chemical shifts resulted
to be not particularly significant since a similar agreement was found for all the force
fields considered. Herein the high flexibility of the investigated peptides and the
poor influence of the chemical environment resulted in chemical shifts comparable
to the ones of a random coil, as confirmed both by NMR and simulations.
Therefore I focused my attention on the reproducibility of J scalar couplings,
specifically highlighting the differences between the 3JHN,Hα, associated to the φ
dihedral angles common to all the amino acids, and the 3J isoDHα,Hβ, related to the ξ
dihedral angle characteristic of isoAspartate backbone. We found that most of the
considered force fields can well reproduce the experimental 3JHN,Hα scalar couplings,
suggesting that in general the dynamic of cyclopeptides can be accurately predicted
with exhaustive explicit-solvent MD simulations. These results are in line with the
study of Wu and coworkers, [229] which reported that a good accuracy can be achieved
in predicting the crystal structures of cyclopeptides. The only exceptions comprise
the GROMOS-54a7 force field, which shows a poor agreement with experimental
3JHN,Hα, and the two variants of OPLS-AA/L force field, which confirmed their
limitations and weaknesses in accurately sampling dihedral angles conformations. A
direct comparison with data presented in literature, concerning the reproducibility
of NMR scalar couplings in the case of linear peptides, is not straightforward:
several choices can indeed influence the estimation of the error (χ2) and in many
studies diverse metric to evaluate this discrepancy has been chosen. Of note, in
reference [230] the ability of different force fields in reproducing the J couplings
of a polyalanine peptide was tested using the same metric and sets of Karplus
parameters as in this thesis, allowing a more quantitative comparison. Herein it
was shown that the force fields ff99sb, OPLS-AA/L, CHARMM-27 and a precedent
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version of GROMOS (53a6) performed quite well obtaining χ2 values ranging from
a minimum of 1.8 to a maximum of 2.3. These values are perfectly in line with the
ones reported in this thesis in the cases of AMBER and CHARMM force fields,
suggesting that cyclopeptides can be simulated with an accuracy comparable to the
one of linear peptides in these frameworks. Conversely, quite different results were
obtained when using the other force fields (OPLS and GROMOS), which display a
significantly worse agreement with experiments in the case of cyclic peptides. On
the other side, more then one study [109,110] reported that OPLS-AA/L performs
worse than AMBER ff99sb and CHARMM-27 in reproducing J scalar couplings: it
is therefore difficult to conclude whether the poor performance of OPLS is due to
cyclization or to intrinsic defects of the force field.
Concerning the reproducibility of the 3J isoDHα,Hβ scalar couplings, characteristic of
isoAspartate, I found that only two out of the eight force fields considered (i.e.
AMBER ff99sb-ildn and AMBER ff99sb*-ildn) are able to achieve an accuracy
comparable to the systematic uncertainty. Overall these data suggest that the
presence of isoAspartate in cyclopeptides backbone can strongly affect the reliability
of the simulations and that transferability of force fields parameters to non standard
amino acids is not straightforward.
I finally investigated how the choice of the parameters to describe isoAspartate
torsional angle energetics could influence the reproducibility of the other residues’
3JHN,Hα. To this aim I considered the AMBER ff99sb-ildn force field and the
OPLS-AA/L force field, for which two possible parameters sets for isoAspartate
torsional potentials have been used. I found that, while AMBER ff99sb-ildn is
robust to variation of these parameters, in OPLS-AA/L, the torsional potential
used for isoAspartate could influence the dynamic of the surrounding atoms, and
specifically of the two residues following isoAspartate.
Of note all the conclusions here reported hold also when considering a different set
of Karplus parameters for the back-calculation of the J couplings.
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4.1.4 Methods
4.1.4.1 Experimental data used for the comparison
As benchmark for the force field evaluation, I used a set of 79 NMR measure-
ments, experimentally obtained from NMR experiments performed on five isoDGR-
containing cyclopeptides. These isoDGR-peptides include two molecules cycled
through a disulfide bridge (CisoDGRC and its acetylated variant acCisoDGRC [75])
and three head-to-tail cyclic hexapeptides (c(CGisoDGRG), c(GCisoDGRG) and
c(CphgisoDGRG) [76]). The NMR measurements consist in 38 chemical shifts, in-
volving the C, Cα, Cβ, HN and Hα atoms of natural amino acids, and 41 J scalar
couplings. Specifically the J couplings can be subdivided in 31 3JHN,Hα, linked
to the φ backbone dihedral angles, and 10 3J isoDHα,Hβ, which describe the backbone
dihedral angle N-Cα-Cβ-C (ξ) characteristic of isoAspartate. In Table 4.1 all the
NMR data employed, subdivided by type and by molecule, are listed.
The acquisition of the NMR data was performed on a Bruker Avance-600 spec-
trometer (Bruker BioSpin) equipped with a triple-resonance TCI cryo-probe with
an x, y, z shielded pulsed-field gradient coil. For each molecule, 1H-1D, TOCSY
(TOtal Correlation SpectroscopY, tmix=60 ms), ROESY (Rotating frame nuclear
Overhauser Effect SpectroscopY, tmix=100-400 ms), HSQC (Heteronuclear Single
Quantum Coherence) and HMBC (Heteronuclear Multiple Bond Correlation) NMR
spectra of 1-10 mM sample (90% H2O, 10% D2O) at 280-285 K and pH 6 have been
Table 4.1: Summary of the NMR data. Quantity of the experimental observables
used as benchmark, subdivided by type (J coupling or Chemical Shift) and by molecule.
Peptide J couplings Chemical Shifts Total
3JHN,Hα
3J isoDHα,Hβ CSC CSCα CSCβ CSHα CSHN
CisoDGRC 5 2 - - - - - 7
acCisoDGRC 5 2 - - - - - 7
c(CGisoDGRG) 5 2 3 3 2 4 3 22
c(GCisoDGRG) 9 2 3 3 1 5 3 26
c(CphgisoDGRG) 7 2 - 2 1 3 2 17
Total 31 10 6 8 4 12 8 79
112
4.1. Are current MD force fields reliable for the study of isoDGR-cyclopeptides?
recorded. Water proton signal was suppressed with excitation sculpting sequence.
For c(CphgisoDGRG) a 1H-1D NMR spectrum in 100% D2O was also acquired.
Proton resonances were assigned by conventional 2D experiments, including TOCSY
and ROESY. Free induction decays were acquired (24-64 scans) over 5000-8000 Hz,
into 2k data block for 256-512 incremental values of the evolution time (States-
TPPI). Data were processed with TOPSPIN 3.2 (Bruker BioSpin GmbH, Rheinstet-
ten, Germany) by apodization with 90° shifted sine-bell squared (qsine) window,
and zero-filling in the indirect dimension to 1k points. Peptide assignments and
peak lists were generated using CcpNmr. [243] The 3JHN,Hα and 3J isoDHα,Hβ coupling con-
stants were obtained directly from the resolved amide, α or β protons resonances of
well digitized mono-dimensional spectra (40k points). The methylene stereo-specific
assignments were derived by comparison of the experimental J coupling values and
relative ROEs.
4.1.4.2 Simulations details
Input conformations of the peptides
An initial conformation for the cyclic head-to-tail hexapeptide c(isoDGRGGG)
was generated using the Maestro 2D sketcher tool and energy minimized. The
CNS [244] (Crystallography & NMR System) program was then employed to replace
Glycines with proper amino acids to generate c(CGisoDGRG), c(GCisoDGRG) and
c(CphgisoDGRG). A second minimization run was finally performed using Gromacs.
The peptides cycled with a disulfide bond were instead directly generated with
CNS and subsequently minimized with Gromacs. The two Cysteines of CisoDGRC
were capped with NH+3 and COO− groups, respectively, consistently with a pH
value of 7. In acCisoDGRC the first Cysteine was instead acetylated, resulting in a
molecule with a total negative charge of -1.
Force fields and parameterization
Each of the cyclopeptides has been simulated with the following six force fields:
AMBER ff99sb-ildn, [233] AMBER ff99sb*-ildn, [216] AMBER ff14sb, [106] OPLS-
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AA/L, [222] CHARMM-27 [235] and GROMOS-54a7. [236] Additionally, I performed
the same simulations with two variants of the AMBER ff99sb-ildn and of the
OPLS-AA/L force fields (denoted as ff99sb-ildn_ASN and OPLS-AA/L_ASN
respectively), in which the dihedral angles parameters specifically optimized for
Asparagine side-chain have been employed in the description of isoAspartate. Thus
I simulated a total of 40 systems, consisting in 5 molecules with 8 different force
field variants.
Parameterization of isoAspartic residue was performed assigning the atom-types of
Asparagine side-chain to the backbone atoms of isoAspartate and the atom-types
of C-terminal carboxylate backbone to the side-chain atoms of isoAspartate. Pa-
rameters for Phenylglycine were derived from the ones of Phenylalanine, applying
appropriate dihedral angles. In the case of AMBER force fields the atomic partial
charges of both Phenylglycine and isoAspartate atoms were derived using the R.E.D.
III (RESP ESP charge Derive) package. [245] Specifically, two different conformations
for both Phenylglycine and isoAspartate dipeptides (i.e. the amino acid capped
with the acetyl and N-methyl groups) have been generated with Maestro, [226] then
GAMESS [246] package was used for geometry optimization in the gas phase and
for the computation of the molecular electrostatic potentials (MEP). For the MEP
computation, the HF/6-31G* level of theory and the Connolly surface algorithm
were employed; additionally four different molecular orientations for each optimized
geometry have been considered using the rigid-body reorientation algorithm im-
plemented in the R.E.D. tool. Finally, the two-stages RESP method was used for
the fitting of the atomic charges following the procedure originally published by
Kollman et al. [247] Intra-molecular constraints were imposed to set the charges of the
acetyl and N-methyl capping groups to zero; additionally charges equivalences were
imposed to hydrogens of methyl and methylene groups, to oxygens of carboxylate
ions and to symmetric atoms in the phenyl group. The derived RESP partial
charges for Phenylglycine and isoAspartate atoms are reported in Table B.1.
For the water molecules topology, I used the TIP3P [113] model in all the simulations
with the exception of the ones performed with the GROMOS-54a7 force field. In
this situation the SPC water model has been preferred: SPC is indeed strongly
recommended by the GROMOS developers since this was the water model used
during force field parameterization and optimization. [115]
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Simulation set up
All the 40 MD simulations have been performed using the Gromacs-5.0.4 software [86]
and the Plumed 2.1.3 plugin. [248] Each system has been solvated in a cubic box and,
in the cases of CisoDGRC and acCisoDGRC, has been neutralized by adding Na+
and Cl− ions to a concentration of 100 mM. The dimensions of the box were chosen
so that the minimum distance between any peptide’s atom and the box edges
was bigger than 1.2 nm. The initial energy minimization has been followed by a
three-stages equilibration procedure consisting in: i. 2 ns equilibration in the NVT
ensemble, where the v-rescale thermostat was used to maintain temperature at 280
K; ii. 2 ns in the NPT ensemble, where Berendsen barostat and v-rescale thermostat
were employed to control pressure and temperature (1 bar and 280 K); iii. 4 ns in
the NPT ensemble where the Berendsen barostat was replaced by the Parrinello-
Rahman one (with the exception of simulations performed with GROMOS-54a7 in
which Berendsen barostat was chosen). Positional restraints on the peptides’ heavy
atoms have been employed in the first two steps of equilibration and have been then
released in the last stage. The relaxation time for the barostat was of 1 ps while
the thermostat coupling time constant was of 100 fs (cyclopeptides and solvent
molecules were coupled to independent thermostats). During the equilibration the
LINCS algorithm was applied to constraint all the bond lengths. In all the cases
the md integrator was used with a time step of 2 fs. A cut-off of 1.0 nm was used
to truncate both the van der Waals and the electrostatic interactions; long range
electrostatic interactions beyond the cut-off were treated with Particle-Mesh Ewald
method (Fourier grid spacing of 0.12 nm and interpolation order of 4). [122,223]
Bias Exchange Metadynamics Simulations
The BE-META simulations, in standard formalism, were performed in the NVT
ensemble, setting the temperature at 280 K by means of the v-rescale thermostat
(coupling time constant of 100 fs) and using the same settings described for
equilibration. [98] During this production run all the bond lengths involving hydrogen
atoms have been constrained. Gaussian hills were added every 1 ps (height: 0.24
kcal mol−1, width: 0.2 rad) and exchanges between pairs of replica were attempted
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every 15 ps. Herein an acceptance rate between 15% and 25% was observed.
In the five molecules all the dihedral angles describing the cycle (with the exception
of the Ω dihedral angles associated to the planarity of the peptide bonds) have
been used as collective variables, resulting in the bias of:
i. 13 CVs for the cyclic head-to-tail hexapeptides. These comprise 5 φ and 5 ψ
dihedral angles plus the 3 dihedral angles describing isoAspartate, namely φ′
(Ci-1-Ni-Cαi-Cβi), ξ (Ni-Cαi-Cβi-Ci) and ψ′ (Cαi-Cβi-Ci-Ni+1);
ii. 14 CVs for CisoDGRC, consisting in: the φ dihedral angles of Arginine,
Glycine and Cysteine-5; the ψ dihedral angles of Cysteine-1, Arginine and
Glycine; the 3 dihedral angles describing isoAspartate (φ′, ξ and ψ′); plus the
5 dihedral angles describing the disulfide bridge. Specifically, these are the
χ1 (N-Cα-Cβ-S and N’-Cα’-Cβ’-S’) and χ2 (Cα-Cβ-S-S’ and Cα’-Cβ’-S’-S)
dihedral angles of the two Cysteines, plus the dihedral χ3 (Cβ’-S’-S-Cβ).
Herein the primed atoms are the ones of Cysteine-5 and the non-primed ones
of Cysteine-1 (or vice versa).
iii. 15 CVs for acCisoDGRC, comprising the 14 CVs used for CisoDGRC plus the
φ dihedral angle of Cysteine-1.
During the BE-META simulations, one of the listed CVs was biased in each replica.
The length of each replica was of 30 ns, except for simulations that did not reach
convergence and that were then prolonged to 40 ns per replica. The convergence was
checked comparing the mono-dimensional free-energy profiles derived by averaging
on the two halves of the simulation as described in section 3.2.2. In all the cases
the convergence was reached and the difference between the two profiles was found
to be lower than 2kbT .
4.1.4.3 Comparison between computed and NMR data
Analysis of BE-META simulations
In order to recover the equilibrium properties of the simulated systems from
BE-META trajectories I used the method proposed by Laio and coworkers. [138]
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Herein the structures visited during the simulations are grouped in microstates
according to the values adopted by a reduced number of CVs, then the equilibrium
population of each microstate is computed exploiting a weighted histogram analysis
method (WHAM) based on the Metadynamics mono-dimensional potentials (see
section 2.2.3).
The clustering of the structures and the evaluation of microstates free-energy was
performed with the help of the Metagui tool. [141] A subset of the biased CVs was
used to this aim. Specifically, in the case of head-to-tail cyclic hexapeptides 7
CVs have been used, consisting in the 6 ψ dihedral angles and in the ξ dihedral
characteristic of isoAspartate. Conversely, for the two peptides cycled with a
disulfide bond the CVs employed for microstates identification are the ψ dihedral
angles of the first four amino acids, the χ1 of Cysteine-5 and the ξ dihedral
characteristic of isoAspartate. The variables identifying this subspaces and the
optimal grid spacings (ranging between the 45° and 52°) have been individuated
after several trials where different combinations of CVs have been tested. The main
criteria used to select these CVs were: i. the microstates had to be characterized
by low internal RMSD between conformations; ii. all the low-energy microstates
(i.e. the ones with energy lower than 3kbT ) had to be connected. Of note, despite
the relatively large bin width used, necessitated by the high dimensionality of the
investigated subspace, the grid employed is able to follow the energy landscape
pretty finely (see Figure B.8).
In this context, it has been possible to compute the average equilibrium value of
an observable X using the following equation: [138]
〈X〉 =
∑
µXµe
−Fµ/kbT∑
µ e−Fµ/kbT
, (4.1)
where Fµ is the free-energy of microstate µ, estimated according to the WHAM
procedure, kb is the Boltzmann constant, T is the temperature and Xµ is the
arithmetic average of X in microstate µ.
117
Chapter 4. Structural characterization of isoDGR-based cyclopeptides
Back-calculation of J couplings and chemical shifts
For each of the structures clustered in a microstate, the Karplus relation (see
equation 3.3), [224] was used to back-calculate the J coupling constants. In the case
of 3JHN,Hα I used θ = φ−60° for L-amino acids, θ = φ+60° for D-amino acids
and both for Glycines. In the case of 3J isoDHα,Hβ, θ was both θ = ξ and θ = ξ−120°,
where ξ is the dihedral angle N-Cα-Cβ-C characteristic of isoAspartate backbone.
Following the examples of [230,249], and considering that Karplus relation is sensitive
to the coefficients used, I employed two sets of Karplus parameters for the back-
calculation of 3JHN,Hα. The first set, denoted as ORIG, comprises parameters from
the original paper, [241] while the second set, called DFT, was derived from DFT
calculations on Alanine dipeptide. [242] The two sets of Karplus parameters used
for the back-calculation of 3JHN,Hα and the ones used for 3J isoDHα,Hβ [225], along with
the estimated systematic errors, are reported in Table 4.2. These errors, arising
in the estimation of the scalar couplings using the Karplus relation, could have
different sources. In fact several factors are neglected in its parameterization: these
include the effect of substituents’ nature, of their relative orientation, of the valence
angles and of the bond lengths. [250] For 3JHN,Hα a systematic error of 0.70 Hz was
assumed, as done in [230]. In the case of 3J isoDHα,Hβ couplings a slightly higher error
(0.90 Hz) was used, both because the substituents effect could be more relevant
and because these parameters are less studied and developed. [251]
The chemical shifts of C, Cα, Cβ, Hα and HN atoms for the head-to tail hexapep-
tides, were back-calculated using the Sparta+ program on each of the structures
clustered in microstates. [239] The prediction of chemical shifts has been limited to
Table 4.2: Karplus parameters. In Table are reported the Karplus parameters used
for the back-calculation of both 3JHN,Hα and 3J isoDHα,Hβ . The associated estimated error σ
is also reported.
Coupling Set A [Hz] B [Hz] C [Hz] σ [Hz]
3JHN,Hα
ORIG [241] 7.09 -1.42 1.55 0.70
DFT [242] 9.44 -1.53 -0.07 0.70
3J isoDHα,Hβ
[225] 10.2 -1.8 1.9 0.90
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Table 4.3: Sparta+ errors. Estimated errors for the chemical shift predictions, as
reported by the Sparta+ developer. [239]
Atoms
C Cα Cβ Hα HN
Error [ppm] 1.09 0.94 1.14 0.25 0.49
those residues which are not neighbors of non standard amino acids (i.e. Phenyl-
glycine and isoAspartate) because: i. Sparta+ has been parameterized empirically
and trained on a database of protein composed by natural amino acids and ii.
Sparta+ uses information from both residues i+1 and i-1 to predict the chemical
shifts of atoms in residue i. The systematic errors associated to these chemical
shift predictions are the ones determined in the original paper (see Table 4.3). [239]
Average J couplings and chemical shifts (CSs) have been then computed using
equation 4.1.
To evaluate the performances of the different force fields I quantified the agree-
ment between back-calculated and experimental data using the following equa-
tion: [110,230,249]
χ2(Xexp, Xcomp) =
1
N
N∑
i=1
(〈Xi〉comp −Xi,exp)2
σ2i
, (4.2)
where X can be both scalar couplings or chemical shifts (deriving from the simula-
tion average and from the NMR experiments), N is the total number of experimental
data used and σi is the error associated to the valueXi (see Tables 4.2 and 4.3).
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4.2 Rationalizing affinity and selectivity of isoDGR-
based hexapeptides
4.2.1 Introduction: isoDGR-based peptides as drug deliv-
ery agents
After the discovery that the isoDGR sequence is an integrin recognition motif, [70]
diverse attempts to study isoDGR-based peptides and peptidomimetics that could
work as integrin inhibitors or as drugs delivery agents have been performed. [75–79]
The isoDGR motif could indeed represent a new opportunity for the development of
a novel generation of integrin-targeting ligands, displaying different characteristics,
including affinity, selectivity and signaling effects, with respect to the widely studied
RGD-based peptides.
Among the most interesting studies in this field, the group of Corti [76] has published
a work in which a set of isoDGR-based cyclic hexapeptides, displaying different
affinity and selectivity profiles for the two integrins αvβ3 and α5β1, both related to
cancer, was presented. In particular, they have shown that one cyclic hexapeptide,
c(CGisoDGRG), after conjugation to human serum albumin (HSA), a serum protein
that works as a transport system for small molecules in blood, selectively recog-
nizes integrin αvβ3, binds to tumor vessels and inhibits tumor growth. Chemical
conjugation of c(CGisoDGRG) with HSA was achieved by using sulfoSuccinimidyl-
4-(N-Maleimidomethyl)Cyclohexane-1-Carboxylate (sulfo-SMCC), a bi-functional
cross-linker often employed to link thiol-groups (which are available in the cyclopep-
tide thanks to the presence of a Cysteine in its sequence) and amino-groups. It
has been shown that this chemical linker plays an important role in regulating
cyclopeptide affinity: indeed conjugation of c(CGisoDGRG) with the linker (in
which the reactive sulfo-succinimide group was blocked with ammonium chloride
during the reaction as described in reference [76], see Figure C.1 and Figure 4.9)
resulted in an improved affinity and selectivity of the peptide toward αvβ3 integrin.
Of note this cyclopeptide, conjugated with HSA, can be used to prepare isoDGR-
120
4.2. Rationalizing affinity and selectivity of isoDGR-based hexapeptides
Figure 4.9: 2D-representation of the investigated molecules. 2D-structures of the
isoDGR-based cyclopeptides c(CGisoDGRG), c(GCisoDGRG) and c(CphgisoDGRG),
and of the c(CGisoDGRG)-linker conjugate.
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Table 4.4: Affinity and selectivity of the investigated molecules. The inhibition
constant Ki, as measured by competitive binding assays, [76] of the three cyclopeptides
c(CGisoDGRG), c(GCisoDGRG), c(CphgisoDGRG) and of the c(CGisoDGRG)-linker
conjugate to integrins αvβ3 and α5β1, is reported.
Cyclopeptide Ki [nM] Ki(α5β1)/Ki(αvβ3)
αvβ3 α5β1
c(CGisoDGRG) 103 ± 18 320 ± 49 3
c(GCisoDGRG) 43 ± 9.6 21 ± 5.1 0.5
c(CphgisoDGRG) 1493 15 0.01
c(CGisoDGRG) + linker 35 ± 6 302 8.6
tagged gold nanoparticles, working as a nanosystem for the delivery of drugs, and
specifically of cytokines, to tumor vessels. Indeed several clinical studies have shown
that conjugation of cytokines, as Tumor Necrosis Factor, with peptides targeting
tumor vasculatures is a useful strategy to improve their therapeutic efficacy. [252]
In this context the conjugated peptide selectively recognizes tumor vasculature
by targeting specific integrin subtypes and allows the administration of extremely
low doses of drugs, avoiding unwanted side effects, possible toxic reactions and
preventing the activation of counter-regulatory mechanisms that could contrast the
therapeutic effects of cytokines.
Since the molecular scaffold of the isoDGR-based peptides is responsible of the
integrin biding affinity and selectivity, it could be of interest rationalizing the
structural basis of integrin recognition by the three cyclopeptides included in the
study: [76] c(CGisoDGRG), c(GCisoDGRG), and c(CphgisoDGRG), the latter highly
selective for α5β1 integrin (see Figure 4.9 and Table 4.4). These three cyclopeptides
display a high similarity in their sequences and differ only in the two amino acids
preceding isoAspartate. Of note, these flanking residues appear to strongly influence
peptide affinity to integrin. Unveiling the conformational determinants underlying
these different affinities and selectivities profiles could be useful to provide the basis
for a rational design of highly active and selective isoDGR-based compounds. Herein
understanding why the conjugation of c(CGisoDGRG) with the chemical linker
results in an improved affinity and selectivity of the peptide toward αvβ3 integrin
would strongly contribute in the development of improved integrin inhibitors.
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From a methodological point of view, this system constitutes an ideal test case to
evaluate the ability of the proposed computational protocol in predicting the effects
of the type of residues flanking the isoDGR motif on cyclopeptides conformation
and on integrin affinity and selectivity. Unlike the introduction of backbone
N -methylation, this feature is expected to regulate integrin affinity by favoring
additional stabilizing interactions with the receptor, and not only by conformational
modulation of the recognition motif. This test would therefore represent a natural
complement to the results described in Chapter 3.
Applying the multi-stage computational protocol I have been able to score the three
cyclopeptides c(CGisoDGRG), c(GCisoDGRG) and c(CphgisoDGRG) according to
their affinity towards integrins αvβ3 or α5β1; additionally, the visual inspection of
the decoy poses herein generated provided an explanation for the high selectivity of
c(CphgisoDGRG) for α5β1. Finally, thanks to a combination of NMR experiments
performed in the laboratory and computational techniques, I proposed possible
models that rationalize the improved affinity of c(CGisoDGRG)-linker conjugate
for αvβ3 with respect to c(CGisoDGRG).
4.2.2 Results and Discussion
4.2.2.1 Conformational analysis
In order to reconstruct the free-energy conformational landscape of c(CGisoDGRG),
c(GCisoDGRG) and c(CphgisoDGRG), I have performed BE-META simulations
using the AMBER ff99sb-ildn force field and biasing all the backbone dihedral
angles of the cyclopeptides except the ones related to the planarity of the peptide
bonds, which are assumed to be always in trans conformation. Therefore for
each peptide a 13-replicas simulation of 390 ns was run. After a careful check
of the convergence (Figure C.2), the free energy has been reconstructed in a
space of reduced dimensionality, defined by a subset of the biased CVs. These
CVs comprise the 6 ψ dihedral angles of all the residues and the ξ dihedral (N-
Cα-Cβ-C) characteristic of isoAspartate. All the details are in Section 4.2.4.1.
Within this space, minima populated more than 10% have been identified and
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Table 4.5: Structural characterization of the BE-META minima. For each
cyclopeptide minima populated more than 10% have been characterized according to
the presence of tight turns (α, β or γ represented in red, orange and green, respectively).
The turns have been individuated detecting the presence of intramolecular backbone
hydrogen bonds1 and the turn types have been assigned comparing the average values of
the dihedral angles involved in the turn with the expected reference values reported in
Table C.1.
Cyclopeptide Population Turns
Type Representation
c(CGisoDGRG)
27% βI c(CGisoDGRG)
27% βI’ c(CGisoDGRG)
17% βI c(CGisoDGRG)
14% II-αRU c(CGisoDGRG)
c(GCisoDGRG)
39% II-αRS and γ c(GCisoDGRG)
30% I-αLS c(GCisoDGRG)
15% βI’ c(GCisoDGRG)
c(CphgisoDGRG)
32% βII’ c(CphgisoDGRG)
28% βI’ and βI c(CphgisoDGRG)
21% βI c(CphgisoDGRG)
1 Hydrogen bonds were individuated with the VMD [215] Hbonds plugin. A donor-acceptor
distance of 3.5 Å and an angle cutoff of 35° have been considered. Only hydrogen bonds
present in at least 40% of the structures were considered.
characterized. The equilibrium minima population has been derived analyzing
the BE-META trajectories following a procedure analogue to the described in
Section 3.4.2 and using equation 3.2. The accuracy of these simulations is supported
by the good reproducibility of the experimental J couplings, as shown in the previous
Section.
The conformational analysis revealed that these cyclopeptides are quite flexible,
being able to populate three or four different minima, which are structurally char-
acterized by diverse patterns of hydrogen bonds and turns, as reported in Table 4.5
and in Figure C.3. This kind of characterization is relevant in cyclopeptides since
it is well recognized that cyclic hexa-peptides generally stabilize their conformation
via a double β-turns fold. [201] The definition of the turns, according to the presence
of hydrogen bonds and to the values adopted by the φ and ψ dihedral angles of
the amino acids involved, is given in Table C.1.
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The structural analysis of the BE-META conformers revealed that none of the
cyclopeptides, with the exception of c(CphgisoDGRG), is able to adopt the stable
double β-turns fold, characteristic of hexapeptides. Locally, the regions of the
cyclopeptides not including isoAspartate can organize themselves in turn struc-
tures, which can adopt either the β conformation or the α conformation, the latter
occurring less frequently in proteins. [253] However, the presence of the additional
isoAspartate Cβ atom in the backbone, which is absent in the other amino acids,
prevents the formation of the second β-turn around isoAspartate and, consequently,
the adoption of the stable double β-turns fold. The high flexibility displayed by
these molecules could therefore be ascribed to the presence of this additional Cβ
atom.
This situation, which prevents the pre-organization of the cyclopeptides in a stable
preferential conformation, hampers a clear evaluation of the interplay between
molecules’ conformation and binding affinity. To account for the system confor-
mational flexibility, I used the conformers extracted from BE-META minima as
input for docking calculations. This choice is in accordance with the well-accepted
assumption that an exhaustive conformational sampling of the cyclopeptides could
be useful to improve the accuracy of docking results. [207]
4.2.2.2 Docking calculations
In order to rationalize the different affinity and selectivity profiles displayed by
the three molecules, I docked for each cyclopeptide the conformers extracted from
BE-META minima into the crystal structures of the two integrins αvβ3 and α5β1
(PDB codes 1L5G [9] and 4WK4, respectively). To this aim two different docking
programs have been used: the Glide software in combination with Prime MM-
GB/SA rescoring (Schrödinger suite) [152,178] and HADDOCK, [153] an information-
driven docking software. Details of the docking protocols adopted are described in
Section 4.2.4.2 and 4.2.4.3. For each of the twelve systems (three cyclopeptides
docked in two integrins using two different docking software), a cluster analysis,
according to geometric criteria, of the decoy poses was performed and an average
score was assigned to each cluster. Then, the best scored cluster, in terms of
MM-GB/SA score or HADDOCK score, resembling the canonical electrostatic
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clamp with integrin was selected.
The correlation between the inhibition constants Ki, experimentally measured
for each integrin-cyclopeptide complex as described in [76], and the corresponding
average cluster scores, obtained with either the Glide software (upper panel) or with
HADDOCK (lower panel), is reported in Figure 4.10. It can be observed that, while
HADDOCK failed to correctly predict the best binders towards both the receptors,
the combination of Glide and MM-GB/SA rescoring perfectly discriminates binders
(i.e. cyclopeptides displaying a Ki in the range of tens of nanomolar for the receptor)
from weak binders (i.e. Ki values in the range of hundreds of nanomolar). The poor
performance of HADDOCK in ranking cyclopeptides according to their binding
affinity is not unexpected, since it is well known that this program has not been
developed to this aim. Accordingly, also the visual inspection of the docking
poses obtained with HADDOCK does not allow to discriminate and rationalize
the different affinity and selectivity profiles of c(CGisoDGRG), c(GCisoDGRG)
and c(CphgisoDGRG) for integrins αvβ3 and α5β1. Therefore, in the following
I will focus on the results obtained using the Glide software. A representative
binding mode for each of the six systems investigated and the associated MM-
GB/SA contributions are reported in Figure 4.11, Figure 4.12 and in Table 4.6,
respectively. The analysis of the MM-GB/SA terms revealed that, in αvβ3 integrin,
the better affinity displayed by c(CGisoDGRG) and c(GCisoDGRG) with respect to
c(CphgisoDGRG) is mainly due to a more favorable polar contribution; conversely,
in α5β1, the better affinity of c(CphgisoDGRG) and c(GCisoDGRG) with respect
to c(CGisoDGRG) can be ascribed to a more favorable non polar term. The
analysis of the decoy poses, complemented by the knowledge of these contributions,
allowed to rationalize the diverse affinity of the three cyclopeptides.
Docking results on integrin αvβ3 (Figure 4.11) show that all the three cyclopeptides
are able to bind the receptor reproducing the canonical electrostatic clamp: on one
side the guanidinium group of Arginine engages a salt bridge with the carboxylate
group of either αv:Asp150 and/or αv:Asp218; on the other side the isoAspartate
carboxylate group contributes to the coordination of the metal cation at the
MIDAS site and establishes hydrogen bonds with β3:Asn215. Moreover, in the
three complexes, the Arginine side chain engages similar hydrophobic interactions
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Figure 4.10: Predicted vs Experimental affinity. For each cyclopeptide, the corre-
lation between Ki inhibition constants and predicted binding affinities, with either the
Prime MM-GB/SA tool (upper panel) or with HADDOCK software (bottom panel), for
αvβ3 (left panel) or α5β1 (right panel) integrins, is represented.
with αv:Tyr178. However, significantly different binding modes within the αvβ3
binding pocket are displayed by c(CGisoDGRG) and c(GCisoDGRG) with respect
to c(CphgisoDGRG). The first two molecules (Figure 4.11, top and middle panel),
indeed, are able to establish a pattern of hydrogen bonds that is not observed in the
αvβ3-c(CphgisoDGRG) complex. Specifically, in these two molecules, the Glycine of
the isoDGR motif forms an hydrogen bond with the carbonyl group of β3:Arg216;
additionally the residues flanking the isoDGR sequence engage two hydrogens
bonds with β3:Arg214 and αv:Tyr178. Further, this pattern of polar interactions
is stabilized by additional hydrophobic contacts: the Cysteine of c(CGisoDGRG)
establish non polar interactions with the side chain of β3:Met180 while the Cysteine
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Figure 4.11: Representative binding modes of c(CGisoDGRG),
c(GCisoDGRG) and c(CphgisoDGRG) in complex with integrin αvβ3,
according to Glide software. αv and β3 subunits are represented in green and blue
surface, respectively. Receptor amino acids engaging direct interactions with the ligands
are shown in stick and labeled with the three-letter code. Metal ions are represented as
yellow spheres and peptides are shown in white sticks.
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Table 4.6: Energetic contributions. The average MM-GB/SA values and individual
contributions are reported for the selected cluster of each of the six systems investigated.
All the values reported are obtained by averaging on the contributions of the best four
poses of the cluster. The Polar term is computed as sum of Coulomb and Generalized
Born electrostatic solvation energy; the Non-Polar term is the sum of van der Waals
and lipophilic energy, while Other contributions include covalent binding, hydrogen-
bonding, pi-pi packing energy and self-contact correction. Additionally, for each system,
the inhibition constant Ki is reported.
Cyclopeptide Ki Energetic Contributions [kcal mol−1]
MM-GB/SA Polar Non Polar Other
αvβ3
c(CGisoDGRG) 103±18 -59.5±0.4 -9.1±1.1 -54.9±0.7 4.5±0.5
c(GCisoDGRG) 43±9.6 -55.9±1.4 -2.6±4.4 -57.5±5.0 4.2±3.5
c(CphgisoDGRG) 1493 -41.8±1.6 8.2±1.7 -54.2±1.5 4.2± 0.9
α5β1
c(CGisoDGRG) 320±49 -36.3±4.3 11.3±1.4 -45.7±1.8 -1.9±2.4
c(GCisoDGRG) 21±5.1 -48.7±1.2 12.8±3.3 -55.6±1.2 -5.9±1.6
c(CphgisoDGRG) 15 -44.8±6.2 10.7±7.0 -54.4±3.6 -1.1±2.9
of c(GCisoDGRG) contacts β3:Tyr122. Differently, c(CphgisoDGRG) can not
engage the numerous polar interactions described above (Figure 4.11, bottom panel).
In the αvβ3-c(CphgisoDGRG) complex, the electrostatic clamp is stabilized only
by hydrophobic interactions with β3:Tyr122 and one polar interaction, consisting
in the thiol group of Cysteine that contacts the carboxylate group of β3:Asp251.
Consistently with these observations, the MM-GB/SA polar contributions of αvβ3-
c(CphgisoDGRG) complex is significantly lower with respect to the one obtained
by the other two cyclopeptides (Table 4.6). Considering that the non polar MM-
GB/SA contributions are similar in the three complexes, these observations well
explain the significantly better affinity towards αvβ3 displayed by c(CGisoDGRG)
and c(GCisoDGRG) with respect to c(CphgisoDGRG). Conceivably, the bulky
hydrophobic residue Phenylglycine is not well tolerated by the buried binding
pocket of αvβ3, characterized by the presence of several polar residues as β3:Arg214,
β3:Arg216 and αv:Tyr178.
Focusing on the complexes with integrin α5β1 (Figure 4.12), docking results
suggest that both c(CGisoDGRG) and c(CphgisoDGRG) perfectly recapitulate the
canonical electrostatic clamp: herein the isoAspartate carboxylate group coordinates
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the metal cation at the MIDAS site and the Arginine guanidinium group establishes
a bidentate salt bridge with α5:Asp227, engaging also an hydrogen bond with
α5:Gln221. A slightly different binding mode of the isoDGR motif is observed
in the α5β1-c(GCisoDGRG) complex: the Arginine guanidinium group forms
hydrogen bonds with α5:Asp228 and α5:Asp227, while isoAspartate, in addition to
coordinating the metal cation of the MIDAS site, establishes hydrogen bonds with
β1:Ser134 and β1:Asn224. In all the three complexes hydrophobic interactions
between the isoDGR motif and the α5:Phe187 stabilize the electrostatic clamp.
In addition to the electrostatic clamp, quite different patterns of interactions are
observed in the three complexes. c(CGisoDGRG)-α5β1 complex (Figure 4.12,
top) is stabilized by an hydrogen bond between the Glycine of isoDGR motif and
β1:Leu225, but the residues flanking the isoDGR motif do not contribute in engaging
further interactions. Conversely, c(GCisoDGRG) (Figure 4.12, middle), in addition
to the hydrogen bond with β1:Leu225, engages further stabilizing interactions
with α5β1, including contacts with α5:Trp157, β1:Asn224 and β1:Tyr133. Of
note, the last two contacts are engaged by the Cysteine preceding isoAspartate,
which in c(CGisoDGRG) is replaced by a Glycine. In agreement with this remark,
the MM-GB/SA non-polar contribution in the α5β1-c(CGisoDGRG) complex
in significantly lower with respect to the one of α5β1-c(GCisoDGRG). Finally,
in α5β1-c(CphgisoDGRG) (Figure 4.12, bottom), the cyclopeptide presents a pi-
stacking interaction between the phenyl group of D-Phenylglycine and β1:Tyr133;
additionally, the thiol group of Cysteine forms an hydrogen bond with the carbonyl
group of β1:Asp259, establishing further contacts with β1:Glu320 and β1:Phe321.
This interactions pattern is consistent with the low nanomolar Ki displayed by
this peptide; accordingly, both polar and non polar MM-GB/SA contributions
are comparable with the ones of α5β1-c(GCisoDGRG). These results well explain
the better affinity for α5β1 shown by c(GCisoDGRG) and c(CphgisoDGRG) with
respect to c(CGisoDGRG), which can be mainly ascribed to non-polar contributions.
Overall these data suggest that the presence of a Glycine as residue preceding
isoAspartate lead to moderate affinity for α5β1: indeed this amino acid, due to
the lack of side chain, is not able to engage additional stabilizing interactions with
the wide binding pocket of the receptor.
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Figure 4.12: Representative binding modes of c(CGisoDGRG),
c(GCisoDGRG) and c(CphgisoDGRG) in complex with integrin α5β1,
according to Glide software. α5 and β1 subunits are represented in pink and gray
surface, respectively. Receptor amino acids engaging direct interactions with the ligands
are shown in stick and labeled with the three-letter code. Metal ions are represented as
yellow spheres and peptides are shown in white sticks.
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Table 4.7: Comparison of Buried Surface Area. The inter-facial Buried Surface
Area (BSA) of c(CphgisoDGRG) in complex with αvβ3 and α5β1 is reported. Specifically,
the involvement of polar or non polar atoms is highlighted. The data concerning BSA
have been computed with the Naccess software v2.1.1 with water represented by a sphere
of radius 1.4 Å. [254]
BSA [Å2]
Total Polar Non-Polar
αvβ3 250 120 130
α5β1 252 96 156
The availability of the crystallographic structures of αvβ3 and α5β1 integrins in
complex with RGD ligands, as well as the knowledge of the key differences in the
binding pockets of these two proteins, which have been exhaustively investigated
in the past, [15,40,78] allowed to rationalize the highly different selectivity displayed
by c(CphgisoDGRG) for α5β1 integrin.
At a first glance, the binding modes adopted by c(CphgisoDGRG) in αvβ3 or
α5β1 seem to be highly similar, with the only exception consisting in the different
positioning of the cyclopeptide Cysteine. This difference in binding mode could
be ascribed to the replacement of β1:Gly261, in α5β1, with β3:Lys253, in αvβ3.
This substitution results in a narrower cleft along the dimer interface in αvβ3,
which prevents the accommodation of cyclopeptide Cysteine in that position. Of
note, these results are in line with previous studies, where the binding mode
of c(phgisoDGRk) cyclopeptide in the two integrins α5β1 and αvβ3 has been
investigated. [40,78] The different selectivity of c(CphgisoDGRG), which displays a
significantly higher affinity for α5β1 with respect to αvβ3, can be explained by
analyzing the inter-facial buried surface area (BSA) of the two complexes, computed
as the difference in receptor accessible surface area between the situations of free and
bound receptor. This analysis suggests that the cyclopeptide occupies a more polar
region in αvβ3 with respect to α5β1 (see Table 4.7). Conceivably, this is related
to the higher acidity of the D3-A3 loop in αv as compared to α5, where the three
Aspartates αv:Asp146,Asp148,Asp150 are replaced by α5:Phe155,Trp157,Ala159,
respectively. [40] In this context, the desolvation energy required to accommodate the
cyclopeptide within the αvβ3 pocket could unfavorably contribute to its binding
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affinity. Of note, this unfavorable contribution is not counterbalanced by additional
polar interactions in the αvβ3-c(CphgisoDGRG) complex, justifying the low affinity
of c(CphgisoDGRG) for αvβ3 and its higher selectivity for α5β1.
4.2.2.3 Rationalizing the effect of c(CGisoDGRG)-linker conjugation
on αvβ3 integrin affinity
Biochemical studies [76] have shown that conjugation of c(CGisoDGRG) with the
chemical linker (see Figure 4.9, bottom right) resulted in an improved affinity and
selectivity of the peptide toward αvβ3 integrin (Table 4.4). Two possible hypothesis
could explain this improvement in binding affinity: i. the chemical linker influences
the conformations of the cyclopeptide, either modulating the equilibrium between
conformers or favoring the adoption of a novel bioactive conformation; ii. the
chemical linker engages additional stabilizing interactions with the receptor. To
solve this issue and to provide a model of the interacting complex we have applied
a combination of NMR and MD strategies.
I started investigating the conformations adopted by the cyclopeptide c(CGisoDGRG)
after conjugation with the chemical linker. Comparison of 2D-ROESY (Rotating
frame nuclear Overhauser Effect SpectroscopY) spectra, acquired in our labora-
tory, of c(CGisoDGRG) and of c(CGisoDGRG)-linker conjugate revealed that the
conformation of the cyclopeptide backbone is not influenced by the presence of the
linker. Indeed, even if some chemical shift displacements can be observed due to the
change of the chemical environment, the pattern of peaks related to c(CGisoDGRG)
is highly similar in the two spectra (see Figure 4.13 and Table C.2). Therefore, in
order to investigate the conformations adopted by the peptide conjugated with the
chemical linker, I have performed BE-META simulations on eight different input
structures, prepared starting from the four backbone conformations individuated in
the BE-META simulation of the cyclopeptide alone (see Table 4.5 and Figure C.3)
and attaching the chemical linker in both R and S configurations. Details on the
linker parameterization are described in Section 4.2.4.5. Since, according to NMR
data, the conformations of the peptide should not be influenced by the presence
of the chemical linker, cyclopeptide backbone has been maintained in its starting
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Figure 4.13: ROESY spectra. Superposition of bidimensional 1H-1H ROESY spectra
of c(CGisoDGRG) (blue) and of c(CGisoDGRG)-linker conjugate (red). The region
of the spectra showing the correlation between HN and Hα protons is reported. The
spectra of 1-5 mM sample in 20 mM of phosphate buffer (90% H2O, 10% D2O) have
been acquired using a mixing time of 300 ms, at temperature of 280 K and pH 6.5.
conformation through dihedral restraints, while the remaining part of the molecule
was free to explore the conformational space. In particular the variables related
to the degrees of freedom of the Cysteine side chain and of the linker have been
biased (see Section 4.2.4.6 for details). The simulations have been analyzed as
described in Section 4.2.4.6; then for each of the eight starting conformers, a pool
of 100 conformations have been extracted from the main conformational minima
that have been used as input for subsequent docking calculations.
During the docking calculations, performed with the Glide software, [152] positional
constraints have been applied to favor the formation of the canonical interaction
clamp between c(CGisoDGRG) and integrin αvβ3 (see Section 4.2.4.7). Totally 381
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Figure 4.14: STD experiments. In the left panel, the off-resonance spectrum (top)
and the STD spectrum (bottom) are shown. Herein the linker-related emerging peaks
are assigned. The experiments have been acquired for a sample containing 5 µM of αvβ3
recombinant extracellular domain integrin and 0.3 mM of ligand (stoichiometric ratio =
1:60) in 20 mM of phosphate buffer pH 6.5, 100 mM NaCl, 0.1 mM CaCl2, 5 mM MgCl2
(90% H2O, 10% D2O). The temperature was set to 280 K. 1H saturation on-resonance
was set at -2 ppm and off-resonance at 100 ppm, using 3 s of total irradiation time. In
the right panel it is shown a 2d-representation of the linker, in which hydrogens that are
in close proximity to αvβ3 protons, according to STD experiments, are highlighted.
decoy poses (155 in the case of peptide-linker in R configuration, 226 in the case of
S configuration) satisfying the positional constraints have been generated. In order
to select, among these wide variety of decoy poses, the structural models that most
reliably reproduce the αvβ3 c(CGisoDGRG)-linker conjugate complex, NMR data
from Saturation Transfer Difference (STD) experiments have been exploited (see
Figure 4.14). These data revealed which hydrogens of the cyclopeptide are in close
proximity to protons of the receptor. Therefore, only decoy poses in which the
hydrogens individuated from STD experiment were found at a distance lower than
4 Å from receptor protons, have been selected and afterward clustered according to
geometric criteria (see Section 4.2.4.7 for details). Representative decoy poses of the
clusters individuated, containing more than 4 structures, are shown in Figure 4.15.
Of note, in these clusters, the cyclopeptide-linker conjugate was found in both R
and S configurations, suggesting that there are no differences in the binding modes
of the two diastereomers.
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Figure 4.15: Proposed docking models. Two possible binding modes of
c(CGisoDGRG)-linker conjugate in complex with integrin αvβ3. Integrin is represented
as surface with the αv and β3 subunits in green and blue, respectively. Receptor amino
acids engaging direct interactions with the ligands are shown in stick and labeled with
the three-letter code. Metal ions are represented as yellow-green spheres and ligands are
shown in orange sticks.
In both the proposed binding modes the electrostatic clamp is well summarized: on
one side the Arginine of the isoDGR motif interacts with the αv subunit, engaging
a salt bridge with Asp218 and polar contacts with Asp150 and/or Thr212; on
the other side, isoAspartate coordinates the metal ion in MIDAS position and
engages polar interactions with β3:Asn215. In both the poses I observed additional
hydrophobic and polar interactions stabilizing the complex.
Specifically, in the poses of cluster 1 (Figure 4.15, left panel) the cyclopeptide
contributes in forming: hydrophobic interactions with αv:Tyr178, β3:Ala218 and
β3:Ala252, polar contacts with β3:Lys253, engaged by the Cysteine, and an hy-
drogen bond with β3:Arg216, engaged by the Glycine of the isoDGR motif. Of
note, also the linker actively contributes in forming additional stabilizing contacts
that well justify the improved affinity of c(CGisoDGRG) after conjugation. Specif-
ically the oxygens of the succinimide can form an hydrogen bond with the side
chains of either αv:Arg248 or β3:Lys253; while the linker terminal amide group
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engages a stable hydrogen bond with the carbonyl group of β3:Asn313. Additional
linker-receptor hydrophobic interactions are also observed, involving αv:Ala215
and αv:Ile216.
Concerning the poses of cluster 2 (Figure 4.15, right panel) the cyclopeptide can
stabilize hydrophobic interactions with αv:Phe177, αv:Tyr178, β3:Ala218 and
β3:Ala252 but not additional polar interactions. However the linker engages several
polar contacts with the β3 integrin subunits: specifically with the ion in ADMI-
DAS position, with β3:Asn313 and with the loop β3:Ser334-Met335-Asp336. In
particular the terminal amide group of the linker engages alternate hydrogen bonds
with the side chain of β3:Ser334 and the carbonyl group of β3:Met335.
Importantly, in both the models, the analysis of the poses, as well as the differences
in sequence and structure of the two integrins, allowed to provide possible explana-
tion of why c(CGisoDGRG)-linker conjugate displays an improved affinity for αvβ3
but not for α5β1. With regards to cluster 1, among the αvβ3 residues directly
involved in the interactions with the linker, the polar residues αv:Arg248 and
β3:Lys253 are not present in α5β1, being replaced by the hydrophobic α5:Leu257
and β1:Gly261, respectively. Concerning cluster 2, the β1 loop corresponding to
β3:Ser334-Met335-Asp336 (i.e. β1:Ser341-Ala342-Asn343), is significantly shifted
with respect to β3 and it is involved in the coordination of the ADMIDAS, therefore
not being available for interactions with the linker.
Overall, the combination of NMR calculations and modeling techniques allowed
to understand that the conjugation of c(CGisoDGRG) with the chemical linker
induces an improvement in αvβ3 integrin affinity and selectivity because of the
engagement of novel direct interactions with the receptor by the linker. Herein, two
possible models of this interacting complex have been proposed: both well reproduce
the experimental data of STD experiments and justify the affinity improvement
observed only in αvβ3.
In this framework further analysis are needed, therefore in the next feature I plan
to: i. rescore by means of MM-GB/SA technique the selected decoy poses of the
complex αvβ3 c(CGisoDGRG)-linker in order to quantify the energetic contribution
of the linker to the binding affinity; ii. confirm the proposed binding modes by using
the information driven docking software HADDOCK that allows to incorporate
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experimental data to instruct docking calculations. Herewith, the data derived
from STD experiments could be exploited as input to drive the calculations and
thus to generate reliable models of the interacting complex.
4.2.3 Conclusion
Peptides based on the isoDGR sequence can be exploited as drug delivery agents
to target tumor vessels, thus allowing the administration of extremely low doses
of drugs and consequently avoiding unwanted side effects. In this context, the
selective recognition of specific integrin subtypes by the isoDGR-based peptide
is fundamental to deliver the conjugated nano-drugs or cytokines to the desired
target. In this Section I have combined BE-META conformational sampling, Glide
and MM-GB/SA rescoring to investigate three integrin-targeting cyclopeptides,
namely c(CGisoDGRG), c(GCisoDGRG) and c(CphgisoDGRG), that were shown
to be potential drug-delivery agents.
The exhaustive conformational sampling of the molecules revealed that they are
quite flexible, not being able to adopt the stable double beta-turns conformations
characteristic of cyclic hexapeptides. I proposed that this high flexibility could be
ascribed to the presence of the additional isoAspartate Cβ atom within the cycle.
The subsequent docking calculations allowed to identify low-nanomolar integrin
binders and to rationalize the diverse affinity and selectivity profiles of the three
molecules for the two integrins αvβ3 and α5β1, both related to cancer. Specifically,
visual inspection of the binding modes, supported by analysis of the MM-GB/SA
contributions, unveiled that bulky hydrophobic residues flanking isoAspartate in
the isoDGR motif could be exploited to modulate the cyclopeptide selectivity
towards α5β1, as confirmed also by previous findings. [78]; conversely, small residues
as Glycine in the same position could be useful to fine-tune molecules selectivity
towards αvβ3.
Finally, a combination of NMR experiments and computational techniques has
been used to explain the improved αvβ3 affinity displayed by c(CGisoDGRG)
after conjugation to a sulfo-SMCC-derived chemical linker. Since NMR data
revealed that conjugation does not influence cyclopeptide conformation, it has been
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concluded that the improved affinity could be related to the presence of additional
interactions engaged by the linker. Therefore, I exploited docking calculations and
STD experiments to propose two models of the interacting complex: herein the
polar interactions observed between the linker and the receptor well justify the
improved affinity.
The satisfactory results obtained in this work suggest that the proposed compu-
tational strategy, combining BE-META, docking and MM-GB/SA rescoring, can
be successfully applied also on isoDGR-based peptides and with diverse receptor
integrins. These data hold promises for the future applications of this compu-
tational method, especially for its employment in screening the impact of the
chemistry/stereo-chemistry of flanking residues of isoDGR-based cyclopeptides on
integrin affinity.
4.2.4 Methods
4.2.4.1 BE-META simulations
BE-META simulations of the three cyclopeptides c(CGisoDGRG), c(GCisoDGRG)
and c(CphgisoDGRG) have been performed and analyzed as described in Sec-
tion 4.1.4.2 and 4.1.4.3. Herein the AMBER ff99sb-ildn force field [101,233] was
used in combination with the TIP3P [113] water model. After reconstruction of the
free-energy landscape in the reduced CVs space (Section 4.1.4.3), the microstates
have been clustered into different metastable states in order to individuate the most
significant local free energy minima; [138,141] finally the population of each minimum
has been computed according to equation 3.2. Only minima populated more than
10% have been considered for further analysis and docking calculations.
4.2.4.2 Docking calculations and MM-GB/SA rescoring with Glide
The software Glide [152] of the Schrödinger suite was employed to perform a first
set of docking runs. As input ligand structures, the conformers extracted from the
BE-META minima populated more than 10% were used (specifically, a bundle of
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30 structures was randomly selected for each minimum of each peptide). Since
these structures had already been subjected to an exhaustive conformational search,
no further energy minimization or sampling was performed. The receptors input
structures (PDB codes: 1L5G [9] and 4WK4 [16] for αvβ3 and α5β1 in complex
with Cilengitide and the disulfide cyclized peptide ACRGDGWC, respectively),
have been prepared with the Protein Preparation Wizard tool of Maestro (version
10.7). All the crystallographic water molecules were removed, missing side-chains,
hydrogen atoms and loops were added; the orientation of the hydroxyl groups
of Serine, Threonine and Tyrosine, the side chains of Asparagine and Glutamine
residues, and the protonation state of Histidine residues were optimized. Finally,
structures were minimized employing an OPLS-AA force field with a root mean
square deviation (RMSD) tolerance on heavy atom of 0.3 Å to remove steric clashes
and reorient side-chain hydroxyl groups. Cilengitide and ACRGDGWC were used
to determine the grid center on αvβ3 and α5β1, respectively, and subsequently
removed. Default grid dimensions, as defined in Glide, for ligands similar in size
to the input ones were used. No constrains were applied. All the ligand–receptor
complexes were generated by using the Extra-Precision mode of Glide considering
a flexible ligand (i.e. flexible side-chains), performing post-docking minimization
and saving at most three possible poses for each ligand input structure. After
docking calculations the poses were ranked according to their Extra-Precision Glide
Score (GS). A first filter was then applied (GS < (GSbest + 5 kcalmol
−1)) and only
poses satisfying this condition were retained for MM-GB/SA rescoring and further
analysis.
The selected decoy poses have been then rescored with the MM-GB/SA method
using Prime. After minimization with the local optimization features, [178] energy
contributions have been calculated with the all atom OPLS force field and with
the GB/SA continuum model. [227] The protein flexibility was taken into account
for residues that were within a distance of 5 Å from the ligand, without setting
any constraints. After the MM-GB/SA calculations, the geometry of the residues
coordinating the metal ions at the binding site was carefully checked and it resulted
to be perfectly recapitulated in all the cases. Concerning the ligand, all the
side-chain atoms were considered flexible during the calculations.
140
4.2. Rationalizing affinity and selectivity of isoDGR-based hexapeptides
4.2.4.3 Docking calculations with HADDOCK
A second set of docking calculations has been performed using HADDOCK, version
2.2. [184] As input ligand structures, I used the conformers extracted from the BE-
META minima populated more than 10% (in this case, a bundle of 10 structures
was randomly selected for each minimum of each peptide). The receptors input
structures were the ones optimized for the docking calculations with Glide. The
same docking procedure has been repeated for each minimum of each peptide with
either αvβ3 or α5β1 integrin.
The solvated docking protocol of HADDOCK, which includes explicit treatment
of water molecules, was employed. [166,192] Ambiguous interaction restraints were
derived from the known interactions of the RGD motif with integrins αvβ3 or
α5β1, as observed in the respective PDB crystal structures (codes: 1L5G and
4WK4). Specifically, I choose as active residues for αvβ3: αv:D150, αv:D218,
β3:MIDAS; for α5β1: α5:Q221, α5:D227, β1:MIDAS; for the cyclopeptides: isoAsp
and Arg residues of the isoDGR motif. Instead, as passive residues for αvβ3/α5β1
I selected all the residues with relative solvent accessibility >10% (as computed
by NACCESS [254]) and within 7 Å from the RGD-based peptide in 1L5G/4WK4
PDB complex structures. During the rigid body docking step 2000 structures
were calculated, allowing the ligand to explore solutions rotated by 180°. The
best 500 solutions in terms of HADDOCK score were selected for a semi-flexible
simulated annealing; finally the best 200 structures after this step have been
subjected to a water-refinement procedure and then printed as output. The semi-
flexible interface includes all receptors’ residues that make intermolecular contacts
within a 5 Å cutoff and the ligand. OPLS-AA and TIP3P force field were used
for protein and water molecules, respectively, as default in HADDOCK. Default
weights have been used for the different contributes of the HADDOCK score
(HS) at each step; in particular, for the last step the HS has been computed as:
HS = 1.0Evdw + 0.2Eelec + 1.0Edesolv + 0.1Eair (see Section 2.3.3).
For each of the six peptide-receptor complex (three peptides vs two receptors), the
cluster analysis of the decoy poses has been performed.
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4.2.4.4 Cluster analysis
The analysis have been performed clustering the docking poses for each of the six
peptide-receptor complexes. The same procedure has been repeated for the decoy
poses obtained with either Glide or HADDOCK docking software.
To this aim I used the clustering algorithm described by Daura et al. [153,198] with
the help of the tool cluster_struc, a C++ program contained in HADDOCK. The
structures have been aligned on the protein backbone residues. The RMSD matrix
between the peptides has been calculated on all the backbone atoms and on the
non-hydrogen side-chain atoms of the isoDGR motif. The RMSD cut-off for the
cluster analysis was set between 2.0 and 2.5 Å and only clusters containing more
than four structures have been considered. To each cluster an average MM-GB/SA
or an average HADDOCK score (in the case of Glide or HADDOCK docking
calculations, respectively) has been assigned by averaging on the score of the best
four poses of the cluster.
For each peptide-receptor complex the best scored cluster of decoy poses, among
the ones in which the canonical electrostatic clamp with integrin was resembled,
was selected. The representation of the decoy poses and the average scores reported
in this Chapter always refers to these clusters.
4.2.4.5 Parameterization of c(CGisoDGRG)-linker conjugate
In order to perform MD simulations of c(CGisoDGRG) conjugated with the linker
using the AMBER ff99sb-ildn force field, it has been necessary to: i. re-compute the
atomic partial charges of the Cysteine residue conjugated with the linker (denoted
as CYL); ii. compute the atomic partial charges of the linker (denoted as LIN); iii.
assign proper atom types and force-field parameters to the molecule.
Charges parameters for LIN and CYL were derived using the R.E.D. III (RESP
ESP charge Derive) package. [245] In order to compute the partial atomic charges,
four different conformations have been generated with Maestro, [226] both for the
LIN capped with a methanethio group (in either S- and R-configuration) and for
the CYL dipeptide capped with an N-methylsuccinimide group (in either S- and
R-configuration). A 2D-representation of the structures used for the partial charges
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computation are reported in Figure C.4. Afterwards the GAMESS [246] package was
used for geometry optimization in the gas phase and for the computation of the
molecular electrostatic potentials (MEP). Herein, the HF/6-31G* level of theory
and the Connolly surface algorithm were employed. Additionally four different
molecular orientations for each optimized geometry have been considered using
the rigid-body reorientation algorithm implemented in the R.E.D. tool. Finally
the two-stages RESP method was used for the fitting of the atomic charges, fol-
lowing the procedure originally published by Kollman et al. [247] During this step,
intra-molecular constraints were imposed to set the charges of the capping groups
(including the acetyl, N-methyl, methanethio and N-methylsuccinimide groups)
to zero; additionally, charges equivalences were imposed to hydrogens of methyl,
methylene and amine groups, as well as to symmetric atoms in the cyclohexane.
Partial atomic charges of the atoms N, HN, C and O of CYL were set to the same
partial charges of the equivalent atoms in Cysteine, according to the AMBER
ff99sb-ildn force field. Since similar results were obtained for partial charges compu-
tation with capping group in S- and R-configuration (differences in partial charges
of equivalent atoms lower than 0.1), only the data coming from the first set of
calculations were used. The derived RESP partial charges for LIN and CYL atoms
are reported in Table C.3.
Finally, the necessary topology files to perform MD simulations with the AMBER
ff99sb-ildn force field of c(CGisoDGRG) conjugated with the linker were generated
using the Antechamber tool. [120] Amber atom types were used, when some parame-
ters were missing the analogous GAFF parameters have been employed. [119]
4.2.4.6 BE-META simulations of c(CGisoDGRG)-linker conjugate
Input conformations for c(CGisoDGRG) conjugated with the linker were generated
with Maestro; in particular four different conformers of c(CGisoDGRG), represen-
tative of the four free-energy minima identified within the BE-META calculation
of the cyclopeptide described in Section 4.2.2.1, were considered. At each of these
conformers, the linker has been attached in both R and S configurations, resulting
in the generation of 8 input structures.
For each of the input structures, energy minimization, equilibration and BE-META
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calculations have been performed restraining the dihedral angles of the cyclopeptide
previously used to identify the microstates (i.e. the 6 ψ dihedral angles and the ξ
dihedral characteristic of isoAspartate). This was done in order to maintain the
cyclopeptide in its initial conformational minimum and to investigate only the
degrees of freedom of the linker. These dihedral angles were restrained with an
harmonic-like potential to the values characteristic of their free-energy minimum
(i.e. the average values computed on all the structures belonging to that minimum)
with a force constant of 100 kJ/mol/rad2 if they were far from the target value
more than 30°. During both equilibration and production run, the same simulation
settings described in 4.1.4.2 were used. In BE-META simulations five Collective
Variables (CVs) were biased, describing the degree of freedom of the Cysteine side
chain and of the linker. Specifically, these are: i. N-Cα-Cβ-S; ii. Cα-Cβ-S-C1; iii.
Cβ-S-C1-C5; iv. C4-N3-C6-C7; v. N3-C6-C7-C8 (the numeration of linker atoms
is according to Figure C.4). The length of each replica, in which one of the 5 CVs
was biased, was of 20 ns. As in the previous cases, the convergence was checked
comparing the mono-dimensional free-energy profiles derived by averaging on the
two halves of the simulation. In all the cases the convergence was reached and the
difference between the two profiles was found to be always lower than 2kbT .
To identify the possible conformational minima of the eight c(CGisoDGRG)-linker
conjugates, I analyzed the BE-META trajectories with the Metagui tool, [141] us-
ing the procedure described in Section 2.2.3. The same CVs biased during the
production run were used for the analysis. From the 4/5 most populated confor-
mational minima herein identified, I saved 25 structures randomly selected, so to
obtain a pool of 100 structures for each of the eight input c(CGisoDGRG)-linker
conformations to be used for docking calculations.
4.2.4.7 Docking calculations of c(CGisoDGRG)-linker conjugate
The pools of structures identified during the sampling step have been used as
ligand input structures for subsequent docking calculations, performed with the
software Glide of the Schrödinger suite. The αvβ3 input structure (PDB codes:
1L5G) has been prepared as described above (see Section 4.2.4.2). Additionally,
all the same settings used during the docking of the cyclopeptide with αvβ3 were
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used, with the following exceptions: i. the grid dimension was enlarged to fit
ligands with dimensions of 28 Å, ii. positional constraints were applied to force the
cyclopeptide to form the canonical interaction clamp with integrin. In particular
the atoms of the Arginine guanidinium group and isoAspartate carboxylic group of
c(CGisoDGRG) were forced to occupy a spherical volume of 3 Å centered at the
position occupied by the analogous atoms of Arginine and Aspartate of Cilengitide
in 1L5G. For each of the input structures, at most three decoy poses, satisfying
these constraints, were printed as output.
NMR data from STD experiments have been used to individuate the hydrogens
of the linker that are in close proximity to the receptor protons (see Figure 4.14).
Only the docking poses in which all the individuated hydrogens were closer than
4 Å to at least one αvβ3 proton have been selected. In the case of equivalent
hydrogens, at least one of the atoms was requested to be closer than the cutoff to
the receptor protons. The selected docking poses have been clustered according to
geometric criteria as described in the previous Section; herein the RMSD matrix
between the docked ligands has been calculated on all the backbone atoms of the
cyclopeptide and on the non-hydrogen atoms of the linker. The RMSD cut-off for
the cluster analysis was set to 3 Å and only clusters containing more than four
structures have been considered.
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Conclusion and Perspectives
The main objective of this PhD work is to investigate how computational tools
could be applied to accelerate the design process and the development of ther-
apeutic cyclopeptides. Cyclopeptides are indeed gaining increasing importance
as modulators of protein-protein interactions and of other difficult therapeutic
targets thanks to their favorable pharmacokinetic properties and to their ability to
maximize the interacting surface with the receptor while constraining ligands into
pre-organized bioactive protein-binding conformations. In particular, cyclopeptides
have been widely and successfully applied in the field of inhibition of integrins, a
class of trans-membrane receptors involved in several human diseases including
thrombosis, strokes, cancer and angiogenesis. Herein, cyclopeptide affinity and
selectivity for the diverse integrins subtypes can be fine-tuned by modulating
the residues flanking the recognition motifs (RGD or isoDGR) or by introducing
chemical modifications, as acetylation and methylation. In this context, it is well
recognized that the three-dimensional conformation adopted, already in solution,
by the cyclopeptide, and particularly by the recognition motif, is critical for the
selective recognition of different integrins; therefore a strong correlation exists
linking cyclopeptide conformation and its integrin affinity. Despite the interest
inspired by cyclopeptides, their optimization as drugs delivery agents or thera-
peutics is still mainly based on empirical approaches, requiring expensive and
time-consuming synthesis campaigns. In this framework, computational techniques
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could be extremely useful to aid and accelerate the process of cyclopeptides design
and optimization. However, the application of these techniques remains challenging
because of the difficulties in determining cyclopeptides preferred conformations,
due to their constrained geometry, and consequently in predicting their binding
affinity.
Within this thesis I have shown that the combination of enhanced sampling molec-
ular dynamic techniques (specifically Bias Exchange Metadynamics, BE-META),
docking calculations and rescoring methods (Molecular Mechanics-Generalized Born
Surface Area, MM-GB/SA) is a reliable approach to perform structure-activity
studies in integrin targeting cyclopeptides. On one side, BE-META allows the
identification of the conformations preferentially adopted by the cyclopeptide in
solution, as well as the evaluation of their relative equilibrium; on the other side
docking calculations, complemented by MM-GB/SA rescoring and cluster analysis,
allow to individuate the conformers with favorable binding properties. As a result,
a reliable ranking of the cyclopeptides according to their binding affinity and
rationalization of their structure-activity relationship is obtained.
The proposed multi-stage computational protocol has been applied in different
projects.
Firstly, as described in Chapter 3, it has been employed to investigate the im-
pact of single and multiple N -methylations on the equilibrium conformation of
five RGD-based cyclic hexapeptides, which displayed highly different affinities for
αIIbβ3 integrin. From a structural point of view, I have found that introduction of
N -methylation in the investigated RGD-based cyclopeptides can modulate their
structural preferences by favoring the accessibility to additional conformations,
characterized by a ∼180° twist of the peptide bond plane preceding the methylated
residue with respect to the unmethylated peptide. In particular, I have shown
that the diverse pre-organization of the cyclopeptide in solution is responsible of
the observed divergences in αIIbβ3 binding strength, rationalizing the interplay
between structure and affinity. Of note, both the conformational sampling and
the predicted ranking of cyclopeptides according to their binding strength are in
excellent agreement with the available experimental data, proving the reliability of
the proposed methodology.
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As a second project, described in Chapter 4, I have investigated the applicability
of the protocol in structure-activity studies of cyclopeptides based on the novel
integrin recognition motif isoDGR. In order to verify the accuracy of MD techniques
in reproducing the equilibrium properties of molecules containing the non-canonical
amino acid isoAspartate, I have systematically tested eight different force fields
variants on five isoDGR-based cyclic peptides, for which NMR experiments have
been acquired. The results suggest that most of the investigated force fields can
properly reproduce the equilibrium J scalar couplings of cyclic peptides, but only
two out of the eight force fields considered (i.e. AMBER ff99sb-ildn and AMBER
ff99sb*-ildn) are accurate in reproducing the NMR observables characteristic of
isoAspartate. I therefore concluded that transferability of force field parameters
is not straightforward and that introduction of isoAspartate, and generally of
non-standard amino acids, into cyclopeptides sequence could affect the reliability
of the simulations. However, using the most accurate force field among the studied
ones, I have been able to investigate the activity and selectivity profiles for the two
integrins αvβ3 and α5β1 of three isoDGR-based cyclopeptides, differing for the
type of flanking residues and showing suitable tumor-homing properties. Interest-
ingly, previous studies have shown that one of these molecules, c(CGisoDGRG),
after conjugation to human serum albumin, can be used as a drug delivery agents
targeting tumor vessels by selectively recognizing integrin αvβ3. The application of
the computational protocol allowed to discriminate low-nanomolar integrin binders
from weak binders; additionally, the visual inspection of the binding modes, com-
plemented by the analysis of the MM-GB/SA contributions, revealed the structural
basis that regulate cyclopeptide selectivity towards α5β1. Herein it has been
suggested that bulky hydrophobic residues preceding isoAspartate in isoDGR-based
peptides could be exploited to drive the selectivity towards α5β1. Lastly, I have
rationalized the findings of previous biochemical studies, in which it was shown
that the chemical linker used to conjugate c(CGisoDGRG) with human serum
albumin plays an important role in regulating cyclopeptide affinity and selectivity
towards αvβ3. Combining NMR experimental data and computational methods,
I proposed two models of the interacting complex well-explaining this improved
αvβ3 affinity and selectivity.
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Overall, in this thesis I have shown that the proposed computational protocol is a
valuable strategy for the study of cyclopeptides conformations and binding affinity,
allowing the investigation of both RGD and isoDGR-based cyclopeptides, and also
being able to account for diverse integrin subtypes as receptor. Of note, both the
mechanisms influencing affinity modulation have been successfully investigated: in
one case the integrin affinity was regulated by tuning the preferred cyclopeptide
conformations, in the second case it was influenced by the engagement of additional
direct interactions with the receptor. Considering these positive results, we plan
to extend and further apply this computational protocol to screen novel integrin-
targeting peptides library with the aim to accelerate and aid the process of design
and development of therapeutic cyclopeptides.
Specifically, considering that the research field of isoDGR-based integrin inhibitors is
relatively recent and new efforts are needed to explore their potential as therapeutics,
drug carriers or agents for diagnostic imaging, I aim to apply the computational
method to study the impact of chemistry and stereo-chemistry of flanking residues of
isoDGR-based cyclopeptides on ligands conformation and integrin binding activity.
Experimentally, I plan to systematically screen a library of head-to-tail cyclic
pentapeptides of the form c(X1isoDGRX2), where Xi can be any of the twenty
existing natural amino acids in both L- and D-configuration. Based on the well
accepted idea that the stereo-chemistry of flanking residues is fundamental in
dictating the backbone conformational preferences of cyclic peptides, while the
side-chain only negligibly affects this equilibrium, I will perform the BE-META
simulations only on nine reference peptides c(X1isoDGRX2), in which X1 and X2
can be L-Alanine, D-Alanine or Glycine. Then, the docking calculations will be
run on the whole library of molecules, using as input backbone-structures the
ones identified within the sampling. In order to accelerate the work-flow, all the
steps, including generation of the library, simulation, docking and analysis will
be automatized by home-made python/bash scripts, which have been already
optimized and tested for the simulations described in Chapter 4. This kind of
screening could be significant for the development of new cyclic isoDGR-based
αvβ3 inhibitors.
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Table A.1: Definition of BE-META minima according to their position in the
six-dimensional space. In Table are listed for each minimum the corresponding lower
and upper bound in the six dimensions.
Name φ(R2) [°] ψ(R2) [°] φ(f5) [°] ψ(f5) [°] φ(L6) [°] ψ(L6) [°]
LB UB LB UB LB UB LB UB LB UB LB UB
A -180 0 60 180 0 180 -180 -60 -180 0 -60 60
B 0 180 -60 60 0 180 -180 -60 -180 0 -60 60
C -180 0 -60 60 -180 0 -60 60 -180 0 -60 60
D 0 180 -60 60 -180 0 -60 60 -180 0 -60 60
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Table A.2: MM-GB/SA vs Glide Score. For each cluster, the average Extra Precision
Glide Score (GS) and the average MM-GB/SA energy values are reported. Additionally,
it is indicated if the poses of the cluster are able (y) or not (n) to summarize canonical-like
interactions, bridging the two domains of integrin αIIbβ3. We observed that GS is not
able to discriminate poses summarizing canonical interactions from the others: as an
example clusters 2 (good) and 7 (bad) display a similar GS. Conversely, the MM-GB/SA
score clearly distinguishes between poses that summarize the canonical interactions
(cluster 1- 6), from the others (cluster 7 to 13).
Cluster 〈GS〉 〈MM-GB/SA〉 Canonical
[kcal mol−1] [kcal mol−1] interactions
1 -9.5 ± 0.7 -68.3 ± 6.1 y
2 -9.1 ± 0.7 -57.7 ± 6.5 y
3 -9.3 ± 0.7 -56.3 ± 9.5 y
4 -9.0 ± 0.6 -56.2 ± 7.0 y
5 -9.1 ± 0.6 -53.4 ± 8.4 y
6 -8.7 ± 0.4 -49.9 ± 10.7 y
7 -9.1 ± 0.8 -46.9 ± 8.6 n
8 -9.3 ± 0.9 -43.2 ± 10.1 n
9 -8.6 ± 0.4 -43.1 ± 9.2 n
10 -8.8 ± 0.6 -40.8 ± 7.5 n
11 -8.5 ± 0.4 -36.0 ± 7.7 n
12 -8.6 ± 0.4 -34.8 ± 6.1 n
13 -8.6 ± 0.3 -28.2 ± 5.1 n
154
Appendix A. Chapter 3: Supplementary Tables and Figures
Table A.3: MM-GB/SA energetic contributions per cluster. The main MM-
GB/SA contributions for each cluster, including Coulomb (Coul), Generalized Born
electrostatic solvation energy (GBS), van der Waals (vdW), lipophilic energy (lipo),
covalent binding (cov), hydrogen-bonding (hb), pi-pi packing energy (pi-pi) and self-contact
correction (self) terms are reported. The errors concerning the Polar, Non Polar and
Additional contributions are the ones of Table 3.4 in the main text.
Cluster Energetic Contributions [kcal mol−1]
Polar Non Polar Additional
〈Coul〉 〈GBS〉 〈vdW〉 〈lipo〉 〈cov〉 〈hb〉 〈pi-pi〉 〈self〉
1 -57.8 73.6 -58.8 -30.1 7.2 -3.0 0.8 -0.3
2 -46.5 59.0 -48.2 -25.5 6.0 -3.0 0.6 0.0
3 -55.1 67.8 -47.8 -25.8 8.2 -3.9 0.2 0.0
4 -64.4 79.6 -48.8 -28.9 9.9 -4.0 0.7 -0.3
5 -49.1 65.6 -49.2 -24.6 6.8 -2.9 0.2 -0.3
6 -68.4 87.0 -52.1 -23.6 9.7 -2.5 0.2 -0.2
7 -25.0 59.9 -59.6 -32.4 11.6 -3.9 2.5 0.0
8 -30.6 59.6 -49.6 -30.3 10.4 -4.4 1.7 0.0
9 -20.6 46.1 -48.1 -26.2 6.0 -1.1 1.0 -0.3
10 -47.2 79.0 -52.7 -24.8 5.7 -3.1 2.2 0.0
11 -8.0 40.1 -49.0 -23.2 5.1 -1.2 0.6 -0.3
12 -38.8 67.1 -44.6 -23.7 5.3 -2.4 2.2 0.1
13 -14.9 54.5 -48.4 -23.3 3.6 -1.0 1.4 -0.1
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Figure A.1: Monodimensional free energy profiles. Convergence of the free energy
profiles for each cyclopeptide, as a function of φ and ψ dihedral angles of R2, f5 and L6.
The black profile represents the time average within (teq, (teq + ttot)/2) , the blue one
represents the time average within the second half ((teq + ttot)/2, ttot) ; the red line is the
average between the black and blue profiles, which are consistent within 2kbT . In Figure,
FES for teq = 1 ns and ttot = 40 ns are reported. [213]
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Figure A.2: BE-META minima in a Ramachandran-like plot. [213] The coordinates
of the main free-energy minima are reported in the six-dimensional space defined by
the φ and ψ dihedral angles of R2, f5 and L6. Shapes and colors represent residue and
minima, respectively.
P
s
i 
/°
  
c(GRGDfL)
0 180 -180 
-180 
-60 
60 
180 
Phi /° 
0 180 -180 0 180 -180 
c(GRGDfL) c(GRGDfL)
Phi /° Phi /° 
c(GRGDfL) c(GRGDfL)
P
s
i 
/°
  
0 180 -180 
-180 
-60 
60 
180 
Phi /° 
0 180 -180 
Phi /° 
R
f
L
min A
min B
min C
min D
161

Appendix B
Section 4.1: Supplementary
Tables and Figures
Table B.1: RESP charges. In Table are reported the RESP atomic partial charges for
Phenylglycine and isoAspartate, derived as described in section 4.1.4.2.
Phenylglycine isoAspartate
Atom Names Partial Charges [e] Atom Names Partial Charges [e]
N -0.3515 N -0.6589
H 0.2453 H 0.3423
Cα -0.0660 Cα 0.1271
Hα 0.1388 Hα 0.0597
Cβ -0.0197 Cβ -0.0177
Cγ* -0.0729 Hβ* 0.0031
Hγ* 0.1071 Cγ 0.7753
Cδ* -0.1717 Oγ* -0.7695
Hδ* 0.1455 C 0.4700
CZ -0.1248 O -0.5650
HZ 0.1392
C 0.5367
O -0.5140
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Figure B.1: Chemical shift χ2, subdivided per type. For each force field, the ability
to reproduce experimental chemical shift displacements is quantified thorough the χ2
function. The differences in the prediction of chemical shift displacements for various
atoms (C, Cα, Cβ, Hα and HN represented in blue, light blue, orange, light green and
green, respectively) are highlighted.
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Figure B.2: χ2 values, indicating the agreement between experimental and
back-calculated 3JHN,Hα, computed with different sets of Karplus parameters.
The χ2 values, estimating the ability of each force field to reproduce experimental 3JHN,Hα
scalar couplings, obtained with ORIG (orange bars) or DFT (brown bars) Karplus
parameters are reported.
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Figure B.3: Comparison between experimental and computed J scalar cou-
plings. For each force field, the ability to reproduce experimental J scalar couplings is
quantified through the χ2 function. The χ2 values obtained, considering alternatively
3JHN,Hα, 3J isoDHα,Hβ , or both these variables together, is shown with orange, blue and gray
bars, respectively. In order to avoid flattening of the data a gap in the y axis has been
introduced. All the 3JHN,Hα scalar couplings have been computed using the DFT set of
Karplus parameters.
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Figure B.4: Influence of isoAspartate on 3JHN,Hα reproducibility. For each force
field, the ability to reproduce experimental 3JHN,Hα scalar couplings is quantified through
the χ2 function. The χ2 values, computed including or excluding the coupling constants
associated to isoAspartate φ′, are reported as orange and yellow bars, respectively. All the
3JHN,Hα scalar couplings have been computed using the DFT set of Karplus parameters.
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Figure B.5: Correlation of 3JHN,Hα computed with different force field variants.
Panels show the correlation between 3JHN,Hα computed with (A) AMBER ff99sb-ildn
force field or its variant ff99sb-ildn_ASN; (B) OPLS-AA/L force field or its variant
OPLS-AA/L_ASN. All the 3JHN,Hα scalar couplings have been computed using the DFT
set of Karplus parameters.
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Figure B.6: Correlation of 3JHN,Hα computed with OPLS-AA/L and OPLS-
AA/L_ASN force field variants. Panels show the correlation between: (A) all
3JHN,Hα, (B) all 3JHN,Hα except isoAspartate, (C) all 3JHN,Hα except the residue preceding
isoAspartate, (D) all 3JHN,Hα except the two residues preceding isoAspartate, (E) all
3JHN,Hα except the residue following isoAspartate, (F) all 3JHN,Hα except the two residues
following isoAspartate, computed with OPLS-AA/L force field or its variant OPLS-
AA/L_ASN. All the 3JHN,Hα scalar couplings have been computed using the DFT set of
Karplus parameters.
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Figure B.7: Influence of isoAspartate parameterization in OPLS on the 3JHN,Hα
χ2. For OPLS-AA/L and OPLS-AA/L_ASN force fields, are reported the χ2 values,
estimating the ability to reproduce: all the experimental 3JHN,Hα scalar couplings (orange
bars), all the 3JHN,Hα couplings except the ones of the residue following isoAspartate
(3J#HN,Hα, yellow bars), all the 3JHN,Hα couplings except the ones of the two residues
following isoAspartate (3J##HN,Hα, brown bars). All the 3JHN,Hα scalar couplings have
been computed using the DFT set of Karplus parameters.
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Figure B.8: Spread in bias potential within bins. In order to verify how finely the
grid follows the free-energy landscape in the CVs subspace, the spread in bias potential
(∆V ) between each microstate µ and its 2*Ndim neighbor bins has been measured, where
Ndim indicates the dimensionality of the subspace. Specifically, for each µ the following
quantities have been computed: i. the average spread 〈∆V 〉, considering all the neighbor
bins with defined energy; ii. the minimum spread ∆Vmin, among the positive ∆V (this
was done to avoid redundancies). The distributions of 〈∆V 〉 and ∆Vmin, referred to the
simulation of c(CGisoDGRG) with the AMBER ff99sb force field, are shown in the left
and right panel, respectively. In approximately 90% of microstates, the average spread is
lower than 2kbT (left panel) and µ has at least one neighbor with an energy closer than
kbT (righy panel), indicating that the grid follows the energy landscape pretty finely.
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Table C.1: Turns type. Definition of the α, β and γ turn types, according to the
values adopted by the involved dihedral angles. α, β and γ turns are associated to the
presence of an intramolecular hydrogen bond between backbone atoms O(i) and HN(i+4),
HN(i+3), HN(i+2), respectively. Here are reported only the reference dihedral angles for
the turn types individuated in the cyclopeptides under investigation, for a complete list
of the turns type see reference [253].
Dihedral angles [°]
Turn Type φ(i+ 1) ψ(i+ 1) φ(i+ 2) ψ(i+ 2) φ(i+ 3) ψ(i+ 3)
I-αLS 48 42 67 33 70 32
II-αRS -59 129 88 -16 -91 -32
II-αRU 54 39 67 -5 -125 -34
βI -60 -30 -90 0
βI’ 60 30 90 0
βII’ 60 -120 -80 0
γ 75 -65
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Table C.2: Chemical Shifts. Chemical shifts of the carbon atoms for the cyclopeptide
c(CGisoGRG) and c(CGisoGRG)-linker conjugate.
Residue Atom Chemical Shift [ppm]
ID Name c(CGisoGRG) c(CGisoGRG)-
linker
Difference
1 Cys C 176.8 175.3 -1.5
1 Cys Cα 57.7 56.2 -1.5
1 Cys Cβ 28.3 35.4 7.1
2 Gly C 173.6 173.6 0.0
2 Gly Cα 45.9 45.9 0.0
3 isoAsp C 176.3 176.2 -0.1
3 isoAsp COO- 179.6 179.3 -0.3
3 isoAsp Cβ 40.5 40.4 -0.1
3 isoAsp Cα 54.5 54.6 0.1
4 Gly C 174.8 174.9 0.1
4 Gly Cα 45.5 45.5 0.0
5 Arg C 177.7 177.4 -0.3
5 Arg Cα 56.8 56.9 0.1
5 Arg Cβ 30.1 29.9 -0.2
5 Arg Cδ 43.3 43.3 0.0
5 Arg Cγ 27.0 27.1 0.1
6 Arg C 174.8 174.9 0.1
6 Arg Cα 45.9 45.9 0.0
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Table C.3: RESP charges. In Table are reported the RESP atomic partial charges for
the Linker (LIN) and the Cysteine used for the conjugation to the linker (CYL), derived
as described in section 4.2.4.5.
LIN CYL
Atom Names Partial Charges [e] Atom Names Partial Charges [e]
C1 -0.4271 N -0.4157
H1 0.2320 H 0.2719
C2 0.4861 Cα -0.0289
O2 -0.4913 Hα 0.1215
N3 0.0601 Cβ -0.0095
C4 0.3980 Hβ* 0.0951
O4 -0.5210 S -0.1589
C5 -0.0317 C 0.5973
H5* 0.0952 O -0.5679
C6 -0.1565
H6* 0.0858
C7 0.0463
H7 0.0573
C8* -0.0301
H8* 0.0222
C9* -0.0671
H9* 0.0309
C10 -0.0334
H10 0.0144
C11 0.7356
O11 -0.5951
N11 -0.9759
H11* 0.4111
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Figure C.1: Peptide-linker conjugation. Sulfo SMCC cross-linker and cyclopeptide
c(CGisoDGRG) are mixed and then left to react at room temperature for 3 hours,
afterward ammonium chloride is added to the solution and left to react for 1 hour at
room temperature. The reaction products are the two peptide-linker conjugates, P1 and
P2, corresponding to conjugation with an amide or a carboxyl group respectively, likely
owing to partial hydrolysis of sulfo-succinimide during the blocking step. [76] The two
products are then separated after the reaction. Only peptide-linker conjugate P1 has
been investigated within this thesis.
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Figure C.2: Monodimensional free energy profiles. Convergence of the free energy
profiles for the cyclopeptides c(CGisoDGRG), c(GCisoDGRG) and c(CphgisoDGRG) as
a function of the biased dihedral angles. The red and blue profiles represent the time
averages within (teq, (teq + ttot)/2) and ((teq + ttot)/2, ttot), respectively; the green line is
the average between the red and blue profiles, which are consistent within 2kbT .
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Figure C.3: Representative conformers of the cyclopeptides c(CGisoDGRG),
c(GCisoDGRG) and c(CphgisoDGRG). For each cyclopeptide a representative
backbone conformation of the minima populated more than 10% is reported. Structures
are shown in sticks, with carbon, nitrogen, oxygen and polar hydrogen atoms colored in
gray, blue, red and white, respectively. The presence of α, β or γ turns is highlighted by
coloring the carbon atoms of the involved residues in dark-red, orange and dark-green,
respectively. Hydrogen bonds are indicated with yellow dashed lines.
180
Appendix C. Section 4.2: Supplementary Tables and Figures
(a) (b)
Figure C.4: 2D-representation of the structures used for the partial charges
computation. The linker LIN capped with a methanethio group and the CYL dipeptide
capped with an N-methylsuccinimide group are represented in the left and right panel,
respectively. The capping groups, whose total charge has been imposed to be 0, are
boxed in dashed lines.
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